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Synthetic organic chemistry mainly focuses on the cleavage and formation of bonds in a 
practical and selective fashion, where the formation of carbon-carbon (C–C)[1] and C–
Heteroatom (C–Het)[2] bonds constitutes one of the most important subjects. During the last 
century, great progress has been made in organic synthesis, with considerable applications to 
pharmaceutical industry, materials chemistry, and crop-protection filed, among others.[3] However, 
the environmental issues associated with organic synthesis are inevitable in terms of chemical 
waste and toxic reagents. Therefore, significant attention has been paid to the development of 
sustainable strategies for molecular assembly in terms of both the economic and environmental 
benefits.[4] In 1988, Anastas and Warner introduced the twelve principles of green chemistry as 
guidelines for minimizing the environmental footprint of chemical syntheses.[5] According to these 
guidelines, the application of catalysis to organic chemistry is essential to increase the economic 
benefits and reduce waste formation by avoiding stoichiometric amounts of metal-based 
catalysts, oxidants or reductants.  
 
 
1.1 Transition Metal-Catalyzed C–H Functionalization  
Since the early contributions using stoichiometric or catalytic amounts of copper in the coupling 
reactions by Glaser[6] and Ullmann[7] in the late of 19th century, significant progress has been 
witnessed in transition-metal-catalyzed cross-coupling reactions between a (hetero)aryl halide 
and an organometallic reagent for the construction of C–C bonds, such as the Suzuki-Miyaura 
coupling,[8] the Stille coupling,[9] the Hiyama coupling,[10] the Kumada-Corriu coupling,[11] and the 
Negishi coupling[12] reactions (Scheme 1.1). Additionally, transition-metal-catalyzed cross-
coupling reactions, such as the Buchwald-Hartwig amination,[13] the Ullmann–Goldberg,[14] and 
the Chan–Evans–Lam-coupling,[15] were successfully explored for C–Het bond formations. 
These important contributions were recognized with the award of the 2010 Nobel Prize in 








Scheme 1.1. Transition metal-catalyzed cross-coupling reactions. 
 
Although traditional cross-coupling reactions represent one of the most reliable methods to 
access (hetero)-aryl-(hetero)aryl moieties, this method requires two fully prefunctionalized 
starting materials, namely organic (pseudo)halides and organometallic reagents e.g. Grignard 
reagents, organostannanes, organozinc and organolithium compounds, which are typically 
sensitive to air and moisture, and require multistep synthetic procedures,[17] and generate 
stoichiometric amounts of salt waste. In contrast, transition metal-catalyzed C−H 
functionalizations[18] provide an opportunity to overcome these limitations to some extent.[19] In 
particular, cross dehydrogenative couplings (CDC) between two aromatic C−H bonds represent 
one of the most straightforward and sustainable concepts to forge bi(hetero)aryl structures 
(C−H/C−H type) with molecular hydrogen as the sole byproduct (Scheme 1.2.).[20]  
 
 
Scheme 1.2. Traditional cross-coupling reactions versus C–H activation. 
 
1.2 General Modes for Metal-Mediated C−H Activation Processes 
In general terms, the transition-metal-facilitated cleavage of C–H bond is the common key step 
in C–H functionalization strategies. Computational chemistry has made a particularly strong 





Excluding radical C–H activation or radical cross-coupling reactions,[22] five different pathways 
can be classified depending on the electronic properties and the nature of the metal (Scheme 
1.3). Electron-rich complexes of late transition metals are prone to cleave the inert C–H bonds 
by oxidative addition, while this mode of action is unfavorable for early transition metals 
(Scheme 1.3a).[23] Most late transition metals in higher oxidation states often act as a Lewis acid 
to cleave C–H bond by an electrophilic substitution mode (Scheme 1.3b).[24] The σ-bond 
metathesis is observed for early transition metals which cannot undergo oxidative addition 
(Scheme 1.3c).[25]  Metals containing an unsaturated M=X bond tend to undergo C–H activation 
via 1,2-addition (Scheme 1.3d).[26] Furthermore, a base-assisted C–H activation event[21b, 27] is 
proposed by the combination of electrophilic attack of the metal with deprotonation by 
carboxylate or carbonate ligands (Scheme 1.3e).  
 
 






Meanwhile, the base-assisted mechanism was further investigated in detail to unveil the 
important role of an internal base for the C–H cleavage processes, and this base-assisted 
mechanism could be further categorized by concerted metalation-deprotonation (CMD),[28]  
ambiphilic metal-ligand activation (AMLA)[29] and base-assisted internal electrophilic substitution 
(BIES).[30] (Scheme 1.4). Both CMD and AMLA mechanisms involving metalation and 
deprotonation steps proceed through a six-membered transition state and are favorable for 
electron-deficient substrates with high kinetic C–H acidity. In sharp contrast the BIES 
mechanism was preferential observed for electron-rich arenes with acetate or carboxylate 
ligands and proceeds via an electrophilic substitution-type pathway.[30-31]  
 
 
Scheme 1.4. Distinct transition state models for base-assisted C–H metalation. 
 
1.3 General Strategies for Selective C–H Functionalizations 
Since C–H bonds are ubiquitous in organic molecules and exhibit similar bond dissociation 
energies (113.5 kcal/mol for C(sp2)−H bonds in benzene),[32] the site-selective activation of 
several C–H bonds in a molecule is a major challenge. To overcome this problem, different 
approaches have been introduced (Scheme 1.5). One of the methods to differentiate the C–H 
bonds in heterocycles is by the inherent reactivity in their kinetic acidities and bond dissociation 
energies (Scheme 1.5a).[33] Another strategy is the introduction of a bulky substituent on the 
substrate, resulting in a steric control by preventing access to the adjacent C–H bonds (Scheme 
1.5b). Nevertheless, both steric bias and electronic bias have intrinsically limited applications in 
molecular synthesis owing to the requirement for particular substrates. A more extensively used 
approach is the installation of Lewis-basic directing groups to precoordinate the transition metal 
center, thus activating the proximal C–H bond and further facilitating the key C–H activation step 
selectively (Scheme 1.5c).[34] In addition, transient directing groups that can be reversibly 
installed in situ and removed in the catalytic C–H cleavage possess have been developed in 
recent years and have great potential to decrease the number of tedious synthetic steps 
(Scheme 1.5e).[35] Moreover, ruthenium-catalyzed σ-activation by strongly influencing the 





traceless directing groups (Scheme 1.5f)[37] are the alternative strategies for the remote meta-
selective C–H activation. In contrast, the palladium/norbornene (NBE) cooperative Catellani-type 
reaciton has emerged as a powerful approach to achieve site-selective C–H activation (Scheme 
1.5g).[38] Here, the ortho selective C–H activation occurs in the presence of Pd/NBE to generate 
a palladium-norbornene species, which can further activate the adjacent C–H bond to finally 
achieve the remote selective meta-C–H bond functionalizations. 
 
Scheme 1.5. Different strategies for selective C–H functionalizations. 
 
1.4 Ruthenium-Catalyzed Selective C–H Activation 
While tremendous contributions have been made in the field of palladium or rhodium complexes-
catalyzed C−H bond activation to promote C−C bond formation, the application of cost-effective 
ruthenium catalysts is now useful and highly desirable for the efficient catalytic conversion of 
C−H bonds.[35a]  
1.4.1 Ruthenium-Catalyzed ortho-Selective C–H Activation 
As early as 1965, Chatt and Davidson presented the ruthenium-mediated C–H activation, in 
which the ruthenium(II)-phosphine complex [RuCl2(Me2PCH2CH2PMe2)2] 1 was employed to 
achieve the C–H bond cleavage of sodium arene 2 in THF for the generation of hydride-






Scheme 1.6. Ruthenium-mediated C–H activation. 
In 1986, the first ortho-metalated ruthenium complex 7 catalyzed regioselective C–H ethylation 
was reported by Lewis and Smith, thus inspiring further developments in C–H activation by 
ruthenium catalystsis. A proposed mechanism for the insertion reaction involves phosphite 
substitution by ethylene, insertion of ethylene for C–C bond formation  into the Ru–C bond, and 
finally reductive elimination to give an ethyl group (Scheme 1.7).[40]  
 
Scheme 1.7. Ruthenium-catalyzed C–H alkylation. 
In 1993, a subsequent report in transition-metal-catalyzed C–H bond activation was achieved by 
the Murai−Chatani−Kakiuchi (Scheme 1.8).[41] This was the first example of chelation-assisted 
catalytic alkylation of aromatic ketones 8 in the presence of a ruthenium(0) catalyst. This 
reaction proceeded by an initial insertion of ruthenium(0) into a C–H bond for the generation of 
active C−Ru−H species, and subsequent reaction of this metal complex with unsaturated 
substrates to provide the desired product 11. Importantly, the use of chelation assistance to form 






Scheme 1.8. Ruthenium-catalyzed C–H alkylation of aromatic ketones. 
In 2001, Milstein and coworkers introduced a novel ruthenium-catalyzed oxidative coupling of 
olefin 13 with arene 12 to furnish aryl alkene 14, where either dioxygen or the alkene 13 can play 
a role of an oxidant, eventually leading to reasonable turnover numbers (Scheme 1.9).[42]  
  
Scheme 1.9. Ruthenium-catalyzed oxidative coupling 
 
In the same year, the first ortho-selective C–H mono- or di-arylations of the aromatic ring in 2- 
arylpyridines, 2-aryloxazolines and 2-arylimidazolines 15 with organic halides 16 in the presence 
of a ruthenium(II)-phosphine complex as the catalyst were reported by Oi and Inoue (Scheme 
1.10).[43] However, this protocol was later shown not to be reproducible. Thus, low-level 
impurities of γ-butyrolactone were found in the NMP solvent, which could hydrolyze under the 
basic conditions to generate a carboxylate.[44]  
 
Scheme 1.10. Ruthenium-catalyzed ortho-selective C–H arylation. 
In 2005, the first generally applicable method for the direct arylation of functionalized arenes 
using ruthenium(II) catalysts was reported by Ackermann[45] by the introduction of phosphine 
oxide R2P(O)H additives that were shown to activate the ruthenium(II) catalyst more efficiently 





substituted secondary phosphine oxide (SPO) (1-Ad)2P(O)H was used as the preligand, leading 
to the effective arylation with the less reactive, but readily available aryl chlorides 19. As to this 
working mode of the SPO-based ruthenium(II) catalyst, a base-assisted metalation was 
proposed to be the decisive feature via transition state A (Scheme 1.12). Later, the same group 
embarked on exploration of other bifunctional ligands, such as carboxylates, for direct arylations 
that were expected to give rise to transition state B. [46] 
 
Scheme 1.11. Ruthenium-catalyzed ortho-selective C–H arylation using phosphine oxide as preligand. 
 
Scheme 1.12. Proposed transition states for base-assisted ruthenations. 
In 2008, the Ackermann group demonstrated the first case of carboxylate-assisted ruthenium(II)-
catalyzed C–H activation, even in apolar solvent, involving the possible generation of a six-
membered ruthenium-carboxylate species (Scheme 1.13a).[47] Subsequently, this most powerful 
strategy also enabled site- and chemo-selective C−H alkylations 25,[48] C−H oxygenations 26,[49] 






Scheme 1.13. Ruthenium-catalyzed C–H arylation, alkylation, hydroxylation, halogenation and cyanation under 
carboxylate assistance. 
The robust nature of the ruthenium(II)-catalyzed C–H activation was not limited to direct arylation 
chemistry. Indeed, this general concept of carboxylate-assisted ruthenium-catalyst was found to 
be broadly applicable for various heterocyclic molecular synthesis in terms of oxidative 
annulations for C–H/N–H[52] and C–H/O–H bond[53] activations in the presence of copper(II) 






Scheme 1.14. Ruthenium-catalyzed oxidative C–H/X–H annulations with alkynes. 
Furthermore, carboxylate assisted ruthenium-catalyzed selective oxidative C(sp2)–H olefinations 
of heteroarenes were accomplished to generate the desired aryl alkenes (Scheme 1. 15). 
Different directing groups were explored for these transformations by the Ackermann group, 
among others, such as, carboxylic acids,[55] oxazoles/triazoles,[56] ketones/aldehydes,[57] 








Scheme 1.15. Ruthenium-catalyzed oxidative annulation and olefinations with olefines. 
Most of these reactions used copper acetate, which acted not only as the oxidant, but also 
served as the essential source of acetate for the carboxylate-assisted ruthenation manifold. In 
order to avoid using the copper salt as an oxidant, an alternative strategy was viable through the 
use of substrates bearing N–O bonds as “internal oxidants” for the syntheses of isoquinolones, 
isoquinolines,[63] olefination or alkyl annulation[64] and benzofuran derivatives (Scheme 1.16).[65] 
 






1.4.2 Ruthenium-Catalyzed meta-Selective C–H Activation 
meta-Selective C–H functionalizations can be elegantly achieved via σ-activation through 
cyclometallation.[36, 66] This strategy usually installs a directing group at the ortho-position to 
produce a significant electronic bias at the arene ring, thus allowing for subsequent 
functionalizations to take place at the para position with respect to the Ru–C bond, leading to an 
overall meta-selective functionalization.  
In 1994, Roper reported the ortho/para-selective stoichiometric nitration of ruthenium aryl 
complexes 29 via σ-activation strategy (Scheme 1.17a).[67] Later, van Koten reported the first 
chelation-assisted oxidative para C–H/C–H functionalization of a ruthenium-arene complex 34, 
furnishing the binuclear complex 35 as well as small amounts of chlorinated ruthenium complex 
36. (Scheme 1.17b).[68] These results presumably clarified that the site-selectivity of C–H 
activation could be controlled by the formation of C–Ru bond via the electronic influence on the 
arene ring.  
 
Scheme 1.17. C–H activation of cyclometalated ruthenium complexes. 
In 1998, the group of Coudret achieved the electrophilic C–H meta-bromination of 
phenylpyridine-ruthenium complex 37 with N-bromosuccinimide (NBS) in excellent yield and 
regioselectivity (Scheme 1.18a).[69] Afterwards, Roper and Wright disclosed the electrophilic 





halogenating reagent and iron powder as catalyst (Scheme 1.18b).[70] These observations 
suggested that the site-selective electrophilic transformation could be controllable by the 
electronic directing effect of the metal centers. 
 
 
Scheme 1.18. Remote C–H bromination of cycloruthenium complexes. 
The first observation for the ruthenium-catalyzed meta-selective C–H functionalization was 
reported by the Ackermann group in 2011(Scheme 1.19).[71] While chelation assisted ruthenium- 
catalyzed ortho-selective C–H alkylations of the phenylpyridine was the major product, an 
unprecedented meta-alkylated arene 43 was also observed, albeit in rather low yield. 
 
Scheme 1.19. The first ruthenium-catalyzed meta-C–H alkylation.  
Inspired by this initial result of ruthenium-catalyzed meta-selective C–H alkylation, Ackermann[72] 
and other groups[73] independently disclosed this method for remote meta-C–H alkylations using 
secondary and tertiary alkyl bromides through an ortho-ruthenation strategy (Scheme 1.20). The 
catalytic remote alkylations were applicable to pyridines, pyrimidines, azoles and imines as 
directing groups, leading to the formation of meta-alkylated arenes with excellent levels of 
position-selectivity. Detailed mechanistic studies of this remote functionalization were supportive 
of a radical mechanism, involving a reversible C–H ruthenation and a subsequent site-selective 
alkylation, which was rationalized by the strong electronic effect of the Ru–C(sp2) bond.[72b-d] 





polymer-based hybrid ruthenium catalyst and in a decarboxylative manner were demonstrated 
by the Ackermann group.[74] Furthermore, ruthenium-catalyzed carboxylate-assisted meta-C–H 
sulfonylations,[75]  benzylations,[76] carboxylations,[77] formylations,[78] acylations,[79] 
halogenations[80] and nitrations[81] were developed, respectively, illustrating the key importance of 
carboxylate-assisted C–H activation with ruthenium(II) complexes in the molecular modifications 
(Scheme 1.20).[35a] 
 
Scheme 1.20. Ruthenium-catalyzed selective meta-C–H activation in the presence of nitrogen-containing directing 
groups. 
1.4.3 Ruthenium-Catalyzed para-Selective C–H Activation 
In contrast to the significant progress in meta-selective C–H functionalizations, challenging C–H 
functionalizations at para position remain underdeveloped.[82] In 2017, Frost reported ruthenium-
catalyzed para-selective C–H alkylations with α-bromo esters 46 (Scheme 1.21).[83] Mechanistic 
studies by experiments and DFT calculations suggested a four-membered ruthenacycle 45a as 
the key intermediate for the transformations. Afterwards, ruthenium-catalyzed para-selective C–
H fluoroalkylation of anilides and ketoximes with α-bromo esters 46 were also demonstrated by 






Scheme 1.21. Ruthenium-catalyzed selective para-C–H alkylation. 
 
1.5 Transition Metal-Catalyzed Electrochemical C–H Activation 
Since early contributions from Volta,[85] Kolbe,[86] and Faraday,[87] electrosynthesis with 
inexpensive and waste-free electricity as a viable redox equivalent has recently experienced a 
renaissance,[88] holding huge potential to accomplish excellent levels of oxidant and resource 
economy.[89] In contrast to classical metal-free electrosynthesis, metalla-electrocatalysis sets the 
stage for transition-metal-catalyzed site-selective C–H activations,[90] forming C−C or C−Het 
bonds without stoichiometric chemical oxidants. 
1.5.1 Palladaelectro-Oxidative C–H Activation 
A pioneering contribution in palladaelectro-oxidative C–H olefinations 50 was reported by the 
Amatore and Jutand group in 2007 (Scheme 1.22).[91] This modified Fujiwara-Moritani-type 
reaction[92] employed catalytic amounts of benzoquinone as the redox mediator and electricity as 
a terminal redox equivalent to replace stoichiometric silver(I) and copper(II) salts as oxidants, 
albeit with a limited scope. 
 
Scheme 1.22. Pallada-electrochemical C–H olefination. 
Subsequently, Kakiuchi exploited palladium-catalyzed electrochemical C–H halogenation of 2-
phenyl pyridine with hydrogen halides or iodine as the halogenation reagents (Scheme 1.23).[93] 
Then, this protocol was further expanded to achieve ortho-selective chlorination using bidentate 





halogenation of arenes by palladaelectro-catalysis, but also for electrocatalytic homocoupling of 
arenes via intermolecular C–H arylation.[95]  
In 2017, a further contribution was made in electrochemical palladium-catalyzed C(sp3)–H 
oxygenation by Mei (Scheme 1.23).[96] This protocol offered a broad scope of synthetically useful 
oxime derivatives under rather mild reaction conditions.[97] In subsequent efforts, the efficient 
palladium-catalyzed oxidative ortho-C(sp2)−H methylation and benzoylation of oximes were 
reported by the Mei group using methyltrifluoroborates and benzoyl acetic acids as coupling 
partners, respectively.[98] Also, palladium-catalyzed anodic ortho-C(sp2)−H acetoxylation,[99] 
halogenation[100] and alkylation[101] were also achieved by the same group.  
Another example of palladium-catalyzed electrooxidative C(sp3)–H acetoxylation of 8-
methylquinoline with tetramethylammonium acetate (TMAOAc, a stronger nucleophile) was 
introduced by the Sanford group (Scheme 1.23).[102] In addition, a pyridine-directed palladium-
catalyzed electrochemical C(sp2)–H bond phosphonation was also reported by Budnikova.[103] 
Moreover, in 2020, the Lei group developed a palladium-catalyzed electro-oxidative 
intramolecular C–H/N-H annulation reaction without an additive, offering a variety of pyrido[1,2-
a]benzimidazoles.[104] 
 
Scheme 1.23. Pallada-electrooxidative C–H activation.  
In 2020, the first asymmetric pallada-electrocatalyzed C–H olefination was achieved by the 





the construction of various axially chiral biaryls 55a-55c. Pleasingly the reaction proceeded 
under undivided cell setup. Further conversion of the thus-obtained products 55 gave expedient 
access to enantioenriched BINOLs, dicarboxylic acids and helicenes (Scheme 1.24).[105]  
 
Scheme 1.24. First examples for asymmetric pallada-electrooxidative C–H activation. 
1.5.2 Rhodaelectro-Oxidative C–H Activation 
Rhodaelectro-oxidative C–H activations have been well documented by Ackermann (Scheme 
1.25). In 2018, they reported the first electrochemical cross-dehydrogenative alkene annulation 
under rhodium catalysis with benzoic acids, amides and indoles 56A (Scheme 1.25a).[106] The 
olefinations of challenging electron-poor benzamides 56B were established in a fully 
dehydrogenative fashion using rhodaelectro-catalysis by the same group in 2020, featuring a 
broad substrate scope (Scheme 1.25b).[107] In 2019, the first electrochemical C−C activation was 
accomplished by expedient oxidative rhodium(III) catalysis. This organometallic C−C activation 
manifold proceeded with ample scope and excellent levels of chemo- and position-selectivities, 
providing unique access to challenging densely substituted arenes 57C, which are not viable by 
any C−H activation methods (Scheme 1.25c).[108]  
Subsequently, the Ackermann group achieved rhodaelectro-catalyzed cascade C–H annulation 
for the synthesis of novel non-planar polycyclic aromatic hydrocarbons (PAHs) 57F from simple 
arylboronic acids 56F (Scheme 1.25f).[109] Later, nitrogen-doped polycyclic aromatic 
hydrocarbons (aza-PAHs)  57H were obtained via a rhodium-catalyzed electrochemical cascade 
C–H annulations of amidoximes 56H with alkynes (Scheme 1.25h).[110] In addition, a flow-
rhodaelectro-catalyzed C–H alkyne annulation was firstly established by the same group. Two 
key rhodacycles were synthesized and detailed mechanistic studies suggest an oxidatively- 





1.25g).[111] Recently, an efficient electrooxidative rhodium-catalyzed alkyne annulation via C–
H/O–H activations was realized using electricity as the sole oxidant, featuring ample substrate 
scope and high site-selectivities (Scheme 1.25i,j).[112] 
 
Scheme 1.25. Rhoda-electrooxidative C–H activations. 
In 2021, the Ackermann group demonstrated a rhodaelectro-catalyzed C–H activation of indole 
56D with alkylidenecyclopropanes (ACPs) for the chemo-selective assembly of cyclopropanes or 
dienes. This unique strategy allowed for the control of selectivity within different mechanistic 
pathways by either β–H or β–C elimination (Scheme 1.25d).[113] Moreover, electrocatalyzed 





ketones 56E were reported by Ackermann (Scheme 1.25e).[114] On a different note, a rhodium-
catalyzed electrochemical phosphorylation of 2-phenylpyridine 56K was also reported by Xu and 
coworkers (Scheme 1.25k).[115]  
 
1.5.3 Ruthenaelectro-Oxidative C–H Activation 
In 2018, Xu and Ackermann[116] (Scheme 1.26a-b) independently reported ruthena-
electrooxidative C–H alkyne annulations with aniline derivatives 58A and weakly O-coordinating 
benzoic acid 58B, leading to the cost-effective preparation of indole derivatives 59A and 
isocoumarins 59B, respectively. Subsequently, naphthol, aromatic carbamates 58C, benzylic 
alcohols 58D, acetophenones 58E and benzoylamides 58F proved to be viable substrates for 
ruthenium-catalyzed dehydrogenative C–H/Het–H alkyne annulations (Scheme 1.26c-f).[117]  
 
Scheme 1.26. Ruthena-electrooxidative C–H/X–H annulation. (X = N, O). 
In 2020, Ackermann developed a novel electrochemical co-catalytic system for the C–H 
oxygenation of synthetically useful amides and ketones 60, employing dual catalysis with 
electrogenerated hypervalent iodine(III) and ruthenium(II) complexes. Thus, catalytic amounts of 
iodoarenes and ruthenium(II) catalyst allowed for versatile C–H oxygenations with ample scope 






Scheme 1.27. Ruthenaelectro-catalyzed C–H activation of ketones amides and pyrazoles. 
Based on the detailed mechanistic studies, a plausible catalytic cycle was proposed for the 
ioda/ruthena-electrocatalyzed C–H oxygenation (Scheme 1.28). The catalytic cycle is initiated by 
C–H activation on the amide with the ruthenium(II) catalyst. Then, the anodically generated 
iodine(III) reagent oxidizes the ruthenium(II) intermediate II, delivering ruthenium(IV) 
intermediate III, which then undergoes rapid reductive elimination and subsequent hydrolysis to 








Scheme 1.28. Proposed catalytic cycle for the ruthenaelectro-catalyzed C–H oxygenation. 
1.5.4 Iridaelectro-Oxidative C–H Activation 
Besides ruthenium and rhodium catalysts, 5d transition metal iridium complexes have also been 
proven as effective cataltsts in C–H functionalizations.[119] While the oxidative reaction in this 
research arena was largely dominated by chemical oxidants, Ackermann made a pioneering 
contribution to the electrooxidative iridium-catalyzed C–H activation with weak O-coordinating 
benzoic acids 62A (Scheme 1.29a).[120] These C–H transformations using p-benzoquinone (BQ) 
as redox mediator presented a high functional-group tolerance, delivering a series of 5-
membered heterocycles 63A. Very recently, the Mei and Guo groups independently reported 
this type of electrochemical annulation with alkynes by iridium catalysis (Scheme 1.29d).[121] 
In 2019, Mei reported the irida-electrochemical vinylic C–H alkyne annulation of acrylic acids 
62B with alkynes, affording α-pyrones 63B with good to excellent yields. In this case, preliminary 
mechanistic studies show that the anodic oxidation was crucial for releasing the product 63B 
and regeneration of the active iridium(III) catalyst (Scheme 1.29b).[122] 
In 2020, the Shi and Xie groups developed an electrochemical approach in promoting directed 
C−H alkynylation with terminal alkyne 65 via iridium catalysis. Detailed mechanistic studies in 
terms of isolation of key iridium(III) intermediates and control experiments suggested an 
oxidatively-induced reductive elimination, giving the desired aromatic alkynes 63C in good yields 






Scheme 1.29. Irida-electrooxidative C–H/O–H annulation. 
 
1.5.5 Cobaltaelectro-Oxidative C–H Activation 
The merger of C–H activation and electrochemistry set the stage to establish new reactivities 
with high levels of resource economy. Despite indisputable advances in electrocatalytic 
organometallic C–H activations with the precious 4d and 5d transition metals, the development 
of less toxic, cost-effective and the sustainable nature of Earth-abundant 3d metals in the 
electrosynthesis is a more environmentally-benign and economically-attractive alternative. 
 





with cobalt catalysts. This proof of concept study realized the direct C–H oxygenation of aryl and 
alkenyl amides 66 with inexpensive and Earth-abundant Co(OAc)2∙4H2O as the catalyst 
(Scheme 1.30).[124] Based on detailed experimental studies, including the full characterization of 
key cyclometalated intermediates of cobaltaelectro-catalyzed C–H activation, Ackermann 
proposed a plausible reaction pathway by involving a Co(III/IV/II) manifold.[125]  
 
 
Scheme 1.30. Cobalta-electrooxidative aryl and vinylic C–H oxygenation. 
 
The cobaltaelectro-catalyzed C–H activation was not limited to C–O bond formations. Thus, 
Ackermann and Lei established an intermolecular C–H amination protocol under mild reaction 
conditions with different directing groups (N,O- or N,N-coordinating auxiliaries) for the C–Het 
formation (Scheme 1.31a,b).[126] Thereafter, Ackermann described a cobalt-catalyzed C–O bond 
formation for the electrochemically promoted C–H acyloxylations (Scheme 1.31e).[127] Moreover, 
cobalta-electrocatalysis was extremely effective for the C–H/N–H annulation of arene and olefin 
derivatives with alkynes,[128] alkenes,[129] allenes,[130] carbon monoxide or isocyanides[131] to 
generate biorelevant heterocycles (Scheme 1.31c,d,f-j). More recently, the robust and versatile 
cobalt catalysis also enabled the electrochemical C–H allylation with non-actived alkenes in the 
biomass-derived solvent γ-valerolactone, generating allylated benzamides with high levels of 







Scheme 1.31. Cobalta-electrooxidative C–H activation. 
 
1.5.6 Nickellaelectro-Oxidative C–H Activation 
Regarding its Earth-abundance, economical reliability and reactivities, nickel is often considered 
to be an potential alternative to expensive palladium catalysts. For this reason, a plethora of C–
H activations have been achieved by utilizing nickel catalysis.[133] Despite this indisputable 
progress, nickella-electrochemical C–H activation remained elusive until recently. 
In 2018, the Ackermann group reported the first example of nickella-electrooxidative C–H 
aminations with ample scope and high levels of chemo- and position-selectivity (Scheme 





electrosynthesis proved particularly potent in the C–H amination 72A of electron-deficient arenes 
70A. Afterwards, the same group developed nickella-electrocatalyzed alkoxylations[135] 72B with 
challenging secondary alcohols 71B and phosphorylations 72C (Scheme 1.32b,c).[136] Detailed 
mechanistic studies provided strong support for a nickel(III/IV/II) manifold for these 
transformations. 
 
Scheme 1.32. Nickella-electrooxidative C–H aminations. 
 
1.5.7 Cupraelectro-Oxidative C–H Activation 
Recently, the Mei group successfully highlighted the efficiency of copper catalysis[137] in 
electrochemical C–H functionalizations (Scheme 1.33a).[138] Here, they employed catalytic 
amounts of Cu(OTf)2 and n-Bu4NI as the redox mediator to facilitate the ortho-selective C–H 
amination of aryl amines 73A bearing the picolinamide (PA) directing group. The detailed 
experimental studies suggested a single electron transfer (SET) and a high valent copper(III) 
species to be involved in the reaction mechanism. In a subsequent report, a redox mediator-free 





73B with AQ as a directing group (Scheme 1.33b).[139] The synthetic utility of this protocol was 
well explored for various amines containing active pharmaceutical ingredients. 
The copper electrocatalysis was not restricted to C–H aminations. Indeed, the Ackermann group 
revealed a first example of cupraelectro-catalyzed C–H/N–H alkyne annulation with electricity as 
the terminal oxidant to provide the bioactive five-membered isoindolones 74C in both a 
dehydrogenative and decarboxylative manner (Scheme 1.33c).[140] 
 
 
Scheme 1.33. Cupraelectro-oxidative C–H activation. 
 
 
1.5.8 Ferraelectro-Oxidative C–H Activation 
Due to growing interest in chemical utilization of less toxic, natural Earth-abundance and cost-
effective metal catalysts, iron catalysis has become a rapidly increasing research area for 
sustainable molecular syntheses via C–H activation.[141] Despite indisputable advances, the iron-
catalyzed oxidative C–H transformations strongly relied on superstoichiometric amounts of cost-
intensive 1,2-dichloroisobutane (DCIB) as the sacrificial oxidant, thereby generating 





disclosed the unprecedented ferraelectrocatalytic strategy for oxidative C–H arylation with 
Grignard reagent 76 for the synthesis of biaryls 77 (Scheme 1.34).[142]  Furthermore, detailed 
mechanistic studies in terms of experiments and DFT calculations suggested an electrooxidative 
iron(II/III/I) manifold.[142-143]  
 
Scheme 1.34. Ferra-electrooxidative C–H activation.  
 
1.5.9 Manganaelectro-Oxidative C–H Activation 
The sustainable electrochemical organometallic C–H activation was further investigated in the 
presence of non-toxic and readily accessible manganese catalysts. As a proof of concept, 
Ackermann showcased the potential of MnCl2 in combination with electrocatalysis for the 
transformative C–H arylation of picolinic acids in the assistance of zinc salt (Scheme 1.35).[142] 
 
Scheme 1.35. Manganaelectro-oxidative C–H arylation. 
 
1.6 Transition Metal Catalyzed B–H Cage Activation of o-Carborane 
Carboranes, polyhedral boron-carbon molecular clusters, have one or more of the BH vertices 
replaced by CH units (Scheme 1.36).[144] Among them, icosohedral 1,2-dicarba-closo-
dodecaborane (o-C2B10H12), which was first reported in 1963,[145] has attracted significant 
attention because of its high symmetry, remarkable stability and subsequent commercial 
availability. This cluster comprises ten boron atoms and two neighboring carbon atoms, and 
each atom is hexacoordinated, featuring 26 delocalized electrons over the entire structure of the 





wide applications as useful functional building blocks in supramolecular design or 
nanomaterials,[147] in medicine as boron neutron capture therapy (BNCT) agents or 
pharmacophores,[148] in organometallic/coordination chemistry[149] and more. Owing to the 
strongly electron-withdrawing character of the o-carborane unit toward carbon substituents, the 
C–H bonds are weakly acidic in this cage (pKa = 22.0)[150] and can be deprotonated with strong 
bases, such as alkyllithium or Grignard reagents. Thus, a larger number of carbon-substituted o-
carboranes have been prepared by the reaction of negatively charged carbon atoms with 
electrophilic reagents (alkylhalides, carbonyl derivatives, and chlorosilanes). In sharp contrast, 
selective functionalization of chemically very similar ten B–H vertices in o-carboranes is very 
challenging and less explored.[151] 
 
Scheme 1.36. Molecular nido-carborane and geometry of o-, m-, p-dicarba-closo-dodecarboranes, IUPAC numbering 
of the cage atoms and their chemical transformations. 
Generally, according to differences in electronegativity and the distance between boron and 
carbon atoms, the 10 B−H bonds of o-carboranes have different electron density, leading to the 
electrophilic substitution reactions of carborane derivatives with the reaction rate B(9,12)–H > 
B(8,10)–H > B(4,5,7,11)–H > B(3,6)–H, which also corresponds to the calculated charge 
distribution on the cage.[152] As charge differences are very small, achieving high regioselectivity 
in these substitution reactions is usually problematic.  
A general strategy for transition metal-catalyzed selective cage B–H functionalization of o-
carboranes involves three principles:[153] (1) electron-rich transition metal catalysts preferably 
functionalize the most electron-deficient B(3,6)–H bonds, which are bonded to both cage 
carbons; (2) electrophilic transition metal catalysts would be appropriate for the functionalization 
of electron-rich B(8,9,10,12)–H bonds (not bonded to any cage carbons); and (3) employing 
directing group with electrophilic transition metal catalysts is essential for B(4,5,7,11)–H 







Scheme 1.37. General strategy for catalytic selective cage B–H functionalization. 
 
1.6.1 Transition Metal-Catalyzed Cage B(3,6)–H Functionalization 
In 1977, a transition metal-catalyzed cage B(3,6)–H deuteration of o-carborane 80 with D2 was 
described by Hawthorne.[154] In 1988, Sneddon developed [Cp*IrCl2]2/Proton Sponge catalyst 
system for the selective cage B(3)–H propenylation of o-carborane with propyne 81 (Scheme 
1.38).[155] A plausible catalytic cycle is proposed in Scheme 1.38, which commences with a 
reduction of complex [Cp*IrCl2]2 to the active iridium(I) species under the reaction conditions. 
Subsequently, oxidative addition of the most electron-deficient cage B(3)–H with the iridium(I) 
species generates the B(3)–Ir intermediate I. Thereafter, propyne 81 insertion followed by 
reductive elimination affords the desired product 82 and regenerates the active iridium(I) catalyst. 
Although only propyne was examined with low reaction efficacy, this example indicated the 






Scheme 1.38. Irridium-catalyzed cage B(3)-propenylation of o-carborane. 
In 2017, the Xie group disclosed an efficient iridium-catalyzed selective cage B(3,6)-diborylation 
of o-carboranes with B2pin2 as coupling partner in THF at 110 °C for 5 h, affording B(3,6)-
diborylated o-carboranes 83A’ in high yields (Scheme 1.39a).[156] Later, a pyridyl-assisted 
rhodium-catalyzed selective B(3)-acyloxylation of o-carboranes and a palladium-catalyzed 
intramolecular B–H/O–H dehydrogenative coupling reaction were reported by Yan[157] and Xie,[158] 
respectively (Scheme 1.39b,c). In addition, Pd/NHC (NHC = N-heterocyclic carbene) catalyzed 
cage B(3,6)-arylation of o-carboranes was achieved by Cao (Scheme 1.39d).[159] Concurrently, 
another phosphine-directed rhodium-catalyzed B(3,6)-diarylation of 1-PAr2-o-carboranes with 
aryl bromides was reported by Chi,[160] offering a series of B(3,6)-diarylated o-carboranes 83D 
(Scheme 1.39d). Inspired by the Sneddon’s work,[155] Xie recently described iridium-catalyzed 
cage B(3,6)-alkenylation of o-carboranes (Scheme 1.39e).[161] A plausible mechanism involving a 
Ir(III/V/III) pathway is proposed for this cage B(3,6)-alkenylation. Thereafter, the same group 
revealed a palladium-catalyzed B(3)-oxidative annulation of 1-hydroxy-o-carborane with internal 
alkynes, leading to facile synthesis of a class of o-carborane-fused oxaboroles 83F in moderate 






Scheme 1.39. Cage B(3,6)–H functionalization of o-carboranes. 
 
1.6.2 Transition Metal-Catalyzed Cage B(4,5,7,11)–H Functionalization 
A general strategy to realize the cage B(4,5,7,11)–H functionalization is introduction of the 
directing group on one of the cage carbon vertices.  
In 2014, Xie disclosed an irridium-catalyzed B(4)–alkenylation of o-carboranes by employing a 
carboxylic acid as the traceless directing group at the cage carbon vertex, generating a range of 
B(4)–alkenylated o-carboranes 85 in high yield with excellent regioselectivity.[163] A plausible 
catalytic cycle is proposed involving a cage B(4)–H activation, followed by alkyne insertion, 
protonation and decarboxylation give the final products 85 (Scheme 1.40a). Later, the same 
group extended this research to B(4,5)-dialkenylation through palladium catalysis (Scheme 
1.40b).[164] Applying a similar methodology, the Lu group synthesized a series of B(4)- and 
B(4,5)-substituted o-carboranes (87A and 87A’) containing α,β-unsaturated carbonyls in 






Scheme 1.40. Cage B(4,5)–H alkenylation of o-carboranes. 





annulation of 1-hydroxyl-o-carboranes 88 with internal alkynes 64 and CO (Scheme 1.41a).[166] 
This protocol provided a new class of C,B-substituted carborano-coumarin derivatives 89 with 
potential applications to pharmaceuticals in moderate to good yields. Although most selective 
cage B–H functionalizations of o-carboranes were catalyzed by noble transition metal catalysts, 
Xie established the unprecedented copper-catalyzed regioselective cage B-H alkyne annulation 
of carboranyl amides 90 with internal alkynes in the presence of a bidentate directing group at 
the cage carbon position, affording previously inaccessible C,B-substituted o-carborane-fused-
pyridone derivatives 91 (Scheme 1.41b).[167] Likewise, terminal alkynes led to dehydrogenative 
B–H/C–H alkynation. The copper(I) complex 92 was isolated, which underwent protonation with 
concentrated hydrochloric acid to afford the B(4)-alkynylated compounds 93. 
 
Scheme 1.41. Cage B(4)–H annulation of o-carboranes 
In 2016, palladium-catalyzed cage B(4,5)-diarylation was accomplished by the treatment of 





glyoxylic acid as a transient directing group for palladium-catalyzed B(4)-arylation or B(4,5)-
diarylation of carboranyl aldehydes 95 or methylamines 97 was also reported by Yan (Scheme 
1.42b).[169] Meantime, with the assistance of an acyl amino directing group at the cage B(9) 
position 99, palladium-catalyzed regioselective B(4)-arylation of o-carboranes with aryl boronic 
acids was achieved by Cao in 2018 (Scheme 1.42c).[170] Importantly, a proof-of-principle study of 
palladium-catalyzed enantioselective intramolecular B–H arylation of o-carboranes 101 was first 








Scheme 1.42. Cage B(4,5)–H arylation of o-carboranes 
In the aforementioned aryl coupling reactions, aryl iodides were employed. In 2017, another 
protocol with atom- and step-economical cross-dehydrogenative coupling of carboranyl 
carboxylic acids 84 with thiophenes was developed in the presence of an iridium catalyst, 
affording B(4)-thienylated o-carboranes 104 in moderate to high yields (Scheme 1.43a).[172] 
Afterwards, this dehydrogenative coupling reaction of o-carboranes was extended to 
(hetero)aryls using a double directing groups strategy. In the presence of iridium(III) catalyst, 
carboranyl carboxylic acids 84 reacted with (hetero)arenes 105 to provide the corresponding 
B(4)-C(sp2) coupling products 106 in high yields (Scheme 1.43b).[173] 
 
 
Scheme 1.43. Cage B(4)–H/C–H dehydrogenative arylation of o-carboranes 
In 2016, two protocols for palladium-catalyzed regioselective cage B(4)-alkynylation of o-
carboranes were established by treatment of carboranyl carboxylic acids 84 with 1 equivalent of 
alkynyl bromides or 2 equivalent of terminal alkynes in the presence of palladium catalyst, giving 





A carboxylic acid directed rhodium-catalyzed B(4,5)-dialkylation of o-carboranes with allylic 
alcohols was described by Lu (Scheme 1.44b).[175] This method was well compatible with various 
aryl-or alkyl-substituted allyl alcohols to provide the corresponding β-aryl or -alkyl ketone 
products 109 in high efficiency. In contrast, B(9)-acyl amino group directed palladium-catalyzed 
B(4)-methylation of o-carboranes with methyl iodide as coupling partner was also described for 
B(4)-alkylation of o-carboranes 111(Scheme 1.44b).[176] Furthermore, a carboranyl carboxylic 
acid-directed rhodium-catalyzed B(4)-hydroxylation with O2 gas was disclosed by Xie, leading to 




Scheme 1.44. Cage B(4,5)-alkynlation, alkylation, oxygenation of o-carboranes 
In 2016, palladium- and ruthenium-catalyzed B(4)-amination of carboranyl carboxylic acids 84 





coupling reaction led to a series of tertiary carboranyl amines 114 and secondary carboranyl 
amines 113 with high functional group tolerance (Scheme 1.45a).[178] Later, Yan reported an 
iridium-catalyzed B(4)-amination of carboranyl carboxylic acids 84 with organic azides and Lee 
disclosed a similar B(4)-amination by employing dioxazolones as the coupling partner and 
rhodium as the catalyst (Scheme 1.45b).[179] 
 
 
Scheme 1.45. Cage B(4,5)-amination of o-carboranes 
 
Recently, Transition metal catalyzed B(4)-halogenation 116, B(4,5)-diiodination 115,[180] B(4)-
homocoupling (118,119)[181] and B(4,5)-disulfenylation 121[182] of o-carboranes were reported by 
the Xie and Cao group, respectively. These protocols have a wide variety of functional group 








Scheme 1.46. Cage B(4,5)-halogenation, homocoupling and disulfenylation of o-carboranes 
With respect to step-economy and bond-forming efficiency, synthetic methods merging multiple 
reaction steps into a simple one-pot process have attracted massive research interests. Thereby, 
a rhodium-catalyzed B(4)–H/C–H cascade cyclization of carboranyl N-arylimines 122 with vinyl 
ketones 49 was developed (Scheme 1.47a).[183] Very recently, a proof-of-concept investigation of 
cascade cross-dehydrogenative coupling featuring two B–H, one C–H and one N–H bonds 
activation was also disclosed. Subsequently, the Xie group extended their studies to include the 
cascade cross-dehydrogenative coupling of carboranyl carboxylic acids 84 with benzoic acids 
56A (Scheme 1.47b).[184] More recently, Lee reported an iridium-catalyzed cyclative indenylation 
of carboranyl carboxylic acids 84 with propargyl alcohols 64, leading to previously unavailable 







Scheme 1.47. Cage B(4,5)-cascade reaction of o-carboranes 
1.6.3 Transition Metal-Catalyzed Cage B(8,9,10,12)–H Functionalization 
Owing to the small differences in electron density at the vertices B(8,9,10,12)–H, palladium-
catalyzed tetrafluorination 129[186] and tetraacetoxylation 137[187] of o-carboranes were described 
by Xie and Cao, respectively (Scheme 1.48a,d). Since then, B(8/9)-chlorination 131,[188] -
alkenylation 132,[189] and -arylation 133[190] were efficiently achieved with the palladium as the 
catalyst by the Cao group (Scheme 1.48b). A breakthrough on regioselective B(8)-arylation of o-









Scheme 1.48. Cage B(8,9,10,12)-halogenation, alkenylation, arylation and tetraacetoxylation of o-carboranes 
1.7 Electrochemical Functionalization of Carboranes 
While significant progress have been realized by the merger of electrocatalysis with 
organometallic C–H activation,[192] electrochemical functionalization of carborane continues to be 
scarce. As early as 2005, Shirokii and Potkin group described the metal-free electrochemical 





electrochemical B–H oxygenation of o-carboranes 90 using a divided cell setup at room 
temperature. This reaction does not require any additional chemical oxidants and generates H2 
and lithium salt as by-products. The control experiments indicate that a high valent copper(III) 
species is likely involved in the electrochemical process (Scheme 1.49).[194] 
 
























During the last decades, transition metal-catalyzed C–H functionalization[18] has emerged as a 
powerful tool for the construction of C–C and C–Het bonds due to the excellent levels of atom-
[195] and step-economy.[196] C–H bonds are ubiquitous in organic compounds, thus, chemo- and 
position-selective functionalizations of C–H bonds are challenging and extremely important. In 
contrast to other 4d transition metal catalysts, such as palladium and rhodium, cost-effective 
ruthenium catalysts[197] are highly desirable for selective C–H activations.  
 
The mechanistic understanding of the fundamental aspects on C–H activation[198] is vital to the 
development of synthetically useful C–H functionalization methods.[21b] In recent years, 
ruthenium(II)-catalyzed C–H activation[198c, 199] has emerged as a transformative tool in molecular 
synthesis, with key applications to drug discovery[200] and agrochemistry.[201] In stark contrast to 
recent findings on rhodium(V)[202] and iridium(V)-catalyzed[119c, 203] C–H activation, detailed 
mechanistic insights into the importance of ruthenium(IV) intermediates in C–H activation 
processes continues to be limited.[204] In this context, a ruthenium(II/IV) manifold enabled C–H 





Scheme 2.1. Ruthenium (II/IV))-catalyzed C–H activation by weak O-coordination 
 
Diketopyrrolopyrroles (DPPs)[205] 143 ‒ relevant small molecules and conjugated semiconducting 
polymers ‒ have attracted the attention of researchers from different areas, including 
optoelectronic materials[206] and bioimaging probes.[207] In comparison to the numerous efforts 
devoted to the modification of the DPP periphery via C–H functionalization or direct arylation 
polymerization (DArP),[208] their de novo assembly leading to π-extended structures continuous 
to be underdeveloped. Thus, ruthenium-catalyzed twofold C–H/N–H activation for sustainable 








Scheme 2.2. Ruthenium (II/IV)-catalyzed double C–H/N–H annulation for diketopyrrolopyroles (DPPs) 144. 
 
 
Recently, the elegant merger of metalla-electrocatalyzed oxidative C–H functionalization without 
expensive and toxic metal oxidants holds the unique power for the resource-economical and 
environmentally-benign molecular construction.[90, 209] Despite considerable progress,[122, 140, 210] 
the development of new catalytic manifolds is still hampered by a lack of mechanistic 
understanding. This holds especially true for ruthenaelectrocatalysis, which continues to be 
underdeveloped. [116-118]  Therefore, another main objective of the thesis is the C–H activation by 













In recent years, transition metal-catalyzed cage B–H activation for the regioselective boron 
functionalization of o-carboranes has emerged as a powerful tool for molecular syntheses.[151] 
However, the electron density of the 10 B–H bonds in o-carboranes are not equal, which results 
in selectivity issues. Despite indisputable progress, efficient approaches for complementary site-
selective functionalizations of o-carboranes are hence in high demand. Therefore, we wish to 




Scheme 2.4. Palladium-catalyzed B(3,4)-arylations. 
Moreover, nitrogen-containing carboranes have received increasing attention in recent years, 
because they possess major potential in drug discovery[211] as well as molecule catalysis.[212] In 
contrast to transition metal-catalyzed regioselective B–H functionalization of closo-carborane, B–
H functionalization of nido-carborane (7,8-C2B9H12-) remains in its infancy.[213] One major 
challenge is represented by the negatively charged cluster, which inhibits the B–H bond from 
undergoing nucleophilic substitutions. While significant recent impetus was gained by the merger 
of electrocatalysis with organometallic C–H activation,[90, 209] electrochemical regioselective cage 
B–H functionalization continues to be scarce,[193-194, 214] Thus, the merger of electrocatalysis with 
B–H functionalization of nido-carborane (7,8-C2B9H12-) should be studied (Scheme 2.5). 
 
 
Scheme 2.5. Electrooxidative cage B–H nitrogenation of nido-carboranes 154. 
While C–S bonds are important structural motifs in various biologically active molecules and 
functional materials,[215] strategies for the assembly of chalcogen-substituted carboranes are 





of thiols to most transition metals, which often leads to catalyst deactivation.[216] Furthermore, 
oxidative cage B/C–H functionalizations largely call for noble transition metal catalysts[170, 217] and 
stoichiometric amounts of expensive chemical oxidants, such as silver(I) salts.[176, 183, 191] Thus, 
we explored the copper-catalyzed electrochemical cage C–H chalcogenations of o-carboranes in 
a dehydrogenative manner, assembling a variety of C-sulfenylated and C-selenylated o-


























3. Results and Discussion 
3.1 Ruthenium(IV) Intermediates in C−H Annulation by Weak O-
Coordination 
The mechanistic understanding of the C–H activation is crucial to develop new type of reactions 
(vide supra). In this regard, we developed the annulations of sulfoxonium ylides 141 with benzoic 
acids 62 to provide an expedient access to diversely decorated isocoumarins with ample scope. 
3.1.1 Optimization and Scope  
Optimization studies on the ruthenium(II)-catalyzed C–H annulation were done by Dr. Yu-Feng 
Liang as shown in Table 3.1.1.[218] We commenced our studies by probing the envisioned redox-
neutral C−H/O−H functionalization of weakly O-coordinating benzoic acid 62 with sulfoxonium 
ylide 141 using [RuCl2(p-cymene)]2 as the catalyst. A base additive was found essential for the 
desired C–H annulation, with NEt3 identified as being optimal (entries 1-5). Interestingly, different 
ruthenium precursors could be employed, highlighting the importance of carboxylate assistance 
(entries 6-8). In contrast, frequently used rhodium, iridium and cobalt complexes fell short in 
delivering the desired product 142 (entries 9-12). 
Table 3.1.1. Optimization of reaction conditions.[a] 
 
Entry Cat. Additive Yield of 3aa [%][b] 
1 [RuCl2(p-cymene)]2 — --- 
2 [RuCl2(p-cymene)]2 NaOAc 30 
3 [RuCl2(p-cymene)]2 Na2CO3 51 
4 [RuCl2(p-cymene)]2 KOtBu 23 
5 [RuCl2(p-cymene)]2 NEt3 76 
6 [RuCl2(p-cymene)]2 NEt3 33[c] 
7 Ru(OAc)2(p-cymene) NEt3 65[c,d] 




8 Ru(O2CMes)2(p-cymene) NEt3 63[c,d] 
9 — NEt3 --- 
10 [Cp*RhCl2]2 NEt3 13 
11 [Cp*IrCl2]2 NEt3 <3 
12 Cp*Co(CO)I2 NEt3 --- 
[a] Reaction conditions: 62a (0.25 mmol), 141a (0.38 mmol), cat. (2.5 mol %), AgSbF6 (10 mol %), additive (0.50 
mmol), DCE (2.0 mL), at 100 °C for 16 h. [b] Yields of isolated products. [c] Without AgSbF6. [d] 5.0 mol % of catalyst. 
 
Utilizing the optimized conditions, we next evaluated the versatility of the redox-neutral 
annulation (Scheme 3.1.1a). Thus, benzoic acids 62 featuring ortho-substituents smoothly 
reacted with sulfoxonium ylides 141. Moreover, mono-C−H functionalization products 142 were 
selectively obtained, when employing Zn(OAc)2 as the Lewis-acid additive. Interestingly, the 
double C−H functionalization products 142i-142r were selectivity generated from meta- and 
para-substituted benzoic acids 62 by the judicious choice of the stoichiometry. Thereby, the 
versatile ruthenium catalysis manifold proved amenable to both electron-rich as well as electron-
deficient arenes 62 (Scheme 3.1.1a). Valuable electrophilic functional groups were fully tolerated. 
Likewise, aryl-substituted sulfoxonium ylides bearing electron-donating or electron-withdrawing 
groups delivered the desired products (142m-142r).  
 
 





Scheme 3.1.1. Ruthenium-catalyzed C–H/O–H annulation with sulfoxonium ylides 141. [a] Zn(OAc)2 (50 mol %). 
 
3.1.2. Proposed Mechanism 
Based on experimental mechanistic studies, a plausible catalytic cycle was proposed in Scheme 
3.1.2. The cyclometalated intermediate B is coordinated by the sulfoxonium ylide 141, leading to 
ruthenium(II) species C. This intermediate C is transformed into key ruthenium(IV) species D by 
α-elimination of DMSO. Insertion with the ruthenium(IV) species generats six-membered 
ruthenacycle E. Finally, proto-demetalation affords the acyclic compound, which undergoes a 
cyclization to get product 142. 

























3.2 Twofold C–H/N–H Annulations towards π-Extended Polyaromatics 
The widespread applications of substituted diketopyrrolopyrroles (DPPs) call for the 
development of efficient methods for their modular assembly. Herein, we developed a novel and 
efficient π-expansion-strategy of DPPs core in a mild and sustainable fashion, employing 
versatile ruthenium catalysis in the process of a C–H activation of DPPs.[219]  
 
3.2.1. Optimization and Scope 
Optimization studies on the ruthenium(II)-catalyzed C–H allylations were done by Dr. Elżbieta 
Gońka.[219] After testing various bases and solvents, the catalytic reaction conditions comprised 
of [RuCl2(p-cymene)]2 (10 mol %), KOAc (1.0 equiv), CuOAc (4.0 equiv) in o-xylene at 100 °C for 
16 h was identified as optimal. With the optimized catalytic conditions in hand, we tested the 
versality of the ruthenium(II)-catalyzed double C–H/N–H annulation of DPP 143 with different 
diaryl alkynes 64 (Scheme 3.2.1). Thereby, π-extended PAHs were accessed from electron-rich 
as well as electron-deficient alkynes in an efficient manner, including sensitive tetra-
bromo/chloro DPPs 144e-144f, which should prove instrumental for further modifications and 
applications of the DPPs 144. The double ruthenium-catalyzed C–H/N–H annulation was not 
restricted to aromatic alkynes. Indeed, the reaction also proceeded well with alkyl alkynes, 
delivering the corresponding products 144g and 144h efficiently. 
 





Scheme 3.2.1. Ruthenium-catalyzed double C–H/N–H annulation with aryl alkynes. 
 




3.2.2. UV-Vis Absorption and Fluorescence Spectroscopy 
The optical properties of the thus-obtained novel compounds 144a–144h were studied by UV-
Vis absorption and fluorescence spectroscopy (Table 3.2.2). The unprecedented DPPs exhibited 
very intense absorption in the UV and visible region, with absorption maxima between 600 – 
640 nm, which results in intense blue to purple color. The absorption maximum in all synthesized 
derivatives is bathochromically shifted in comparison with the previously synthesized, 
unsubstituted compounds,[220] whereas both Stoke shift and absorption coefficient are similar.  
 
Table 3.2.2. Spectroscopic data of π-extended diketopyrrolopyrroles 144a–144h. 
Compound 𝜆𝑚𝑎𝑥
𝑎𝑏𝑠  𝜆𝑚𝑎𝑥
𝑒𝑚  Stokes shift [cm-1] 𝜀𝑚𝑎𝑥[M
-1 cm-1] 
144a 635 645 244 52083 
144b 635 646 268 71946 
144c 632 641 222 66051 
144d 631 640 223 47269 
144e 633 644 270 76626 
144f 633 643 246 76107 
144g 630 639 223 71598 




















3.3 Ruthenaelectro(II/III/I)-Catalyzed Alkyne Annulations 
In this section, a ruthenium-catalyzed electrochemical dehydrogenative annulation reaction of 
imidazoles with alkynes was developed, allowing for the synthesis of various bridgehead 
N−fused [5,6]-bicyclic heteroarenes through regioselective electrochemical C−H/N−H annulation 
without chemical oxidants. Novel aza-ruthena-bicyclo-[3.2.0]-heptadienes were fully 
characterized and identified as the key intermediates for this transformation. Experimental and 
DFT mechanistic studies were suggestive of an oxidatively-induced reductive elimination 
pathway within a ruthenium(II/III) regime.[221] 
 
3.3.1. Optimization and Scope of Alkenyl Imidazole  
The study was commenced by probing various reaction conditions for the envisioned ruthenium-
catalyzed electrooxidative C–H/N–H annulation of alkenyl imidazole 145 with alkyne 64 in an 
operationally simple undivided cell setup equipped with a GF (graphite felt) anode and a Pt 
cathode (Table 3.3.1). After considerable preliminary experimentations, we observed that the 
desired product 146a was obtained by catalytic amounts of [RuCl2(p-cymene)]2, along with KPF6 
as the optimal catalytic additive, and DMF as the best solvent (entries 1-5). The yield was found 
to be reduced when sodium salts were used, such as NaCl and NaPF6 (entries 6-7). Gratifyingly, 
reducing the reaction time to 8 h led to the same yield of product 146a (entry 8). The reaction 
with a Pt anode resulted in a sharp drop in yield (entry 10). The addition of the redox mediator of 
BQ did not improve the performance of the ruthenium catalyst (entries 11-12). Control 
experiments verified the essential role of the electricity, the additive, and the ruthenium catalyst 
(entries 13–15). A set of otherwise typical transition metal catalysts were also probed but gave 
none or significantly reduced amounts of product 146a (entries 16-20). 
 
Table 3.3.1. Optimization of ruthenaelectro-catalyzed annulation.[a] 
 
Entry Catalyst Additive Solvent Yield [%][b] 




1 [RuCl2(p-cymene)]2 KPF6 MeOH 10%[c] 
2 [RuCl2(p-cymene)]2 KPF6 t-AmOH/H2O 12%[d] 
3 [RuCl2(p-cymene)]2 KPF6 DMA 33% 
4 [RuCl2(p-cymene)]2 KPF6 NMP 10% 
5 [RuCl2(p-cymene)]2 KPF6 DMF 75% 
6 [RuCl2(p-cymene)]2 NaCl DMF 50% 
7 [RuCl2(p-cymene)]2 NaPF6 DMF 66% 
8 [RuCl2(p-cymene)]2 KPF6 DMF 75%[e] 
9 [RuCl2(p-cymene)]2 KPF6 DMF 56%[f] 
10 [RuCl2(p-cymene)]2 KPF6 DMF 46%[g] 
11 [RuCl2(p-cymene)]2 KPF6 DMF 33%[h] 
12 [RuCl2(p-cymene)]2 KPF6 DMF 28%[i] 
13 [RuCl2(p-cymene)]2 KPF6 DMF 10%[j] 
14 [RuCl2(p-cymene)]2 --- DMF 50% 
15 --- KPF6 DMF --- 
16 Ru(p-cymene)(OAc)2 KPF6 DMF 53% 
17 Co(OAc)2·4H2O KPF6 DMF --- 
18 [Cp*RhCl2]2 KPF6 DMF 36% 
19 [Cp*IrCl2]2 KPF6 DMF 10% 
20 Pd(OAc)2 KPF6 DMF --- 
[a] Reaction conditions: undivided cell, 145 (0.40 mmol), 64 (0.80 mmol), catalyst (5.0 mol %), additive (20 mol %), 
solvent (4.0 mL), 140 °C, 16 h, constant current at 4.0 mA, GF anode, Pt-plate cathode. [b] Yields of isolated products. 
[c] 60 °C. [d] t-AmOH/H2O = 1/1, 100 °C. [e] 8.0 h. [f] 5.0 h. [g] Pt-plate as anode. [h] BQ (10 mol %). [i] BQ (10 mol %), 
100 °C. [j] no electricity. DMF = N,N-Dimethylformamide, BQ = 1,4-Benzoquinone. 
 
With the optimal reaction conditions in hand, we explored the versatility of the electrochemical 
annulations with diversely decorated alkynes 64 (Scheme 3.1.1). Electron-rich as well as 
electron-poor aromatic moieties at the alkynes 64 were amenable to the ruthenaelectro-
catalyzed C–H functionalizations. Thereby, a variety of synthetically useful electrophilic 
functional groups, such as chloro (146f), cyano (146g) and bromo (146l) substituents, were fully 
tolerated, which should prove invaluable for late-stage manipulations. We next turned our 
attention to diversified alkenyl imidazoles 145. Imidazoles bearing a range of substituents at 
different sites on the alkene or the imidazole were effectively transferable to deliver products 
146m–146q. In addition, benzimidazole substrates with a β-methyl group and without a β-
substituent on the alkene were effective for C–H/N–H activation 146r-146s. Notably, thiophenyl 




substituted benzimidazole also was a competent substrate, giving the corresponding annulation 
product 146t with high efficacy. 
 
Scheme 3.3.1. Scope of the electrochemical C–H/N–H activation with alkynes 64. (146c, 146h, 146i and 146l did by 
Msc. Ralf Steinbock) 







3.3.2. Optimization and Scope of of benzimidazoles  
Next, we investigated the electrooxidative annulation of benzimidazoles 147 with alkyne 64, as 
shown in Table 3.3.2. After considerable optimizations of ruthenium complexes, bases and 
solvents, a catalytic system containing [Ru(p-cymene)Cl2] (5 mol%), KOAc (2.0 equiv) in a 
mixture of solvents of t-AmOH and H2O at 100 °C for 4 h was identified as the ideas reaction 
condition (entry 5). Control experiments highlighted the essential role of the ruthenium catalyst 
and electricity (entries 6-12). 
 
Table 3.3.2: Optimization of Electrochemical annulation with benzimidazole 147.[a] 
 
Entry x y Base Solvent Yield of 148a [%] 
1 0.4 0.8 --- t-AmOH/H2O (3/1, 4 mL)  48%[b] 
2 0.4 0.8 K2CO3 (1 equiv) t-AmOH/H2O (3/1, 4 mL)  46%[c] 
3 0.2 0.4 K2CO3 (1 equiv) t-AmOH/H2O (1/1, 6 mL)  47%[d] 
4 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)  70%[d] 
5 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)  75%[e] 
6 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)    --- [e,f] 
7 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)   24%[e,g] 
8 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)   40%[e,h] 
9 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)   56%[e,i] 
10 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)    --- [e,j] 
11 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)    --- [e,k] 
12 0.2 0.4 KOAc (2 equiv) t-AmOH/H2O (1/1, 6 mL)    --- [e,l] 




[a] Reaction conditions: Undivided cell, 147 (x mmol), 64 (y mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 100 °C, 16 h under 
N2, constant current at 4.0 mA, GF anode, Pt-plate cathode, isolated yields. [b] KPF6 (20 mol %) as additive. [c] 10 h. [d] 
8 h. [e] 8 mA, 4 h. [f] no catalyst. [g] no current. [h] Pt instead of GF. [i] [Cp*RhCl2]2 (5.0 mol %) as catalyst. [j] Pd(OAc)2 
(10 mol %) as catalyst. [k] Co(OAc)2·4 H2O (10 mol %) as catalyst. [l] [Cp*IrCl2]2 (5.0 mol %) as catalyst. 
 
With the best conditions in hand, we next investigated the generality of the metalla-
electrocataylsis by the assembly of the benzimidazoisoquinoline skeleton 148 through 
annulation of alkynes 64 with 2-arylimidazoles 147 (Scheme 3.3.2). Substitutions at the 2-aryl 
group and the benzimidazole gave the desired benzimidazoisoquinolines (148b-148q). Likewise, 
2-naphthylbenzimidazole and 2-phenylnaphthoimidazole also afforded the corresponding 
products (148j,148k). The unsymmetrical 1-phenyl-1-propyne gave the product 148n with a high 
level of regioselectivity. Importantly, chloro, bromo, ester, amide and enolizable ketone 
substituents were thereby fully tolerated to deliver products 148f-148g, 148o-148q. 
 
 Scheme 3.3.2. Electrochemical C–H/N–H activation with alkynes 64. (148d, 148f, 148h and 148n did by Msc. Ralf 
Steinbock) 




3.3.3 Mechanistic Studies  
3.3.3.1 H/D Exchange and Competition Experiments 
The optimized reaction was conducted in the presence of the cosolvent CD3OD and D2O. A H/D 
scrambling was observed in the reisolated substrate 145a and the product 146a, which 
suggested a reversible C–H cleavage, occurring by an organometallic C–Ru bond formation 
(Scheme 3.3.3.1a). Intermolecular competition experiments showed a slight preference for 
electron-poor alkynes 64 and electron-rich arenes 147 (Scheme 3.3.3.1b). 
 
Scheme 3.3.3.1. Mechanistic studies. (Competition experiments did by Msc. Ralf Steinbock) 





3.3.3.2 Isolation and Characterization of Ruthenium(II) Intermediate 
Next, we probed the isolation of intermediates by stoichiometric experimentation. Thus, we first 
selectively prepared the ruthenacycle Ru-II (Scheme 3.3.3.2a). Second, the ruthenacycle Ru-II 
delivered the unprecedented aza-ruthena(II)-bicyclo-[3.2.0]-heptadienes Ru-IVa and Ru-IVb 
upon stoichiometric reaction with the alkynes 64. Ru-IVa and Ru-IVb were unambiguously 
characterized by X-ray diffraction analysis. Notably, the metallacyles Ru-II and Ru-IV proved 
also to be competent under catalytic reaction conditions (Scheme 3.3.3.2b). It is noteworthy that 
the aza-ruthena(II)-bicyclo-[3.2.0]-heptadiene Ru-IVa was stable, but gave the product 146a 
under electrolysis, being suggestive of an oxidation-induced reductive elimination within a 









Scheme 3.3.3.2. Isolation and characterization of ruthenium(II) complexes. (a) ruthenium complex synthesis; (b) 




3.3.3.3 Cyclic Voltammetry Studies of Ruthenium(II) Intermediate 
Furthermore, we probed the electrochemical C–H activation by means of cyclovoltammetric 
analysis of the well-defined ruthenacycles along with Msc. Alexej Scheremetjew in the 
Ackermann group (Scheme 3.3.3.3). Thus, we observed at ambient temperature an irreversible 
oxidation of the ruthenium(II) complex Ru-II at Ep = 0.60 V vs. SCE. The aza-ruthena(II)-bicyclo-
[3.2.0]-heptadiene Ru-IVa featured a considerably higher oxidation wave at Ep = 1.20 V vs. SCE, 
both of which could be rationalized by an oxidation-induced reductive elimination within a 
ruthenium(II/III) regime. 
































Scheme 3.3.3.3. Cyclic voltammetry in DMF with 100 mm KPF6 under N2 at 100 mV/s of Ru-II (5 mM) and Ru-V (5 
mM). CV was performed by Msc. Alexej Scheremetjew. 
 
 
3.3.3.4 Proposed Mechanism 
Finally, based on our mechanistic studies, we proposed a plausible catalytic cycle to commence 
by a fast organometallic C–H activation (Scheme 3.3.3.4). Thereby, ruthena(II)cycle Ru-II is 
generated. Thereafter, alkyne 64 coordination and migratory insertion furnish the aza-ruthena-
bicyclo-[3.2.0]-heptadiene Ru-IV, which undergoes anodic oxidation to deliver the ruthenium(III) 
complex Ru-V. Subsequent pericyclic ring opening yields ruthenium(III) complex Ru-VI. 
Oxidation-induced reductive elimination forms ruthenium(I) complex Ru-VII, which is anodically 
reoxidized to release the product and regenerate ruthenium(II) catalyst. 


























3.4 Regioselective B(3,4)–H Arylation of o-Carboranes  
Significant progress has been achieved in the regioselective functionalization of o-carboranes 
(vide supra). Despite indisputable advances,[151] efficient approaches for complementary site-
selective functionalizations of o-carboranes are hence in high demand. Thus, metal-catalyzed 
position-selective B(3,4)−H functionalizations of o-carboranes has thus far not been reported. In 
this chapter, a palladium-catalyzed regioselective di- or mono-arylation of o-carboranes was 
achieved by weakly coordinating amides at room temperature.[222] Thereby, a series of B(3,4)-
diarylated and B(3)-monoarylated o-carboranes anchored with valuable functional groups were 
accessed for the first time. This strategy provided an efficient approach for the selective 
activation of B(3,4)–H bonds for functionalizations of o-carboranes. 
 
 
3.4.1. Optimization and Scope of B(3,4)–H Arylation of o-Carboranes   
Optimization studies on the palladium-catalyzed B(3,4)–H arylation were initially performed by Dr. 
Yu-Feng Liang[222] and after testing various additives and solvents, catalytic reaction conditions 
comprised of Pd(OAc)2 (10 mol %), AgTFA (2.0 equiv) and TFA (1.0 equiv.) in HFIP at room 
temperature for 16 h were identified as optimal for the uncommon B(3,4)-di-arylated product 150. 
While replacing AgTFA with Ag2CO3 resulted in the formation of B(3)−H mono-arylation product 
153 as the major product. With the optimized reaction conditions in hand, Dr. Yu-Feng Liang 
probed the scope of the B−H di-arylation of o-carboranes 149 with different aryl iodides 19a 
(Scheme 3.4.1.1). The versatility of the room temperature B(3,4)−H di-arylation was 
demonstrated by tolerating valuable functional groups, including bromo (150c), chloro (150d, 
150f), and enolizable ketone (150e) substituents. 





Scheme 3.4.1.1. Palladium-catalyzed B(3,4)-diarylation carried out by Dr. Yu-Feng Liang. 
 
Next, we explored the effect exerted by the N-substituent at the amide moiety (Scheme 3.4.1.2). 
Tertiary amides 151 proved to be suitable substrates with optimal conditions. The effect of 
varying the cage carbon substituents R1 on the reaction was also probed, and both aryl and alkyl 
substituents gave the B−H arylation products 152a-152g. 
 





Scheme 3.4.1.2. Palladium-catalyzed B(3,4)-diarylation with different o-carboranes. (152c did by Becky Bongsuiru Jei) 
 
Thereafter, the robustness of the palladium-catalyzed B−H functionalization was subsequently 
investigated by Dr. Yu-Feng Liang and Becky Bongsuiru Jei for the challenging catalytic B−H 
monoarylation of o-carboranes (Scheme 3.4.1.3). The B(3)−H monoarylation proceeded 
smoothly with valuable functional groups, featuring aldehyde (153d) bromo (153c) and nitro 
(153b) substituents, which allow for invaluable further late-stage manipulation. 
 





Scheme 3.4.1.3. Palladium-catalyzed B(3)-arylation. (153a, 153b and 153d did by Dr. Yu-Feng Liang. 153c did by 
Becky Bongsuiru Jei) 
 
 
3.4.2 Proposed Mechanism 
A plausible reaction mechanism is proposed to commence by an organometallic B(3)–H 
activation of 149 by weak assistance of the amide group and AgTFA to form cationic 
intermediate I (Scheme 3.4.2). Oxidative addition with ArI 19a affords proposed palladium(IV) 
cationic intermediate II, followed by reductive elimination to give the B(3)-mono-arylation product 
153. Subsequent B(4)-arylation occurs assisted by the weakly-coordinating amide to generate 
the B(3,4)-di-arylation product 150. Due to the innate reactivity of the B(4)–H bond in 153, which 
is inherently higher than that of the B(6)–H bond, the B(3,6)-di-arylation product is not formed. 
 


























3.5 Electrochemical B–H Nitrogenation of nido-Carboranes 
While the use of electricity as a redox reagent to facilitate chemical reactions has been 
recognized as an increasingly viable and environmentally-friendly strategy,[90, 209] the merger of 
electrosynthesis with cage B–H functionalization of carboranes continues to be scarce. In this 
context, we have developed a strategy for unprecedented electrochemical regioselective cage 
B–H nitrogenation of nido-carborane in a dehydrogenative manner, assembling a variety of N-
heterocycle-, amino acid- and BODIPY-labeled nido-carboranes.[223] 
 
3.5.1 Optimization and Scope 
The study was started by probing various reaction conditions for the envisioned electrochemical-
catalyzed B–N coupling of nido-carborane 154 with pyridine 155 at room temperature in an 
operationally simple undivided cell setup equipped with a GF (Graphite Felt) anode and a Pt-
plate cathode (Table 3.5.1). After considerable preliminary experimentation, we were delighted to 
observe that the desired B-pyridine nido-carborane product 156 was obtained in 60% yield in 
DME/H2O as the reaction medium (entries 1-4). Further electrolyte optimization indicated that 
NMe4Cl was best (entries 5-7). Increasing the amount of H2O to 1.0 mL led to a significant 
decrease in the yield (entries 8-9), while reducing it to 0.2 mL increased the catalytic efficiency to 
83% isolated yield of product 156 (entry 10). Control experiments confirmed the essential role of 
the H2O, the electricity, the NMe4Cl additive and the GF as the anode material (entries 11-16).  
 
Table 3.5.1: Optimization of the reaction conditions.[a] 
 
Entry Electrolyte Solvent Yield [%][b] 
1 --- MeOH/H2O  8%[c] 
2 --- THF/H2O  36%[c] 
3 --- CH3CN/H2O  40%[c] 
4 --- DME/H2O  60%[c] 
5 nBuNPF6 DME/H2O  20%[c] 




6 nBuNBF4 DME/H2O  63%[c] 
7 NMe4Cl DME/H2O  65%[c] 
8 NMe4Cl DME/H2O 32%[d] 
9 NMe4Cl DME/H2O  50%[e] 
10 NMe4Cl DME/H2O  87% (83%)[f] 
11 NMe4Cl DME  10% 
12 NMe4Cl DME/H2O  ---[g] 
13 --- DME/H2O  67% 
14 KCl DME/H2O  75% 
15 NaCl DME/H2O  70% 
16 NMe4Cl DME/H2O 73%[h] 
[a] Reaction conditions: 154 (0.10 mmol), 155 (0.30 mmol), electrolyte (2 equiv.), DME (4.0 mL), H2O (0.2 mL), 25 °C, 
3 h. [b] Yield was determined by 1H NMR with CH2Br2 as the standard. [c] H2O (0.5 mL). [d] H2O (1.0 mL). [e] DME 
(5.0 mL), H2O (1.0 mL). [f] Isolated yields in parenthesis. [g] No electricity. [h] Pt-plate as anode. DME = 1,2-
Dimethoxyethane, THF = Tetrahydrofuran. 
 
With the optimized reaction conditions in hand, we probed its versatility for the B−N coupling of 
nido-carboranes 154 with different N-heterocyclic substrates 155 (Scheme 3.5.1.1). Electron-rich 
as well as electron-deficient groups on the pyridine 155 were amenable to the electrocatalyzed 
B−H oxidation coupling, providing the corresponding products in good to excellent yields (156a-
156m). Thereby, a variety of synthetically useful functional groups, such as ester (156h), amide 
(156i), chloro (156j) and bromo (156k), were fully tolerated, which could prove instrumental for 
further late-stage manipulations. In addition, various isoquinolines (155n-155q) and even the 
carbazole-substituted pyridine (155r), afforded the corresponding electro-oxidative B−N coupling 
product in good to excellent yields (156n-156r). Notably, the free NH2-amino group (155d, 155l) 
was also tolerated under the mild electro-oxidative conditions, although the amine-substituted 
and Boc-protected amino isoquinoline products (156p-156q) were isolated in somewhat lower 
yields. Interestingly, the Steglich catalyst 4-dimethylaminopyridine (DMAP) was also a 
competent pyridine derivative in the electrochemical reaction, providing the DMAP decorated 
nido-carborane product (156m) with good efficacy.  
The robustness of the electrooxidative B−N formation at room temperature was next evaluated 
by other N-heterocyclic substrates, such as imidazole with N = 11.47 in MeCN according to the 
Mayr’s scale,[224] N-substituted derivatives of imidazoles, thiazole and azaindoles, giving the 
corresponding B−N products in good to excellent yields (156s-156aa). In  addition, dialkyl 




substituted nido-carboranes at the C(cage) site also proceed well under these electrochemical 
conditions, providing the corresponding B−N coupling products in good yields (156bb-156cc). 
Thus, the oxidant- and catalyst-free electrochemical oxidative B−N coupling provides a new 
route to a convenient and versatile synthesis of N-heterocycle-substituted nido-carboranes.  
 
Scheme 3.5.1.1. Electrooxidative B−H nitrogenation of nido-carborane with N-heterocycles. (156b-156g, 156i-156k, 
156q, 156s, 156t and 156x-156aa did by Becky Bongsuiru Jei) 






Encouraged by the unique efficiency of the electrocatalyzed metal-free B−N oxidative coupling 
with various N-heterocyclic substrates, we became intrigued to explore the late-stage amino acid 
and BODIPY diversification of structurally complex nido-carboranes (Scheme 3.5.1.2). Both 
amino acid- and BODIPY-labeled pyridine proved to be suitable substrates (157a-157e).  
 
 
Scheme 3.5.1.2. Electrooxidative B−H nitrogenation of nido-carborane with amino acids and BODIPY pyridines. 








The strategy was not restricted to intermolecular transformations. Actually, the intramolecular 
B−N couplings of nido-carborane 158 was likewise accomplished (Scheme 3.5.1.3), and either 
aryl or alkyl substituents at the cage-carbon site afforded comparable results (159a, 159b). 
 
 
Scheme 3.5.1.3. Electrooxidative intramolecular B−N annulation. 
 
3.5.2 Competition Experiments 
The high efficacy of the electrocatalyzed B−H activation for the synthesis of N-heterocyclic nido-
carboranes motivated us to delineate its mode of action. Thus, an intermolecular competition 
experiment between pyridine and imidazole revealed a slight preference for pyridine, likely due 
to the higher nucleophilicity of pyridine when compared to imidazole (pyridine: N = 11.05 in H2O, 
imidazole: N = 9.63 in H2O)[224] (Scheme 3.5.2).  
 
 
Scheme 3.5.2. Competition experiments. 
 




3.5.3 Cyclic Voltammetry and Stability of 156a 
Furthermore, we probed the electrochemical B−H activation by means of cyclovoltammetric 
analysis of the nido-carborane along with Msc. Alexej Scheremetjew in the Ackermann group 
(Scheme 3.5.3). Thus, we observed an irreversible oxidation of the nido-carborane at Ep/2 = 0.56 
V vs. Ag/Ag+ at ambient temperature, which is indicative of a direct oxidation of the nido-
carborane under electrochemical condition. Furthermore, the calculated half-wave oxidation 
potential of 154a using DFT computation by Dr. Rositha Kuniyil at the B97D3/def2-QZVP+ 
CPCM(DME)//B97D3/def2-TZVP level of theory is in good agreement with the one observed in 
our CV studies (exp: Ep/2= 0.87 V vs. SCE, calc: E1/2= 0.86 V vs. SCE). Then, we also analyzed 
the thermal and chemical stability of 156a. We found that compound 156a (0.4 mL DMSO-d6) 
was quite stable when being heated to 120 °C for 10 h with only minor decomposition. In 
addition, the solution of 156a (0.4 mL CD3CN) was treated with 0.1 mL H2O, HCl, or NaOH, 
respectively. To this end, the 11B NMR experiments demonstrate that 156a has an excellent 
stability in a neutral environment, however, it is not stable in strongly acidic or alkaline 
environments.  
































 154a + 155a
 156a
 
Scheme 3.5.3. Cyclic voltammograms at 100 mV/s, nBu4NPF6 (0.1M in DME), concentration of substrates 1.0 mM. 
CV was performed by Msc. Alexej Scheremetjew. 
 
 




3.5.4 Spectroscopic Data of BODIPY-Labelled nido-Carborane 
The optical properties of the thus-obtained novel BODIPY-labeled nido-carborane 157d and 
157e were studied in detail by UV-Vis absorption and fluorescence spectroscopy in various 
solvents (Table 3.5.4). The unprecedented BODIPY-labeled nido-carboranes exhibited very 
intense absorption in the UV and visible region, with an absorption maximum between 507–
582 nm and high Stokes shift, resulting in an intense red to purple color. This could be 
rationalized by the possible donor–acceptor–donor structure of the compounds 157d and 157e, 
as the nido-carborane core is an electron acceptor. These spectroscopic data indicated the 
unique potential applications of the BODIPY-labeled nido-carborane compounds in 
pharmaceuticals, luminescent materials and bioimaging. 
 
Table 3.5.4. Spectroscopic data of BODIPY-labelled nido-carboranes 157d and 157e. 
 





DCM 512 569 1956 68812 
CHCl3 513 567 1856 69790 
Actone 507 559 1834 73746 
DMF 509 561 1821 69557 





DCM 577 634 1558 63459 
CHCl3 582 640 1557 60882 
Actone 570 623 1492 65681 
DMF 574 602 810 58557 




3.5.5 Proposed Mechanism 
Based on CV analysis and literature reports,[225] a plausible reaction mechanism is proposed in 
Scheme 3.5.5, which commences with an anodic single electron-transfer (SET) process from 
nido-carborane ainon to form intermediate I, followed by the oxidation to generate intermediate II. 
Subsequently, deprotonation of the bridge proton results in the formation of cage-open 
carborane intermediate III. Finally, the pyridine undergoes nucleophilic attack on the electron 




deficient B(9/11)–H site of the intermediate III with consecutive transfer of H to the B(10) and 
B(11) forming a new bridge proton. In addition, molecular H2 is generated as the by-product 
through cathodic proton reduction, which was confirmed by head-space GC analysis. 
 





















3.6 Cupraelectro-Catalyzed Chalcogenations of o-Carboranes 
In this section, we will disclose copper-catalyzed electrochemical direct chalcogenations of o-
carboranes at room temperature. Thereby, a series of cage C-sulfenylated and C-selenylated o-
carboranes anchored with valuable functional groups were accessed with high levels of position- 
and chemo-selectivity control. The cupraelectrocatalysis provided efficient approaches to 
activate otherwise inert cage C–H bonds for the late-stage diversification of o-carboranes. 
 
3.6.1 Optimization and Scope 
We commenced our studies by probing various reaction conditions for the envisioned copper-
catalyzed cage C−H thiolation of o-carborane in an operationally simple undivided cell setup 
equipped with a GF (graphite felt) anode and a Pt cathode (Table 3.6.1). After extensive 
experimentation, we observed that the thiolation of substrate 160 proceeded efficiently with 
catalytic amounts of CuOAc and 2-phenylpyridine in the presence of LiOtBu as the base, n-
Bu4NI as the electrolyte at room temperature under a constant current of 2 mA (entry 1). The 
yield was reduced when other copper sources or additives were used (entries 2-5). Surprisingly, 
n-Bu4NPF6 as the electrolyte failed to facilitate the carborane modification, indicating that n-
Bu4NI operates not only as electrolyte, but also as a redox mediator (entry 6). Altering the 
stoichiometry of the electrolyte or using KI did not improve the performance (entries 7,8). 
Product formation was not observed, when the reaction was conducted with DCE as the solvent, 
while CH3CN resulted in a drop of the catalytic performance (entries 9,10). Control experiments 
confirmed the essential role of the electricity and the catalyst (entries 11,12), while a sequential 
procedure was found to be beneficial (entries 13-15). 
 








Entry Deviation from standard conditions Yield [%][b] 
1 none 90% (85%)[c] 
2 Cu(OAc)2 instead of CuOAc 51% 
3 CuI instead of CuOAc 43% 
4 2,6-Lutidine instead of 2-PhPy 71% 
5 1,10-Phen instead of 2-PhPy 16% 
6 TBAPF6 instead of TBAI --- 
7 TBAI (3 equiv.) 49% 
8 KI (1 equiv) as additive 67% 
9 DCE instead of THF --- 
10 CH3CN instead of THF 49% 
11 No electricity 14%[d] 
12 No [Cu] --- 
13 Procedure B (161b) 66% (62%)[e,d] 
14 Procedure B: second step without electricity (161b) ---[f] 
15 Procedure B (161a) 92%[e] 
[a] Reaction conditions: Procedure A: 160a (0.10 mmol), 161a (0.3 mmol), CuOAc (15 mol %), 2-PhPy (15 mol %), 
LiOtBu (0.2 mmol), TBAI (2.0 equiv.), solvent (3.0 mL), platinum cathode (10 mm × 15 mm × 0.25 mm), graphite felt 
(GF) anode (10 mm × 15 mm × 6 mm), 2 mA, under air, rt, 16 h. [b] Yield was determined by 1H NMR with CH2Br2 as 
the internal standard. [c] Isolated yields in parenthesis. [d] KI (1.0 equiv) as additive. [e] Procedure B: 161a (0.3 mmol), 
LiOtBu (0.2 mmol), TBAI (2.0 equiv), solvent (3.0 mL), 2 mA, rt, 3 h, then adding 160a (0.10 mmol), 2-PhPy (15 
mol %), CuOAc (15 mol %), 2 mA, rt, 16 h. [f] 161b (0.3 mmol), LiOtBu (0.2 mmol), KI (1.0 equiv.), TBAI (2.0 equiv.), 
solvent (3.0 mL), 2 mA, rt, 3 h, then adding 160a (0.10 mmol), 2-PhPy (15 mol %), CuOAc (15 mol %), rt, 16 h.  
With the optimized reaction conditions in hand, we explored the versatility of the cage C−H 
thiolation of o-carborane 160a with different thiols 161 (Scheme 3.6.1.1). Electron-rich as well as 
electron-deficient substituents on the arenes were found to be suitable for the electrocatalyzed 
C−H activation, providing the corresponding thiolation products 162a-162o in good to excellent 
yields. Thereby, a variety of synthetically useful functional groups, such as fluoro (162e and 
162m), chloro (162f, 162k, and 162n) and bromo (162g and 162l), were fully tolerated, which 
should prove instrumental for further late-stage manipulations. Various disubstituted aromatic 
and heterocyclic thiols afforded the corresponding cage C−S modified products 162p-162s. 
Notably, aliphatic thiols efficiently underwent the electrochemical transformation to provide the 
corresponding cage alkylthiolated products 162t-162u. 







Scheme 3.6.1.1. Electrochemical C−H thiolation of o-carborane. [a] Procedure B. [b] KI (1 equiv.). [c] CuI as the catalyst. 
(162c-162d, 162g-162h, 162j-162l, 162n, 162p-162r, 162t did by Becky Bongsuiru Jei) 
 
 




Encouraged by the efficiency of the cupraelectro-oxidative cage C−H thiolation, we became 
intrigued to explore the chalcogenantion of differently-decorated o-carboranes 160 (Scheme 
3.6.1.2). Electronically diverse o-carboranes 160 served as competent coupling partners, giving 
the corresponding thiolation products (163a-163e) with high levels of efficacy in a position-
selective manner. The strategy was not restricted to phenyl-substituted o-carboranes. Indeed, 
substrates bearing benzyl and even alkyl groups also performed well to deliver the desired 
products 163f-163i. It is noteworthy that the C−H activation approach was also compatible with 
selenols to give the o-carborane 163j. 
 
 
Scheme 3.6.1.2. Electrochemical C−H chalcogenation of o-carboranes. [a] Procedure B. [b] KI (1 equiv.). (163a, 163c, 
163d and 163e did by Becky Bongsuiru Jei) 





3.6.2 Late-stage Functionalization 
Next, late-stage functionalization of the thus obtained carborane 162g was studied. 
Sonogashira-Hagihara coupling of carborane 162g with trimethylsilylacetylene gave the 
alkynylated derivative 164a (Scheme 3.6.2). Buchwald-Hartwig amination of carborane 162g 
with carbazole selectivity resulted in the formation of amine 164b, which offers a new route to 
cage C-substituted carborane-based host materials for possible applications to phosphorescent 
organic light-emitting diodes.[226] 
 
 
Scheme 3.6.2. Late-stage diversification. 
 
3.6.3 Control Experiments and Cyclic Voltammograms 
The high efficacy of the cupraelectro-catalyzed cage C−H chalcogenation motivated us to 
delineate the mode of action. To this end, control experiments were performed (Scheme 3.6.3a). 
First, electrocatalysis in the presence of TEMPO or Ph2C=CH2 gave the desired product 162a. 
Second, the cupraelectrocatalysis occurred efficiently in the dark. Third, detailed 




cyclovoltammetric analysis of the thiol and iodide mediator by Msc. Alexej Scheremetjew 
(Scheme 3.6.3b) showed an irreversible oxidation of the thiol anion at Ep = -0.62 V vs. Ag/Ag+ 
and two oxidation events for the iodide at Ep = 0.12 V vs. Ag/Ag+ and Ep = 0.44 V vs. Ag/Ag+, 
which is in agreement with the literature reported iodide oxidation potential[227] and suggestive of 
the preferential oxidation of the iodide as redox mediator. Moreover, the use of n-Bu4NI as a 




Scheme 3.6.3. Control experiments and cyclic voltammograms. CV studies did by Msc. Alexej Scheremetjew. 





3.6.4 Proposed Mechanism 
Based on the findings, a plausible reaction mechanism is proposed in Scheme 3.6.4, which 
commences with an anodic single electron-transfer (SET) oxidation of the thiol anion E to form 
the sulfur-centered radical F. Subsequently, the copper(I) species A reacts with the sulfur radical 
F to deliver copper(II) complex B, which next reacts with o-carborane 160a in the presence of 
LiOtBu to generate a copper(II)-o-carborane complex C. Thereafter, the complex C is oxidized 
by the anodically generated redox mediator I2 to furnish the copper(III) species D, which 
subsequently undergoes reductive elimination, affording the final product and regenerating the 
catalytically active complex A. Alternatively, the direct oxidation of copper(II) complex C by 
electricity to generate copper(III) species D can not be excluded at this stage. 
 
 











4. Summary and Outlook 
The development of highly step- and atom-economical C–H, and B–H activations by inexpensive 
and Earth-abundant metals has emerged as an increasingly powerful tool in molecular 
syntheses. The selective functionalization of otherwise inert C–H bonds remains a big challenge 
due to the ubiquitous C–H bonds in organic compounds. Despite remarkable advances in the 
field, most of the reported approaches largely relied on precious metal catalysts, harsh reaction 
conditions and the necessity of stoichiometric amounts of chemical oxidants, compromising the 
overall sustainability of the strategy.  In this thesis, new methods have been developed for 
sustainable selective C–H activation and cage B–H/C–H activation of carboranes by cost-
effective ruthenium, ruthenaelectro-catalysis and cupraelectro-catalysis. 
In the first part, we have unraveled ruthenium(IV) complexes as key intermediates in redox-
neutral C–H/O–H activation of benzoic acid with easily-accessible sulfoxonium ylides by weak 
O-coordiantion. Base on the experimental and computational studies, a ruthenium(II/IV) catalysis 
manifold was proposed for the synthesis of various isocomarin derivatives (Scheme 4.1a). 
Furthermore, a new strategy towards the synthesis of π-extended DPPs was presented that 
employed sustainable, inexpensive, and widely applicable ruthenium catalysis. This method 
allowed for the rapid synthesis of new DPP derivatives, featuring various substituents on the 
ethylene bridge (Scheme 4.1b). 
 
Scheme 4.1. Ruthenium-catalyzed annulations. 




In contrast to the chemical oxidative C–H functionalizations, electrocatalytic C–H activations 
employ electricity as the redox reagent to replace toxic and expensive chemical oxidants, which 
has been recognized as an increasingly viable, environmentally-friendly strategy and closely 
related to the trend of atom- and step-economy.  
In the second part, we have reported on the electrocatalytic organometallic C–H/N–H 
functionalization of imidazoles (Scheme 4.2). Novel aza-ruthena-bicyclo-[3.2.0]-heptadienes 
were isolated and identified as the key intermediates, setting the stage for alkyne annulations 
from synthetically meaningful alkenyl and aryl imidazoles with ample scope. The C–H activation 
employed electricity as the only oxidant and generated molecular hydrogen as the sole 
byproduct. Mechanistic studies by experiment and DFT provided strong support for an oxidation-
induced reductive elimination of aza-ruthena-bicyclo-[3.2.0]-heptadienes by environmentally-
benign electricity. These findings should prove instrumental for the mechanistic understanding 
and design of ruthenium(II)-catalyzed oxidative C–H activations. 
 
 
Scheme 4.2. Ruthenaelectro(II/III/I)-catalyzed alkyne annulations. 
 
In the third part, we described the cage B–H/C–H functionalizations of carboranes.  
First, a palladium-catalyzed direct arylations at cage B(3,4) positions in o-carboranes has been 
achieved at room temperature with the aid of weakly-coordinating, synthetically useful amides 
(Scheme 4.3). Thus, palladium-catalyzed B–H activations enabled the assembly of a variety of 
arylated o-carboranes. This method featured high position-selectivity, high tolerance of functional 
groups, and mild reaction conditions, thereby offering a platform for the design and synthesis of 
boron-substituted o-carboranes. Our findings offered a facile strategy for selective activations of 




B(3,4)–H bonds, which will be instrumental for future design of optoelectronics nanomaterials, 
and boron neutron capture therapy agents. 
 
Scheme 4.3. Palladium(II)-catalyzed B(3,4)–H arylation of o-carboranes. 
 
Second, metal-free electrocatalyzed direct B–N oxidative couplings of nido-carborane with N-
heterocyclic compound have been achieved at room temperature with molecular hydrogen as 
the sole by-product (Scheme 4.4). This method featured mild reaction conditions and high 
tolerance of functional groups leading to various amino acid- and BODIPY-labeled nido-
carboranes, thereby offering a new platform for the design and synthesis of N-substituted nido-
carborane by environmentally-benign electricity. A plausible mechanism was established by 
cyclic voltammetry studies and computation. The thus-obtained BODIPY-labeled nido-carborane 
displayed enhanced spectroscopic features. 
 
 
Scheme 4.4. Electrocatalzed B–H nitrogenation of nido-carboranes. 




Last, an efficient and operationally-benign electrocatalytic organometallic cage C–H 
chalcogenation of o-carboranes with thionols and selenols has been achieved at room 
temperature. This strategy featured mild reaction conditions and high tolerance of functional 
groups, leading to the facile assembly of a series of o-carboranes, thereby offering a new 
platform for the design of cage C–S/Se substituted o-carboranes by environmentally-sound 
electricity. A plausible mechanism was established by control experiments and detailed 
cyclic voltammetry studies. Our findings should prove instrumental for the further development of 
decorated carboranes and boron clusters by molecular electrocatalysis. 
 
 























5. Experimental Section 
5.1 General Remarks 
Catalytic reactions under an atmosphere of air were conducted in the sealed tubes or Schlenk 
tubes. Unless otherwise noted, other reactions were performed under N2 atmosphere using pre-
dried glassware and standard Schlenk techniques. 
If not otherwise noted, yields refer to isolated compounds, estimated to be >95% pure as 
determined by 1H NMR.  
Vacuum 
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
Melting Points (M.p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. The reported values are uncorrected. 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were visualized 
under UV-light. Chromatographic purification of products was accomplished by flash column 
chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 mm). 
Gas Chromatography (GC)  
The conversions of the reactions were monitored by applying coupled gas 
chromatography/mass spectrometry using G1760C GCDplus with mass detector HP 5971, 5890 
Series II with mass detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with 
mass detector 5975C (Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with 
HP-5MS columns (30 m × 0.25 mm × 0.25 m). 
Gel Permeation Chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped with two 
sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 20.000; 
internal diameter = 20 mm; length = 600 mm; Flush rate = 10.0 mL/min and chloroform (HPLC-
quality with 0.6% ethanol as stabilizer) was used as the eluent. 





Infrared spectra were recorded with a BRUKER Alpha-P ATR FT-IR spectrometer. Liquid 
samples were measured as a film, solid samples neat. The analysis of the spectra was carried 
out using the software from BRUKER OPUS 6. The absorption was given in wave numbers 
(cm−1) and the spectra were recorded in the range of 4000–400 cm‒1.  
Mass Spectrometry  
Electron-ionization (EI) mass spectra were recorded on a Jeol AccuTOF instrument at 70 eV. 
Electrospray-ionization (ESI) mass spectra were obtained on Bruker micrOTOF and maXis 
instruments. All systems were equipped with time-of-flight (TOF) analyzers. The ratios of mass 
to charge (m/z) were reported and the intensity relative to the base peak (I = 100) is given in 
parenthesis.  
Nuclear Magnetic Resonance Spectroscopy (NMR)  
Nuclear magnetic resonance (NMR) spectra were recorded on VARIAN Inova 500, 600, VARIAN 
Mercury 300, VX 300, VARIAN Avance 300, VARIAN VNMRS 300 and BRUKER Avance III 300, 
400 and HD 500 spectrometers. All chemical shifts were given as δ-values in ppm relative to the 
residual proton peak of the deuterated solvent or its carbon atom, respectively. 1H and 13C NMR 
spectra were referenced using the residual proton or solvent carbon peak (see table), 
respectively. 13C and 19F NMR were measured as proton-decoupled spectra. 
 1H NMR 13C NMR 
CDCl3 7.26 77.16 
[D]6-DMSO 2.50 39.52 
The observed resonance-multiplicities were described by the following abbreviations: s (singlet), 
d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet) or analogous representations. The 
coupling constants J were reported in Hertz (Hz). Analysis of the recorded spectra was carried 
out with MestReNova 10 software. 
EPR Spectroscopy 
EPR spectra were measured on a Bruker ELEXSYS E500 spectrometer, equipped with the 
digital temperature control system ER 4131VT using nitrogen as coolant. All spectra were 
measured at room temperature or at temperatures around 150K, and were recorded at about 9.4 
GHz microwave frequency,100 kHz field modulation frequency, and around 10 mW microwave 
power. 
Electrochemistry 





Germany) and graphite felt (GF) electrodes (10 mm × 15 mm × 6 mm, SIGRACELL®GFA 6 EA, 
obtained from SGL Carbon, Wiesbaden, Germany) were connected using stainless steel 
adapters. Electrolysis was conducted using an AXIOMET AX-3003P potentiostat in constant 
current mode. For reactions performed with the standardized electrochemistry kit, ElectraSyn 2.0 
from Ika, the commercialized electrodes and 10 mL undivided cells were used, if not stated 
otherwise. For reactions in flow an Ismatec REGLO Digital MS-2/12 (ISM 596) peristaltic pump 
was employed. CV studies were performed using a Metrohm Autolab PGSTAT204 workstation 
and Nova 2.0 software. Divided cells separated by a P4-glassfrit were obtained from 
Glasgerätebau Ochs Laborfachhandel e. K. (Bovenden, Germany). 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored 
under inert atmosphere (N2) according to the following standard procedures.  
Purified by solvent purification system (SPS-800, M. Braun): CH2Cl2, toluene, tetrahydrofuran, 
dimethylformamide, diethylether, 1,2-dichloroethane, N-methyl-2-pyrrolidone (NMP), N,N-
dimethylacetamide (DMA), dimethylsulfoxide (DMSO) and γ-valerolactone (GVL) was dried over 
CaH2 for 8 h, degassed and distilled under reduced pressure. 1,2-dimethoxyethane (DME) was 
dried over sodium and freshly distilled under N2. 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) was 
distilled from 3 Å molecular sieves. 2,2,2-trifluoroethanol (TFE) was stirred over CaSO4 and 
distilled under reduced pressure. Water was degassed by repeated Freeze-Pump-Thaw 
degassing procedure. 1,4-dioxane and di-n-butyl-ether (nBu2O) were distilled from sodium 
benzophenone ketyl. 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used without further 
purification. The following compounds were known and were synthesized according to 
previously described methods. 
Sulfoxonium ylides 141[228], 143[229], 64[230], 145[231], 147[232], 149[233], 154[225] and 160[233]. 
The following compounds were synthesized and provided by the persons listed below:  




In the project of ruthenaelectro-catalytic C–H/N–H annulation, Ralf Steinbock carried out some 





experiments and GC-Headspace analysis. CV studies were performed by Alexej Scheremetjew.  
DFT calculations were performed Dr. Rositha Kuniyil. On-line NMR monitoring in flow was 
performed by Dr. Lars H. Finger. Dr. Antonis M. Messinis helped to get the crystal of ruthenium 
intermediates.  
In the project of metal-free electrocatalytic B–H nitrogenation of nido-carboranes, Becky 
Bongsuiru Jei carried out some experiments for the scope (156b, 156c, 156d, 156e, 156f, 156g, 
156i, 156j, 156k, 156q, 156s, 156t, 156x, 156y, 156z, 156aa, 157c). Alexej Scheremetjew 
carried out GC-Headspace analysis and CV studies. DFT calculations were performed by Dr. 
Rositha Kuniyil. 
In the project of cupraelectro-catalytic C–H chalcogenation of o-carboranes, Becky Bongsuiru 
Jei carried out some experiments for the scope (162c, 162d, 162g, 162h, 162j, 162k, 162l, 162n, 
162p, 162q, 162r, 162t, 163a, 163c, 163d, 163e). Alexej Scheremetjew carried out CV studies.  
Binbin Yuan carried out DFT studies. Dr. A. Claudia Stückl carried out EPR measurements and 
analyzed all EPR data. Dr. Christopher Golz analyzed all the X-ray data in the thesis. 
 
5.2 General Procedures 
General Procedure A: Ruthenium(II)-Catalyzed C–H/O–H Annulation of ortho-Substituted 
Benzoic Acids 
Benzoic acid 62 (0.25 mmol), sulfoxonium ylide 141 (0.38 mmol), [RuCl2(p-cymene)]2 (3.8 mg, 
2.5 mol %), AgSbF6 (8.6 mg, 10 mol %), NEt3 (51 mg, 2.0 equiv), and DCE (2.0 mL) were placed 
in a 25 mL Schlenk flask under N2 atmosphere. The mixture was stirred at 100 °C for 16 h. At 
ambient temperature, the reaction mixture was transferred into a separatory funnel with EtOAc 
(20 mL) and washed with brine (5.0 mL). The mixture was extracted with EtOAc (3 × 20 mL) and 
the combined organic layer was dried over Na2SO4, concentrated under reduced pressure and 
purified by column chromatography on silica gel using a mixture of n-hexane and EtOAc to 
afford the desired product 142. 
 
General Procedure B: Ruthenium(II)-Catalyzed mono-C–H Activation of meta- and para-
substituted Benzoic Acids 
Benzoic acid 62 (0.75 mmol), sulfoxonium ylide 141 (0.083 mmol), [RuCl2(p-cymene)]2 (3.8 mg, 
2.5 mol %), AgSbF6 (8.6 mg, 10 mol %), Zn(OAc)2 (23 mg, 50 mol %), NEt3 (76 mg, 3.0 equiv), 
and DCE (2.0 mL) were placed in a 25 mL Schlenk flask under N2 atmosphere. The mixture was 
stirred at 100 °C for 2 h. Then, sulfoxonium ylide 141 (0.083 mmol) dissolved in DCE (0.5 mL) 





DCE (0.5 mL) was added. The resulting mixture was then stirred for 12 h. At ambient 
temperature, the reaction mixture was transferred into a separatory funnel with EtOAc (20 mL) 
and washed with brine (5.0 mL). The mixture was extracted with EtOAc (3 × 20 mL) and the 
combined organic layer was dried over Na2SO4, concentrated under reduced pressure and 
purified by column chromatography on silica gel using a mixture of n-hexane and EtOAc to 
afford the desired product 142. 
 
 
General Procedure C: Ruthenium(II)-Catalyzed double C–H Activation of meta- and para-
substituted Benzoic Acids 
Benzoic acid 62 (0.25 mmol), sulfoxonium ylide 141 (0.75 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 
5.0 mol %), AgSbF6 (17.2 mg, 20 mol %), NEt3 (51 mg, 2.0 equiv), and DCE (2.0 mL) were 
placed in a 25 mL Schlenk flask under N2 atmosphere. The mixture was stirred at 100 °C for 16 h. 
At ambient temperature, the reaction mixture was transferred into a round bottom flask with 
EtOAc (20 mL) and washed with brine (5.0 mL). The mixture was extracted with EtOAc (3 × 20 
mL) and the combined organic layer was dried over Na2SO4, concentrated under reduced 
pressure and purified by column chromatography on silica gel using a mixture of n-hexane and 
EtOAc to afford the desired product 142. 
 
General Procedure D: Ruthenium(II)-Catalyzed Double C-H/N-H Annulation 
To the pre-oven dried 25 mL Schlenk flask diketopyrrolopyrrole 143 (0.25 mmol, 1.0 equiv), 
alkyne 64 (1.00 mmol, 4.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), Cu(OAc)2∙H2O (1.00 mmol, 
4.0 equiv), KOAc (0.25 mmol, 1.0 equiv) were added. The Schlenk tube was evaporated and 
refilled with N2 and o-xylene (2 mL) was added. The reaction was stirred at 100 °C for 16 h 
under a N2 atmosphere. At ambient temperature, the reaction mixture was transferred to the 
separation funnel with the CH2Cl2 and washed with the NH4Cl(aq) solution and dried over 
Na2SO4. The solvent was removed under vacuo and the remaining residue was washed with n-
hexane. The precipitate was separated by the centrifuge, dissolved in CH2Cl2 and filtrated 
through filtration paper giving the desired product. 
 
General Procedure E: Ruthenium(II)-Catalyzed Double Double C-H/N-H Annulation 
To the pre-oven dried 25 mL Schlenk flask diketopyrrolopyrrole 143 (0.25 mmol, 1.0 equiv), 
alkyne 64 (1.00 mmol, 4.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), Cu(OAc)2∙H2O (1.00 mmol, 
4.0 equiv), KOAc (0.25 mmol, 1.0 equiv) were added. The Schlenk tube was evaporated and 





under a N2 atmosphere. At ambient temperature, the reaction mixture was transferred to the 
separation funnel with CH2Cl2 and washed with the NH4Cl(aq) solution and dried over Na2SO4. 
The solvent was removed under vacuo and the remaining residue was purified by column 
chromatography on silica gel (n-hxane:CH2Cl2) giving the desired product. 
 
General Procedure F: Electrochemical C–H/N–H Activation with Alkenyl Imidazoles 
The electrocatalysis was carried out in an undivided cell under N2, with a graphite felt (GF) 
anode (10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). Alkenyl 
imidazoles 145 (0.4 mmol, 1.0 equiv), alkyne 64 (0.8 mmol, 2.0 equiv), KPF6 (14.7 mg, 20 mol %) 
and [RuCl2(p-cymene)]2 (12.5 mg, 5.0 mol %) were dissolved in DMF (4.0 mL). Electrocatalysis 
was performed at 140 °C with a constant current of 4.0 mA maintained for 8 h. The GF anode 
was washed with EtOAc (3×10 mL) in an ultrasonic bath. Evaporation of the solvent and 
subsequent purification by column chromatography on silica gel afforded the corresponding 
products 146.  
 
General Procedure G: Electrochemical C–H/N–H Activation of 2-Phenylbenzimidazoles 
The electrocatalysis was carried out in an undivided cell under N2, with a graphite felt GF anode 
(10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). 2-
Phenylbenzimidazoles 147 (0.2 mmol, 1.0 equiv), alkyne 64 (0.4 mmol, 2.0 equiv), KOAc (0.4 
mmol, 2.0 equiv), 1-AdCO2H (7.2 mg, 20 mol %) and [RuCl2(p-cymene)]2 (6.2 mg, 5.0 mol %) 
were dissolved in t-AmOH/H2O (1/1, 6.0 mL). Electrocatalysis was performed at 100 °C with a 
constant current of 8.0 mA maintained for 4 h. The GF anode was washed with EtOAc (3×10 mL) 
in an ultrasonic bath. Evaporation of the solvent and subsequent purification by column 
chromatography on silica gel afforded the corresponding products 148. 
 
General Procedure H: Palladium-Catalyzed B(3,4)−H Diarylation 
o-Carborane 149a (1-CONEt2-2-Ph-o-C2B10H10) (0.20 mmol), 4-iodotoluene 19a (0.48 mmol), 
Pd(OAc)2 (10 mol %), AgTFA (0.48 mmol), TFA (0.20 mmol) and HFIP (0.50 mL) were placed in 
a 25 mL Schlenk tube under N2 atmosphere. The mixture was stirred at 25 °C for 16 h. Then, the 
reaction solution was concentrated to dryness in vacuum and purified by column 
chromatography on silica gel using a mixture of n-hexane and EtOAc (20/1 in v/v) and Gel 
Permeation Chromatography (GPC) to afford the desired product 150a. 
 
General Procedure I: Palladium-Catalyzed B(3)−H Arylation of o-Carboranes 





Pd(OAc)2 (10 mol %), Ag2CO3 (0.24 mmol) and HFIP (0.50 mL) were placed in a 25 mL Schlenk 
tube under N2 atmosphere. The mixture was stirred at 25 °C for 4 h. Then, 4-iodotoluene 19a 
(0.08 mmol) was added. And 4 h later, another portion of 4-iodotoluene 19a (0.08 mmol) was 
added. The resulting mixture was then stirred for 8 h. Then, the reaction solution was 
concentrated to dryness in vacuum and purified by column chromatography on silica gel using a 
mixture of n-hexane and EtOAc (20/1 in v/v) and Gel Permeation Chromatography (GPC) to 
afford the desired product 153a. 
 
General Procedure J: Electrochemical-Catalyzed B−H Nitrogenation of nido-Carboranes 
The electrocatalysis was carried out in an undivided cell under air, with a graphite felt (GF) 
anode (10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). nido-
Carborane 154a (0.10 mmol, 1.0 equiv), pyridine 155a (0.30 mmol, 3.0 equiv), and NMe4Cl (0.20 
mmol, 2.0 equiv) were dissolved in DME (4.0 mL) and H2O (0.2 mL). Electrocatalysis was 
performed at room temperature with a constant current of 6.0 mA maintained for 3 h. The GF 
anode was washed with CH2Cl2 (3×10 mL). Evaporation of the solvent and subsequent 
purification by column chromatography on silica gel with CH2Cl2/n-hexane (1/1) afforded the 
corresponding products 156a.  
 
General Procedure K: Cupraelectro-Catalyzed C−H Chalcogenation of o-Carboranes 
The electrocatalysis was carried out in an undivided cell under air, with a graphite felt (GF) 
anode (10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). o-
Carborane 160 (0.10 mmol, 1.0 equiv), thiol 161 (0.30 mmol, 3.0 equiv), CuOAc (15 mol %), 2-
PhPy (15 mol %), LiOtBu (0.2 mmol, 2.0 equiv) and TBAI (0.2 mmol, 2.0 equiv) were dissolved 
in THF (3.0 mL). Electrocatalysis was performed at room temperature with a constant current of 
2.0 mA maintained for 16 h. The GF anode was washed with ethyl acetate (3×10 mL). 
Evaporation of the solvent and subsequent purification by column chromatography on silica gel 
with n-hexane or gel permeation chromatography (GPC) afford the corresponding products 162.  
 
General Procedure L: Cupraelectro-Catalyzed C−H Chalcogenation of o-Carboranes 
The electrocatalysis was carried out in an undivided cell under air, with a graphite felt (GF) 
anode (10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). Thiol 
161 (0.30 mmol, 3.0 equiv), LiOtBu (0.2 mmol, 2.0 equiv) and TBAI (0.2 mmol, 2.0 equiv) were 
dissolved in THF (3.0 mL). Electrocatalysis was performed at room temperature with a constant 
current of 2.0 mA maintained for 3 h. Then, o-carborane 160 (0.10 mmol, 1.0 equiv), CuOAc (15 





performed at room temperature with a constant current of 2.0 mA maintained for another 16 h. 
The GF anode was washed with ethyl acetate (3×10 mL). Evaporation of the solvent and 
subsequent purification by column chromatography on silica gel with n-hexane or gel permeation 
chromatography (GPC) afford the corresponding products 162.  
 
 
5.3 Experimental Procedures and Analytical Data 
5.3.1 Ruthenium(IV) Intermediates in C−H Annulation 
5.3.1.1 Characterization Data 
 
Methyl-3-phenyl-1H-isochromen-1-one (142a).  
The representative procedure A was followed using 2-methylbenzoic acid (62a) (34 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-phenylethan-1-one (141a) (74 mg, 0.38 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142a (45 mg, 76%) as a 
colorless solid. M.p. = 133 °C. 1H NMR (300 MHz, CDCl3): δ = 7.94–7.84 (m, 2H), 7.60–7.52 (m, 
1H), 7.52–7.41 (m, 3H), 7.35–7.26 (m, 2H), 6.89 (s, 1H), 2.87 (s, 3H). 13C NMR (75 MHz, CDCl3): 
δ = 161.7 (Cq), 153.1 (Cq), 143.6 (Cq), 139.0 (Cq), 134.0 (CH), 131.9 (Cq), 131.0 (CH), 129.8 
(CH), 128.8 (CH), 125.1 (CH), 124.2 (CH), 119.0 (Cq), 102.3 (CH), 23.2 (CH3). IR (ATR): 3061, 
1712, 1592, 1471, 1227, 1074, 796, 691 cm–1. MS (ESI) m/z (relative intensity): 259 (60) 




1-Oxo-3-phenyl-1H-isochromen-8-yl acetate (142b).  
The representative procedure A was followed using 2-acetoxybenzoic acid (62b) (45 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-phenylethan-1-one (141a) (74 mg, 0.38 mmol). 





colorless solid. M.p. = 137 °C. 1H NMR (300 MHz, CDCl3): δ = 7.90–7.83 (m, 2H), 7.78–7.68 (m, 
1H), 7.51–7.44 (m, 3H), 7.39 (d, J = 7.9 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 6.95 (s, 1H), 2.48 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ = 169.7 (Cq), 158.8 (Cq), 154.2 (Cq), 152.0 (Cq), 140.0 (Cq), 
135.6 (CH), 131.6 (Cq), 130.2 (CH), 128.9 (CH), 125.3 (CH), 124.1 (CH), 122.4 (CH), 113.3 (Cq), 
101.6 (CH), 21.2 (CH3). IR (ATR): 3068, 1770, 1731, 1609, 1564, 1189, 1079, 689 cm–1. MS 
(ESI) m/z (relative intensity): 303 (100) [M+Na] +, 281 (20) [M+H] +. HR-MS (ESI): m/z calcd. for 
C17H12O4 [M+H]+: 281.0806, found: 281.0802. The analytical data correspond with those 
reported in the literature.[234] 
 
 
8-Fluoro-3-phenyl-1H-isochromen-1-one (142c).  
The representative procedure A was followed using 2-fluorobenzoic acid (62c) (35 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-phenylethan-1-one (141a) (74 mg, 0.38 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142c (33 mg, 55%) as a 
colorless solid. M.p. = 121 °C. 1H NMR (300 MHz, CDCl3): δ = 7.94–7.84 (m, 2H), 7.71–7.67 (m, 
1H), 7.53–7.44 (m, 3H), 7.30 (d, J = 7.6 Hz, 1H), 7.22–7.11 (m, 1H), 6.94 (s, 1H). 13C NMR (75 
MHz, CDCl3): δ = 163.0 (d, 1J = 265.1 Hz, Cq), 157.8 (Cq), 154.6 (Cq), 140.1 (Cq), 136.3 (d, 3J = 
10.1 Hz, CH), 131.5 (Cq), 130.3 (CH), 128.9 (CH), 125.4 (CH), 121.8 (d, 4J = 4.4 Hz, CH), 115.2 
(d, 2J = 21.2 Hz, CH), 109.3 (Cq), 101.1 (CH). 19F NMR (282 MHz, CDCl3): δ = -107.2. IR (ATR): 
3105, 1725, 1640, 1475, 1228, 1079, 803, 684 cm–1. MS (ESI) m/z (relative intensity): 263 (100) 




3-(4-Chlorophenyl)-8-methyl-1H-isochromen-1-one (142d).  
The representative procedure A was followed using 2-methylbenzoic acid (62a) (34 mg, 0.25 
mmol) and 1-(4-chlorophenyl)-2-[dimethyl(oxo)-λ6-sulfaneylidene]ethan-1-one (141b) (87 mg, 





92%) as a colorless solid. M.p. = 156 °C. 1H NMR (300 MHz, CDCl3): δ = 7.78 (d, J = 8.7 Hz, 
2H), 7.58–7.51 (m, 1H), 7.78 (d, J = 8.7 Hz, 2H), 7.33–7.25 (m, 2H), 6.84 (s, 1H), 2.84 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 161.3 (Cq), 152.0 (Cq), 143.6 (Cq), 138.8 (Cq), 135.8 (Cq), 134.1 
(CH), 131.3 (CH), 130.4 (Cq), 129.0 (CH), 126.3 (CH), 124.3 (CH), 118.9 (Cq), 102.5 (CH), 23.2 
(CH3). IR (ATR): 3097, 1714, 1493, 1095, 1074, 1014, 825, 687 cm–1. MS (ESI) m/z (relative 
intensity): 293 (60) [M+Na]+, 271 (100) [M+H]+. HR-MS (ESI): m/z calcd. for C16H11ClO2 [M+H]+: 




8-Methyl-3-[3-(trifluoromethyl)phenyl]-1H-isochromen-1-one (142e).  
The representative procedure A was followed using 2-methylbenzoic acid (62a) (34 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-[3-(trifluoromethyl)phenyl]ethan-1-one (141c) 
(99 mg, 0.38 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142e 
(54 mg, 71%) as a colorless solid. M.p. = 159 °C. 1H NMR (300 MHz, CDCl3): δ = 8.12 (s, 1H), 
8.06 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.64–7.56 (m, 2H), 7.39–7.30 (m, 2H), 6.96 (s, 
1H), 2.87 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 161.1 (Cq), 151.5 (Cq), 143.8 (Cq), 138.5 (Cq), 
134.2 (CH), 132.8 (Cq), 131.6 (CH), 130.9 (q, 2J = 32.9 Hz, Cq), 129.4 (CH), 128.2 (CH), 126.3 (q, 
3J = 3.9 Hz, CH), 124.4 (CH), 123.9 (q, 1J = 270.9 Hz, Cq), 121.9 (q, 3J = 3.9 Hz, CH), 119.2 (Cq), 
103.4 (CH), 23.2 (CH3). 19F NMR (282 MHz, CDCl3): δ = -62.7. IR (ATR): 2932, 1721, 1333, 
1309, 1222, 1166, 1113, 1073 cm–1. MS (ESI) m/z (relative intensity): 327 (70) [M+Na]+, 305 (100) 




8-Methyl-3-(o-tolyl)-1H-isochromen-1-one (142f).  
The representative procedure A was followed using 2-methylbenzoic acid (62a) (34 mg, 0.25 





Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142f (51 mg, 85%) as a 
colorless solid. M.p. = 141 °C. 1H NMR (300 MHz, CDCl3): δ = 7.63–7.50 (m, 2H), 7.37–7.25 (m, 
5H), 6.56 (s, 1H), 2.89 (s, 3H), 2.54 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 162.0 (Cq), 155.2 
(Cq), 143.5 (Cq), 139.1 (Cq), 136.8 (Cq), 134.0 (CH), 132.8 (Cq), 131.1 (CH), 131.1 (CH), 129.7 
(CH), 129.1 (CH), 126.0 (CH), 124.1 (CH), 118.8 (Cq), 106.4 (CH), 23.3 (CH3), 20.8 (CH3). IR 
(ATR): 2926, 1710, 1646, 1593, 1573, 1490, 1223, 723 cm–1. MS (ESI) m/z (relative intensity): 
273 (90) [M+Na]+, 251 (100) [M+H]+. HR-MS (ESI): m/z calcd. for C17H14O2 [M+H]+: 251.1067, 
found: 251.1062. 
 
3-Phenyl-1H-isochromen-1-one (142g).  
The representative procedure B was followed using benzoic acid (62d) (92 mg, 0.75 mmol) and 
2-[dimethyl(oxo)-λ6-sulfaneylidene]- 1-phenylethan-1-one (141a) (49 mg, 0.25 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 10/1) yielded 142g (37 mg, 67%) as a colorless 
solid. M.p. = 90 °C. 1H NMR (300 MHz, CDCl3): δ = 8.31 (d, J = 8.0 Hz, 1H), 7.88 (dd, J = 7.8, 
1.8 Hz, 2H), 7.76–7.67 (m, 1H), 7.53–7.42 (m, 5H), 6.95 (s, 1H). 13C NMR (75 MHz, CDCl3): δ = 
162.3 (Cq), 153.6 (Cq), 137.5 (Cq), 134.9 (CH), 132.0 (Cq), 130.0 (CH), 129.6 (CH), 128.8 (CH), 
128.2 (CH), 126.0 (CH), 125.2 (CH), 120.5 (Cq), 101.8 (CH). IR (ATR): 3062, 1720, 1636, 1607, 
1483, 1234, 1107, 767, 690 cm–1. MS (ESI) m/z (relative intensity): 245 (50) [M+Na]+, 223 (100) 
[M+H]+. HR-MS (ESI): m/z calcd. for C15H10O2 [M+H]+: 223.0754, found: 223.0758. The 
analytical data correspond with those reported in the literature.[235] 
 
 
3-(p-Tolyl)-1H-isochromen-1-one (142h).  
The representative procedure B was followed using benzoic acid (62d) (92 mg, 0.75 mmol) and 
2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-(p-tolyl)ethan-1-one (141e) (53 mg, 0.25 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 10/1) yielded 142h (38 mg, 65%) as a colorless 
solid. M.p. = 114 °C. 1H NMR (300 MHz, CDCl3): δ = 8.32 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 8.2 Hz, 





NMR (75 MHz, CDCl3): δ = 162.4 (Cq), 153.9 (Cq), 140.3 (Cq), 137.7 (Cq), 134.8 (CH), 129.6 
(CH), 129.5 (CH), 129.2 (Cq), 127.9 (CH), 125.9 (CH), 125.2 (CH), 120.4 (Cq), 101.1 (CH), 21.4 
(CH3). IR (ATR): 2918, 1731, 1630, 1066, 1008, 816, 752, 688 cm–1. MS (ESI) m/z (relative 
intensity): 259 (90) [M+Na]+, 237 (100) [M+H]+. HR-MS (ESI): m/z calcd. for C16H12O2 [M+H]+: 
237.0910, found: 237.0905. The analytical data correspond with those reported in the 
literature.[236] 
 
1-Oxo-8-(2-oxo-2-phenylethyl)-3-phenyl-1H-isochromen-6-yl acetate (142i).  
The representative procedure C was followed using 4-acetoxybenzoic acid (62e) (45 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-phenylethan-1-one (141a) (147 mg, 0.75 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142i (73 mg, 73%) as a 
colorless solid. M.p. = 195 °C. 1H NMR (300 MHz, CDCl3): δ = 8.17–8.08 (m, 2H), 7.88–7.80 (m, 
2H), 7.66–7.59 (m, 1H), 7.57–7.50 (m, 2H), 7.48–7.42 (m, 3H), 7.28 (s, 1H), 7.09 (d, J = 2.2 Hz, 
1H), 6.92 (s, 1H), 4.91 (s, 2H), 2.36 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 196.7 (Cq), 168.5 
(Cq), 161.1 (Cq), 154.7 (Cq), 154.1 (Cq), 142.0 (Cq), 141.1 (Cq), 137.2 (Cq), 133.1 (CH), 131.5 (Cq), 
130.2 (CH), 128.9 (CH), 128.6 (CH), 128.3 (CH), 125.6 (CH), 125.3 (CH), 117.6 (CH), 116.6 (Cq), 
102.0 (CH), 45.6 (CH2), 21.3 (CH3). IR (ATR): 2000, 1643, 1603, 1575, 1061, 1003, 910, 530 
cm–1. MS (ESI) m/z (relative intensity): 421 (95) [M+Na]+, 399 (100) [M+H]+. HR-MS (ESI): m/z 




The representative procedure C was followed using 4-methoxybenzoic acid (62f) (38 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-phenylethan-1-one (141a) (147 mg, 0.75 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142j (59 mg, 64%) as a 





2H), 7.64–7.57 (m, 1H), 7.57–7.49 (m, 2H), 7.49–7.40 (m, 3H), 6.94–6.82 (m, 3H), 4.86 (s, 2H), 
3.93 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 197.1 (Cq), 163.7 (Cq), 161.4 (Cq), 153.8 (Cq), 141.9 
(Cq), 141.7 (Cq), 137.4 (Cq), 132.9 (CH), 131.8 (Cq), 129.9 (CH), 128.8 (CH), 128.6 (CH), 128.3 
(CH), 125.2 (CH), 120.6 (CH), 112.3 (Cq), 107.5 (CH), 102.4 (CH), 55.6 (CH3), 45.7 (CH2). IR 
(ATR): 3059, 1711, 1599, 1468, 1212, 1160, 735, 628 cm–1. MS (ESI) m/z (relative intensity): 393 





The representative procedure C was followed using 4-(tert-butyl)benzoic acid (62g) (45 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-phenylethan-1-one (141a) (147 mg, 0.75 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142k (80 mg, 81%) as a 
colorless solid. M.p. = 198 °C. 1H NMR (300 MHz, CDCl3): δ = 8.20–8.12 (m, 2H), 7.90–7.83 (m, 
2H), 7.65–7.58 (m, 1H), 7.57–7.50 (m, 2H), 7.49–7.40 (m, 4H), 7.36 (d, J = 1.9 Hz, 1H), 6.99 (s, 
1H), 4.93 (s, 2H), 1.43 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 197.3 (Cq), 161.8 (Cq), 158.0 (Cq), 
153.2 (Cq), 139.3 (Cq), 139.1 (Cq), 137.5 (Cq), 132.9 (CH), 132.0 (Cq), 130.2 (CH), 129.8 (CH), 
128.8 (CH), 128.6 (CH), 128.3 (CH), 125.1 (CH), 122.3 (CH), 116.8 (Cq), 102.9 (CH), 45.9 (CH2), 
35.2 (Cq), 31.0 (CH3). IR (ATR): 2965, 1716, 1688, 1600, 1496, 1212, 756, 688 cm–1. MS (ESI) 
m/z (relative intensity): 419 (30) [M+Na]+, 397 (100) [M+H]+. HR-MS (ESI): m/z calcd. for 




The representative procedure C was followed using 4-(dimethylamino)benzoic acid (62h) (41 mg, 





mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142l (72 mg, 75%) 
as a colorless solid. M.p. = 189 °C. 1H NMR (300 MHz, CDCl3): δ = 8.17–8.12 (m, 2H), 7.83 (dd, 
J = 7.9, 1.7 Hz, 2H), 7.62–7.57 (m, 1H), 7.54–7.48 (m, 2H), 7.46–7.38 (m, 3H), 6.83 (s, 1H), 
6.61 (d, J = 2.5 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H), 4.83 (s, 2H), 3.08 (s, 6H). 13C NMR (75 MHz, 
CDCl3): δ = 197.7 (Cq), 162.0 (Cq), 153.4 (Cq), 153.0 (Cq), 141.0 (Cq), 140.9 (Cq), 137.6 (Cq), 
132.7 (CH), 132.3 (Cq), 129.5 (CH), 128.6 (CH), 128.5 (CH), 128.3 (CH), 125.1 (CH), 116.7 (CH), 
107.2 (Cq), 105.4 (CH), 102.8 (CH), 46.1 (CH2), 39.9 (CH3). IR (ATR): 3051, 1694, 1597, 1494, 
1448, 1388, 1335, 559 cm–1. MS (ESI) m/z (relative intensity): 406 (40) [M+Na]+, 384 (100) 
[M+H]+. HR-MS (ESI): m/z calcd. for C25H21NO3 [M+H]+: 384.1594, found: 384.1588. 
 
 
6-Methyl-8-[2-oxo-2-(p-tolyl)ethyl]-3-(p-tolyl)-1H-isochromen-1-one (142m).  
The representative procedure C was followed using 4-methylbenzoic acid (62i) (34 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-(p-tolyl)ethan-1-one (141f) (158 mg, 0.75 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142m (80 mg, 84%) 
as a colorless solid. M.p. = 201 °C. 1H NMR (300 MHz, CDCl3): δ = 8.04 (d, J = 8.2 Hz, 2H), 
7.73 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.28–7.20 (m, 3H), 7.11 (s, 1H), 6.84 (s, 1H), 
4.84 (s, 2H), 2.45 (s, 3H), 2.43 (s, 3H), 2.40 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 197.0 (Cq), 
161.8 (Cq), 153.5 (Cq), 145.1 (Cq), 143.6 (Cq), 140.0 (Cq), 139.7 (Cq), 139.5 (Cq), 135.0 (Cq), 
133.4 (CH), 129.5 (CH), 129.3 (CH), 129.2 (Cq), 128.4 (CH), 125.6 (CH), 125.0 (CH), 116.5 (Cq), 
101.6 (CH), 45.3 (CH2), 21.7 (CH3), 21.6 (CH3), 21.3 (CH3). IR (ATR): 2919, 1716, 1686, 1567, 
1408, 1333, 1272, 765, 690 cm–1. MS (ESI) m/z (relative intensity): 405 (20) [M+Na]+, 383 (100) 








(142n). The representative procedure C was followed using 4-methylbenzoic acid (62i) (34 mg, 
0.25 mmol) and 1-(4-chlorophenyl)-2-[dimethyl(oxo)-λ6-sulfaneylidene]ethan-1-one (141g) (173 
mg, 0.75 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142n (92 
mg, 87%) as a colorless solid. M.p. = 212 °C. 1H NMR (300 MHz, CDCl3): δ = 8.07 (d, J = 8.7 Hz, 
2H), 7.76 (d, J = 8.7 Hz, 2H), 7.50 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 7.26 (s, 1H), 7.15 
(s, 1H), 6.88 (s, 1H), 4.81 (s, 2H), 2.48 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 196.2 (Cq), 161.5 
(Cq), 152.3 (Cq), 145.5 (Cq), 139.3 (Cq), 139.2 (Cq), 139.1 (Cq), 135.9 (Cq), 135.7 (Cq), 133.9 (CH), 
130.3 (Cq), 129.7 (CH), 129.1 (CH), 128.9 (CH), 126.4 (CH), 126.0 (CH), 116.6 (Cq), 102.5 (CH), 
45.4 (CH2), 21.8 (CH3). IR (ATR): 2916, 1717, 1690, 1589, 1568, 1400, 1168, 966 cm–1. MS (ESI) 
m/z (relative intensity): 445 (70) [M+Na]+, 423 (100) [M+H]+. HR-MS (ESI): m/z calcd. for 




isochromen-1-one (142o). The representative procedure C was followed using 4-
methylbenzoic acid (62i) (34 mg, 0.25 mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-[3-
(trifluoromethyl)phenyl]ethan-1-one (141h) (198 mg, 0.75 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 142o (113 mg, 92%) as a colorless solid. M.p. 
= 220 °C. 1H NMR (300 MHz, CDCl3): δ = 8.38 (s, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.08 (s, 1H), 
8.01 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.73–7.65 (m, 2H), 7.63–7.54 (m, 1H), 7.31 (s, 
1H), 7.19 (s, 1H), 7.00 (s, 1H), 4.85 (s, 2H), 2.50 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 195.9 
(Cq), 161.4 (Cq), 151.7 (Cq), 145.8 (Cq), 139.0 (Cq), 138.8 (Cq), 137.8 (Cq), 134.2 (CH), 132.6 (Cq), 
131.4 (CH), 130.4 (q, 1J = 268.2 Hz, Cq), 129.7 (q, 3J = 3.6 Hz, CH), 129.4 (CH), 129.3 (CH), 
128.1 (CH), 127.4 (q, 1J = 270.1 Hz, Cq), 126.3 (q, 3J = 3.8 Hz, CH), 126.2 (CH), 125.6 (q, 2J = 
27.3 Hz, Cq), 125.0 (q, 3J = 3.8 Hz, CH), 124.0 (q, 2J = 26.4 Hz, Cq), 121.9 (q, 3J = 3.8 Hz, CH), 
116.7 (Cq), 103.3 (CH), 45.5 (CH2), 21.7 (CH3). 19F NMR (282 MHz, CDCl3): δ = -62.7, -62.8. IR 
(ATR): 3082, 1718, 1643, 1611, 1321, 1166, 1125, 695 cm–1. MS (ESI) m/z (relative intensity): 








6-Methyl-8-[2-oxo-2-(o-tolyl)ethyl]-3-(o-tolyl)-1H-isochromen-1-one (142p).  
The representative procedure C was followed using 4-methylbenzoic acid (62i) (34 mg, 0.25 
mmol) and 2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-(o-tolyl)ethan-1-one (141i) (158 mg, 0.75 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142p (62 mg, 65%) as a 
colorless solid. M.p. = 196 °C. 1H NMR (300 MHz, CDCl3): δ = 8.02 (dd, J = 7.6, 1.2 Hz, 1H), 
7.57–7.50 (m, 1H), 7.45–7.39 (m, 1H), 7.38–7.25 (m, 6H), 7.18 (s, 1H), 6.58 (s, 1H), 4.82 (s, 2H), 
2.55 (s, 3H), 2.52 (s, 3H), 2.51 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 201.0 (Cq), 162.0 (Cq), 
155.3 (Cq), 145.3 (Cq), 139.5 (Cq), 139.3 (Cq), 138.5 (Cq), 138.1 (Cq), 136.7 (Cq), 133.8 (CH), 
132.7 (Cq), 131.9 (CH), 131.2 (CH), 131.1 (CH), 129.7 (CH), 129.1 (CH), 128.7 (CH), 126.0 (CH), 
125.7 (CH), 125.6 (CH), 116.5 (Cq), 106.5 (CH), 48.5 (CH2), 21.8 (CH3), 21.2 (CH3), 20.8 (CH3). 
IR (ATR): 2963, 1716, 1645, 1458, 1326, 1047, 994, 727 cm–1. MS (ESI) m/z (relative intensity): 




6-[2-Oxo-2-(p-tolyl)ethyl]-3-(p-tolyl)-1H-isochromen-1-one  (142q).  
The representative procedure C was followed using benzoic acid (62d) (31 mg, 0.25 mmol) and 
2-[dimethyl(oxo)-λ6-sulfaneylidene]-1-(p-tolyl)ethan-1-one (141f) (158 mg, 0.75 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 10/1) yielded 142q (71 mg, 77%) as a colorless 
solid. M.p. = 205 °C. 1H NMR (300 MHz, CDCl3): δ = 8.04 (d, J = 8.2 Hz, 2H), 7.75 (d, J = 8.2 Hz, 
2H), 7.68–7.64 (m, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.36–7.28 (m, 3H), 7.26 (d, J = 8.2 Hz, 2H), 
6.93 (s, 1H), 4.90 (s, 2H), 2.46 (s, 3H), 2.41 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 196.9 (Cq), 
161.8 (Cq), 153.5 (Cq), 143.6 (Cq), 140.2 (Cq), 139.7 (Cq), 139.6 (Cq), 134.9 (Cq), 134.2 (CH), 
131.9 (CH), 129.5 (CH), 129.3 (CH), 129.1 (Cq), 128.4 (CH), 125.6 (CH), 125.1 (CH), 119.0 (Cq), 





1000, 768 cm–1. MS (ESI) m/z (relative intensity): 391 (80) [M+Na]+, 369 (100) [M+H]+. HR-MS 
(ESI): m/z calcd. for C25H20O3 [M+H]+: 369.1485, found: 369.1484. 
 
 
1-(4-Chlorophenyl)-8-(2-(4-chlorophenyl)-2-oxoethyl)-1H-isochromen-1-one (142r).  
The representative procedure C was followed using benzoic acid (62d) (31 mg, 0.25 mmol) and 
1-(4-chlorophenyl)-2-[dimethyl(oxo)-λ6-sulfaneylidene]ethan-1-one (141g) (174 mg, 0.75 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 142r (87 mg, 85%) as a 
colorless solid. M.p. = 218 °C. 1H NMR (300 MHz, CDCl3): δ = 8.07 (d, J = 8.9 Hz, 2H), 7.77 (d, 
J = 8.9 Hz, 2H), 7.72–7.65 (m, 1H), 7.53–7.39 (m, 5H), 7.35–7.31 (m, 1H), 6.95 (s, 1H), 4.86 (s, 
2H). 13C NMR (75 MHz, CDCl3): δ = 196.0 (Cq), 161.5 (Cq), 152.3 (Cq), 139.4 (Cq), 139.3 (Cq), 
139.2 (Cq), 136.0 (Cq), 135.7 (Cq), 134.5 (CH), 132.4 (CH), 130.2 (Cq), 129.7 (CH), 129.1 (CH), 
128.9 (CH), 126.4 (CH), 126.0 (CH), 119.0 (Cq), 102.6 (CH), 45.6 (CH2). IR (ATR): 2921, 1730, 
1686, 1590, 1492, 1072, 997, 687 cm–1. MS (ESI) m/z (relative intensity): 431 (100) [M+Na]+, 
409 (20) [M+H]+. HR-MS (ESI): m/z calcd. for C23H14Cl2O3 [M+H]+: 409.0393, found: 409.0389. 
 
5.3.2 Twofold C–H/N–H Annulations towards π-Extended Polyaromatics 









c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and 1,2-di-m-tolylethyne 64a (0.8 mmol, 165 mg). 
yielding 144a (100 mg, 71%) as the purple crystals.  M. p. = over the limit of the detection. 1H 
NMR (300 MHz, CDCl3) δ = 7.60 (d, J = 5.2 Hz, 2H), 7.20 – 6.80 (m, 18H), 2.35 – 2.15 (m, 12H). 
13C NMR (126 MHz, CDCl3) δ = 156.5 (Cq), 143.6 (Cq), 138.0 (Cq), 137.4 (Cq), 137.3 (Cq), 136.7 
(Cq), 136.4 (Cq), 136.3 (Cq), 135.7 (Cq), 133.1 (CH), 132.5 (Cq), 132.4 (Cq), 131.3 (CH), 131.2 
(CH), 131.0 (CH), 130.9 (CH), 128.7 (CH), 128.7 (CH), 128.0 (Cq), 127.8 (CH), 127.7 (CH), 
127.6 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 127.3 (CH), 126.8 (CH), 126.7 (CH), 124.8 
(CH), 123.8 (Cq), 96.6 (Cq), 21.4 (CH3), 21.3 (CH3), 21.3 (CH3). IR (ATR): 3089, 1687, 1628, 
1502, 1347, 1095, 1033, 788, 757, 692, 490 cm−1. (The lack of symmetry is caused by the 
presence of rotameric species at the room temperature). HR-MS (ESI) m/z calc. for 





The general procedure D was followed using 3,6-di(thiophen-2-yl)-2,5-dihydropyrrolo[3,4-
c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and 1,2-bis(3-methoxyphenyl)ethyne 64b (0.8 mmol, 
191 mg). yielding 144b (80 mg, 52%) as the purple crystals. M. p. = 346 °C. 1H NMR (400 MHz, 
CDCl3) δ = 7.57 (d, J = 5.2 Hz, 2H), 7.22-7.07 (m, 4H), 6.98-6.93 (m, 1H), 6.89-6.83 (m, 3H), 
6.83-6.60 (m, 9H), 6.51 (s, 1H), 3.70-3.59 (m, 12H). 13C NMR (101 MHz, CDCl3) δ = 159.1 (Cq), 
159.1 (Cq), 158.5 (Cq), 158.4 (Cq), 156.3 (Cq), 143.3 (Cq), 137.5 (Cq), 137.0 (Cq), 137.0 (Cq), 
136.7 (Cq), 133.7 (CH), 133.3 (CH), 129.0 (CH), 128.9 (CH), 128.2 (CH), 128.2 (CH), 128.0 (CH), 
124.8 (CH), 123.5 (Cq), 123.1 (CH), 123.0 (CH), 122.9 (CH), 115.9 (CH), 115.9 (CH), 115.8 (CH), 
115.7 (CH), 115.7 (CH), 114.0 (CH), 113.9 (CH), 113.5 (CH), 113.4 (CH), 113.2 (CH), 113.2 (CH), 
96.6 (Cq), 55.2 (CH3), 55.1 (CH3), 55.1 (CH3), 55.1 (CH3). (The lack of symmetry is caused by 
the presence of rotameric species at the room temperature). IR (ATR): 3090, 1685, 1632, 1575, 










The general procedure D was followed using 3,6-di(thiophen-2-yl)-2,5-dihydropyrrolo[3,4-
c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and 1,2-bis(3-methoxyphenyl)ethyne 64c (0.8 mmol, 
251 mg). yielding 144c (92 mg, 50%) as the purple crystals. M. p. = over the limit of the 
detection. 1H NMR (400 MHz, CDCl3) δ = 7.75 – 7.68 (m, 1H), 7.65 – 7.33 (m, 7H), 7.26 – 7.15 
(m, 1H), 6.91 – 6.80 (m, 1H). 13C NMR (126 MHz, CDCl3) δ = 156.2 (Cq), 142.7 (Cq), 142.6 (Cq), 
136.7 (Cq), 136.5 (Cq), 135.9 (Cq), 135.9 (Cq), 134.3 (CH), 134.3 (CH), 133.8 (CH), 133.5 (CH), 
133.4 (CH), 133.4 (CH), 133.4 (CH), 133.3 (CH), 133.3 (CH), 133.3 (CH), 132.8 (Cq), 132.7 (Cq), 
128.8 (CH), 128.7 (Cq), 127.7 (CH), 127.5 (CH), 127.3 (CH), 127.0 (CH), 125.1 (CH), 125.0 (CH), 
124.8 (Cq), 124.8 (Cq), 124.8 (Cq), 124.8 (Cq), 124.7 (Cq), 124.4 (Cq), 124.4 (CH), 124.4 (CH), 
124.3 (CH), 122.9 (Cq), 122.8 (Cq), 122.7 (Cq), 122.6 (Cq), 122.6 (Cq), 122.5 (Cq), 96.8 (Cq). 19F 
NMR (471 MHz, CDCl3): δ = -62.79, -62.93, -62.97, -63.08. (The lack of symmetry is caused by 
the presence of rotameric species at the room temperature). IR (ATR): 2927, 2851, 1706, 1632, 
1326, 1164, 1070, 803, 699, 664 cm–1. HR-MS (ESI) m/z calc. for C46H21F12N2O2S2+ [M+H]+: 








g]indolizine-7,14-dione (144d).  
The general procedure D was followed using 3,6-di(thiophen-2-yl)-2,5-dihydropyrrolo[3,4-
c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and 1,2-bis(3-methoxyphenyl)ethyne 64d (0.8 mmol, 
171 mg). yielding 144d (90 mg, 62%) as the purple crystals. M. p. = over the limit of the 
detection. 1H NMR (500 MHz, CDCl3) δ = 7.62 (d, J = 5.2 Hz, 2H), 7.24–7.14 (m, 4H), 7.06 (d, J 
= 7.6 Hz, 2H), 7.03–6.74 (m, 12H). 13C NMR (126 MHz, CDCl3) δ = 162.4 (d, 
1JC-F = 247 Hz, Cq), 
161.8 (d, 1JC-F = 247 Hz, Cq), 156.2 (Cq), 142.9 (Cq), 137.3 (d, 
4JC-F = 7.9 Hz, Cq), 136.6 (Cq), 
136.4 (Cq), 134.1 (d, 
3JC-F = 8.5 Hz, Cq), 133.9 (CH), 129.8 (d, 
3JC-F = 9 Hz, CH), 129.7 (d, 
3JC-F = 
9 Hz, CH), 129.0 (d, 3JC-F = 8.5 Hz, CH), 128.8 (d, 
4JC-F = 8.3 Hz, CH), 128.4 (Cq), 126.2 (d, 
2JC-F 
= 19.5 Hz, CH), 124.5 (CH), 122.6 (Cq), 117.4 (d, 
2JC-F = 20 Hz, CH), 115.4 (d, 
2JC-F = 21 Hz, CH), 
114.6 (d, 2JC-F = 21 Hz, CH), 96.7 (Cq). 19F NMR (471 MHz, CDCl3): δ = -112.58, -112.85, -113.30, 
-113.56. (The lack of symmetry is caused by the presence of rotameric species at the room 
temperature). IR (ATR): 1702, 1610, 1582, 1479, 1431, 1146, 758, 695, 489 cm–1. HR-MS (ESI) 





The general procedure D was followed using 3,6-bis(5-octylthiophen-2-yl)-2,5-
dihydropyrrolo[3,4-c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and 1,2-bis(3-
chlorophenyl)ethyne 64e (0.8 mmol, 198 mg). yielding 144e (81 mg, 51%) as the purple crystals 
M. p. = over the limit of the detection. 1H NMR (400 MHz, CDCl3) δ = 7.68 (d, J = 5.1 Hz, 2H), 
7.28 – 7.15 (m, 13H), 7.11 (s, 1H), 7.02 (s, 1H), 6.96 (d, J = 7.7 Hz, 1H), 6.91 – 6.83 (m, 2H). 13C 
NMR (101 MHz, CDCl3) 156.2 (Cq), 142.9 (Cq), 137.0 (Cq), 136.7 (Cq), 136.4 (Cq), 134.2 (Cq), 
134.1 (Cq), 134.0 (CH), 133.9 (Cq), 133.5 (Cq), 133.3 (Cq), 130.5 (CH), 130.4 (CH), 130.2 (CH), 
129.6 (CH), 129.5 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 127.9 (CH), 124.5 
(CH), 122.6 (Cq), 96.7 (Cq). (The lack of symmetry is caused by the presence of rotameric 










The general procedure D was followed using 3,6-bis(5-octylthiophen-2-yl)-2,5-
dihydropyrrolo[3,4-c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and 1,2-bis(3-
bromophenyl)ethyne 64f (0.8 mmol, 269 mg). yielding 144f (103 mg, 53%) as the purple crystals. 
M. p. = over the limit of the detection. 1H NMR (300 MHz, CDCl3) δ = 7.68 (d, J = 5.2 Hz, 2H), 
7.47 – 7.37 (m, 6H), 7.34 (s, 1H), 7.27 – 7.05 (m, 8H), 6.99 (d, J = 7.9 Hz, 1H), 6.87 (d, J = 5.4 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ = 156.2 (Cq), 142.8 (Cq), 137.2 (Cq), 137.1 (Cq), 136.6 
(Cq), 136.3 (Cq), 134.0 (CH), 133.5 (CH), 133.3 (CH), 133.0 (CH), 132.9 (CH), 131.4 (CH), 130.8 
(CH), 129.8 (CH), 129.7 (CH), 129.2 (CH), 129.1 (CH), 128.9 (CH), 128.7 (CH), 128.5 (Cq), 
124.5, 122.6 (Cq), 122.2 (Cq), 122.1 (Cq), 121.5 (Cq), 121.4 (Cq), 96.7 (Cq). (The lack of 
symmetry is caused by the presence of rotameric species at the room temperature). IR (ATR): 
1697, 1635, 1559, 1470, 1347, 1094, 787, 746, 682, 482 cm−1. HR-MS (ESI) m/z calc. for 





The general procedure D was followed using 3,6-di(thiophen-2-yl)-2,5-dihydropyrrolo[3,4-





(60 mg, 58%) as the purple crystals. M. p. = 333 °C. 1H NMR (300 MHz, CDCl3) δ = 7.74 (d, J = 
5.3 Hz, 2H), 7.27 (d, 2H), 3.48-3.39 (m, 4H), 2.80-2.71 (m, 4H), 1.86-1.76 (m, 4H), 1.72-1.62 (m, 
4H), 1.14 (t, J = 6.6 Hz, 6H), 1.09 (t, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ = 157.5 (Cq), 
143.5 (Cq), 141.1 (Cq), 137.2 (Cq), 133.1 (CH), 127.4 (Cq), 122.8 (CH), 120.2 (Cq), 96.1 (Cq), 30.9 
(CH2), 30.6 (CH2), 28.2 (CH2), 24.1 (CH2), 23.7 (CH2), 14.4 (CH3), 14.3 (CH3). IR (ATR): 3074, 
2963, 2951, 2928, 2867, 1683, 1640, 1546, 1028, 768, 698, 467 cm−1. HR-MS (ESI) m/z calc. for 





The general procedure D was followed using 3,6-di(thiophen-2-yl)-2,5-dihydropyrrolo[3,4-
c]pyrrole-1,4-dione 143a (0.2 mmol, 60 mg) and octadec-9-yne 64h (0.8 mmol, 200 mg). yielding 
144h (89 mg, 56%) as the purple crystals. M. p. = 287 °C. 1H NMR (400 MHz, CDCl3) δ = 7.73 
(d, J = 5.2 Hz, 2H), 7.27 (d, J = 5.5 Hz, 2H), 3.44 (t, J = 8.0 Hz, 4H), 2.75 (t, J = 8.1 Hz, 4H), 
1.81 – 1.71 (m, 4H), 1.68 – 1.59 (m, 4H), 1.53 – 1.28 (m, 40H), 0.95 – 0.88 (m, 12H). 13C NMR 
(101 MHz, CDCl3) δ = 157.5 (Cq), 143.6 (Cq), 141.3 (Cq), 137.1 (Cq), 133.1 (CH), 127.4 (Cq), 
122.7 (CH), 120.3 (Cq), 96.1 (Cq), 31.9 (CH2), 31.9 (CH2), 30.8 (CH2), 30.5 (CH2), 29.9 (CH2), 
29.8 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 28.6 (CH2), 26.3 (CH2), 22.7 (CH2), 22.7 (CH2), 
14.1 (CH3), 14.1 (CH3). IR (ATR): 2954, 2918, 2848, 1676, 1538, 1505, 1349, 1017, 772, 700 
cm−1. HR-MS (ESI) m/z calc. for C50H73N2O2S2 [M+H]+: 797.5108, found: 797.5091. 
 
5.3.2.2 Investigation of Rotameric Species 
Due to the lack of the symmetry on the 1H NMR spectra for compounds 144a-144f, we have 
investigated the possibility of the presence of the rotameric species at the room temperature. In 
order to do that, we have measured 1H NMR spectra for compound 144a in different 
temperatures using 1,1,2,2-tetrachloroethane-d2 as a solvent. In comparison to the 1H NMR 
spectrum measured at 298 K, where four signals for all methyl groups can be easily 





observation clearly shows that the lack of symmetry, observed on spectra at room temperature 














5.3.3 Ruthenaelectro(II/III/I)-Catalyzed Alkyne Annulations 
5.3.3.1 Characterization Data 
 
8-Methyl-5,6,7-triphenylimidazo[1,2-a]pyridine (146a) 
The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64a (142 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146a (108 mg, 75%) as a white solid. M.p.: 242 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.64 (d, J = 1.2 Hz, 1H), 7.34 – 7.27 (m, 6H), 7.23 – 7.13 (m, 3H), 7.07 – 7.02 (m, 2H), 6.95 – 
6.88 (m, 3H), 6.86 – 6.79 (m, 2H), 2.53 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 145.8 (Cq), 
138.6 (Cq), 137.8 (Cq), 137.3 (Cq), 133.9 (Cq), 133.3 (Cq), 133.1 (CH), 131.5 (CH), 130.2 (CH), 
130.2 (CH), 128.7 (CH), 127.6 (overlapped, CH), 127.0 (CH), 126.7 (Cq), 126.6 (CH), 126.1 (CH), 
123.8 (Cq), 112.2 (CH), 15.2 (CH3). IR (ATR): 2922, 1495, 1474, 1443, 1285, 1141, 752, 700, 
515 cm−1. MS (ESI) m/z (relative intensity): 361 (100) [M+H]+. HR-MS (ESI) m/z calc. for 
C26H21N2 [M+H]+: 361.1699, found: 361.1706. The analytical data corresponds with those 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64b (165 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146b (117 mg, 75%) as a white solid. M.p.: 183 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.63 (s, 1H), 7.29 (s, 1H), 7.22 – 6.96 (m, 9H), 6.79 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 7.6 Hz, 1H), 
6.62 (d, J = 8.5 Hz, 2H), 2.52 (t, J = 1.4 Hz, 3H), 2.29 (s, 3H), 2.03 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 145.7 (Cq), 138.8 (Cq), 138.2 (Cq), 138.0 (Cq), 137.1 (Cq), 136.3 (Cq), 133.9 (Cq), 





127.5 (CH), 127.2 (CH), 126.7 (CH), 126.7 (CH), 126.5 (CH), 123.5 (Cq, overlapped), 112.3 (CH), 
21.3 (CH3), 21.1 (CH3), 15.2 (CH3). IR (ATR): 2920, 1583, 1475, 1287, 1141, 775, 701, 530 cm−1. 
MS (ESI) m/z (relative intensity): 389 (100) [M+H]+. HR-MS (ESI) m/z calc. for C28H25N2 [M+H]+: 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64c (190 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146c (127 mg, 76%) as a white solid. M.p.: 262 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.61 (d, J = 1.3 Hz, 1H), 7.35 – 7.32 (m, 1H), 7.25 – 7.12 (m, 4H), 7.10 – 6.96 (m, 2H), 6.91 (d, J 
= 7.6 Hz, 1H), 6.85 – 6.76 (m, 3H), 6.51 – 6.29 (m, 3H), 3.66 (s, 3H), 3.48 (s, 3H), 2.50 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ = 159.8 (Cq), 158.5 (Cq), 145.8 (Cq), 138.7 (Cq), 138.7 (Cq), 137.8 
(Cq), 135.2 (Cq), 133.2 (Cq), 133.2 (CH), 130.2 (CH), 129.8 (CH), 128.1 (CH), 127.7 (CH), 126.8 
(CH), 126.5 (Cq), 124.3 (CH), 124.0 (Cq), 122.5 (CH), 117.0 (CH), 115.6 (CH), 114.8 (CH), 112.5 
(CH), 112.4 (CH), 55.3 (CH3), 55.2 (CH3), 15.3 (CH3). IR (ATR): 1599, 1474, 1473, 1430, 1316, 
1287, 1244, 1045, 762 cm−1. MS (ESI) m/z (relative intensity): 421 (100) [M+H]+, 185 (10). HR-




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64d (251 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 





7.70 (s, 1H), 7.60 (t, J = 4.7 Hz, 1H), 7.57 – 7.46 (m, 3H), 7.27 – 7.11 (m, 5H), 7.11 – 6.90 (m, 
5H), 2.55 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 145.8 (Cq), 137.8 (overlapped, Cq), 137.2 (Cq), 
134.5 (CH), 134.2 (Cq), 133.8 (CH), 133.3 (CH), 131.8 (Cq), 131.5 (q, 2JC-F = 18 Hz, Cq), 131.2 (q, 
2JC-F = 18 Hz, Cq), 130.0 (CH), 129.5 (CH), 128.4 (q, 3JC-F = 3 Hz, CH), 127.9 (CH), 127.8 (CH), 
127.3 (q, 3JC-F = 3 Hz, CH), 127.1 (CH), 126.0 (Cq), 125.8 (q, 3JC-F = 3 Hz, CH), 125.2 (Cq), 123.6 
(q, 1JC-F = 272 Hz, Cq), 123.5 (q, 1JC-F = 272 Hz, Cq), 123.2 (q, 3JC-F = 5 Hz, CH), 112.0 (CH), 15.2 
(CH3). 19F NMR (376 MHz, CDCl3): δ = –63.3 (s), –63.4 (s). IR (ATR): 1343, 1314, 1297, 1163, 
1117, 1076, 780, 705, 668 cm−1. MS (ESI) m/z (relative intensity): 497 (100) [M+H]+, 519 (10) 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64e (171 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146e (100 mg, 63%) as a white solid. M.p.: 182 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.67 (s, 1H), 7.44 – 7.28 (m, 2H), 7.26 – 7.15 (m, 3H), 7.11 – 6.98 (m, 5H), 6.90 (t, J = 7.2 Hz, 
1H), 6.70 – 6.59 (m, 2H), 6.55 (dd, J = 9.5, 2.4 Hz, 1H), 2.52 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 162.7 (d, 1JC-F = 248 Hz, Cq), 161.7 (d, 1JC-F = 246 Hz, Cq), 145.7 (Cq), 139.2 (d, 3JC-F 
= 8 Hz, Cq), 138.0 (Cq), 137.3 (Cq), 135.5 (d, 3JC-F = 8 Hz, Cq), 133.5 (CH), 131.8 (Cq), 130.6 (d, 
3JC-F = 7 Hz, CH), 130.0 (CH), 128.7 (d, 3JC-F = 7 Hz, CH), 127.8 (CH), 127.2 (d, 4JC-F = 3 Hz, CH), 
127.0 (CH), 125.9 (d, 4JC-F = 3 Hz, CH), 125.7 (Cq), 124.7 (Cq), 118.2 (d, 2JC-F = 21 Hz, CH), 117.1 
(d, 2JC-F = 22 Hz, CH), 116.1 (d, 2JC-F = 22 Hz, CH), 113.4 (d, 2JC-F = 21 Hz, CH), 112.1 (CH), 15.2 
(CH3). 19F NMR (376 MHz, CDCl3): δ = –111.7 (s), –114.3 (s). IR (ATR): 3029, 1611, 1579, 1472, 
1430, 1227, 931, 765, 695 cm−1. MS (ESI) m/z (relative intensity): 397 (100) [M+H]+, 419 (10) 








The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64f (198 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146f (120 mg, 70%) as a white solid. M.p.: 198 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.67 (s, 1H), 7.39 – 7.28 (m, 4H), 7.26 – 7.12 (m, 4H), 7.08 – 6.98 (m, 2H), 6.96 – 6.81 (m, 3H), 
6.73 (t, J = 6.8 Hz, 1H), 2.52 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 145.7 (Cq), 138.8 (Cq), 
138.0 (Cq), 137.4 (Cq), 135.2 (Cq), 134.7 (Cq), 133.5 (CH), 133.0 (Cq), 131.8 (Cq), 131.4 (CH), 
130.3 (CH), 130.1 (CH), 130.0 (CH), 129.6 (CH), 129.3 (CH), 128.5 (CH), 128.4 (CH), 
127.9 (CH), 127.0 (CH), 126.7 (CH), 125.7 (Cq), 124.8 (Cq), 112.1 (CH), 15.2 (CH3). IR (ATR): 
3046, 1592, 1564, 1463, 1289, 1145, 770, 697, 533 cm−1. MS (ESI) m/z (relative intensity): 429 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64g (183 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146g (110 mg, 67%) as a white solid. M.p.: 240 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.70 (s, 1H), 7.70 – 7.65 (m, 1H), 7.63 – 7.49 (m, 3H), 7.31 – 7.24 (m, 2H), 7.23 – 7.17 (m, 3H), 
7.14 – 7.05 (m, 3H), 7.05 – 6.92 (m, 2H), 2.53 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 145.8 
(Cq), 138.3 (Cq), 137.5 (Cq), 137.0 (Cq), 135.6 (CH), 134.8 (CH), 134.6 (Cq), 134.4 (CH), 134.2 
(CH), 133.6 (CH), 132.8 (CH), 130.9 (Cq), 130.4 (CH), 130.1 (CH), 130.0 (CH), 128.3 (CH), 
128.1 (CH), 127.4 (CH), 126.0 (Cq), 125.4 (Cq), 118.0 (Cq), 117.4 (Cq), 113.9 (Cq), 111.9 (Cq), 





m/z (relative intensity): 411 (100) [M+H]+, 433 (10) [M+Na]+. HR-MS (ESI) m/z calc. for C28H19N4 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64h (165 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146h (107 mg, 69%) as a white solid. M.p.: 259 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.63 (d, J = 1.1 Hz, 1H), 7.31 – 7.29 (m, 1H), 7.24 – 7.11 (m, 7H), 7.05 – 7.00 (m, 2H), 6.75 – 
6.66 (m, 4H), 2.52 (s, 3H), 2.35 (s, 3H), 2.13 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 145.9 (Cq), 
130.0 (Cq), 138.5 (Cq), 138.3 (Cq), 135.4 (Cq), 134.3 (Cq), 133.4 (Cq), 132.8 (CH), 131.3 (CH), 
131.1 (Cq), 130.3 (CH), 130.1 (CH), 129.5 (CH), 127.9 (CH), 127.7 (CH), 127.1 (Cq), 126.6 (CH), 
123.6 (Cq), 112.4 (CH), 21.5 (CH3), 21.2 (CH3), 15.3 (CH3). IR (ATR): 1600, 1513, 1483, 1442, 
1287, 1144, 817, 731, 702 cm−1. MS (ESI) m/z (relative intensity): 389 (100) [M+H]+. HR-MS 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64i (165 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146i (119 mg, 71%) as a white solid. M.p.: 197 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.62 (d, J = 1.3 Hz, 1H), 7.31 (d, J = 1.3 Hz, 1H), 7.23 – 7.13 (m, 5H), 7.05 – 7.00 (m, 2H), 6.85 
(d, J = 8.7 Hz, 2H), 6.71 (d, J = 8.7 Hz, 2H), 6.47 (d, J = 8.7 Hz, 2H), 3.80 (s, 3H), 3.64 (s, 3H), 
2.50 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 159.4 (Cq), 157.5 (Cq), 145.8 (Cq), 138.9 (Cq), 
138.2 (Cq), 133.3 (Cq), 132.9 (CH), 132.5 (CH), 131.4 (CH), 130.2 (CH), 129.8 (Cq), 127.6 (CH), 
126.5 (CH), 126.4 (overlapped, Cq), 123.5 (Cq), 114.1 (CH), 112.5 (CH), 112.1 (CH), 55.2 (CH3), 





MS (ESI) m/z (relative intensity): 421 (100) [M+H]+, 185 (10). HR-MS (ESI) m/z calc. for 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64j (251 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146j (137 mg, 69%) as a white solid. M.p.: 266 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.68 (d, J = 1.1 Hz, 1H), 7.63 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.25 – 7.17 (m, 6H), 
7.04 – 6.98 (m, 2H), 6.95 (d, J = 8.0 Hz, 2H), 2.54 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 
145.8 (Cq), 140.8 (Cq), 137.7 (Cq), 137.2 (Cq), 137.1 (Cq), 133.7 (CH), 131.7 (Cq), 131.7 (CH), 
131.2 (q, 2JC-F = 33 Hz, Cq), 130.7 (CH), 130.0 (CH), 128.6 (q, 2JC-F = 33 Hz, Cq), 127.9 (CH), 
127.1 (CH), 126.0 (q, 3JC-F = 4 Hz, CH), 125.8 (Cq), 125.2 (Cq), 124.2 (q, 3JC-F = 4 Hz, CH), 
123.8 (q, 1JC-F = 273 Hz, Cq), 123.5 (q, 1JC-F = 273 Hz, Cq), 112.0 (CH), 15.2 (CH3). 19F NMR (282 
MHz, CDCl3): δ = –62.7 (s), –62.9 (s). IR (ATR): 1615, 1323, 1157, 1109, 1065, 1019, 850, 704 
cm−1. MS (ESI) m/z (relative intensity): 497 (100) [M+H]+, 519 (10) [M+Na]+. HR-MS (ESI) m/z 




The general procedure A was followed using 145a (74 mg, 0.4 mmol) and 64k (171 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146k (82 mg, 52%) as a white solid. M.p.: 249 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.66 (d, J = 1.2 Hz, 1H), 7.29 – 7.26 (m, 2H), 7.25 – 7.14 (m, 4H), 7.07 – 6.99 (m, 4H), 6.79 – 
6.74 (m, 2H), 6.68 – 6.60 (m, 2H), 2.52 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 162.5 (d, 1JC-F = 
250 Hz, Cq), 161.1 (d, 1JC-F = 250 Hz, Cq), 145.7 (Cq), 138.3 (Cq), 137.8 (Cq), 133.2 (CH), 133.1 





(CH), 129.7 (d, 4JC-F = 4 Hz, Cq), 127.8 (CH), 126.8 (CH), 126.1 (Cq), 124.3 (Cq), 116.1 (d, 2JC-F = 
22 Hz, CH), 114.2 (d, 2JC-F = 22 Hz, CH), 112.0 (CH), 15.2 (CH3). 19F NMR (377 MHz, CDCl3): δ 
= –111.3 (s), –115.6 (s). IR (ATR): 3025, 1601, 1508, 1481, 1288, 1216, 1143, 782, 700 cm−1. 
MS (ESI) m/z (relative intensity): 397 (100) [M+H]+, 419 (10) [M+Na]+. HR-MS (ESI) m/z calc. for 




The general procedure F was followed using 145a (74 mg, 0.4 mmol) and 64l (269 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146l (141 mg, 68%) as a white solid. M.p.: 276 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.65 (d, J = 1.2 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.27 – 7.17 (m, 4H), 7.17 – 7.12 (m, 2H), 7.11 
– 7.05 (m, 2H), 7.03 – 6.97 (m, 2H), 6.68 (d, J = 8.4 Hz, 2H), 2.50 (s, 3H). 13C NMR (75 MHz, 
CDCl3): δ = 145.7 (Cq), 138.1 (Cq), 137.4 (Cq), 136.1 (Cq), 133.4 (CH), 132.9 (CH), 132.5 (Cq), 
132.3 (CH), 132.0 (Cq), 131.7 (CH), 130.5 (CH), 130.1 (CH), 127.9 (CH), 127.0 (CH), 125.7 (Cq), 
124.6 (Cq), 123.3 (Cq), 120.7 (Cq), 112.0 (CH), 15.2 (CH3). IR (ATR): 2149, 1977, 1948, 1474, 
1070, 1011, 822, 732, 700 cm−1. MS (ESI) m/z (relative intensity): 516 (100) [M+H]+, 441 (10). 




The general procedure F was followed using 145b (43 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146m (63 mg, 55%) as a white solid. M.p.: 135 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.59 (d, J = 1.3 Hz, 1H), 7.41 – 7.36 (m, 3H), 7.35 (d, J = 1.3 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.23 
– 7.17 (m, 4H), 7.17 – 7.12 (m, 2H), 2.72 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 145.7 (Cq), 
138.6 (Cq), 133.6 (Cq), 133.0 (Cq), 132.9 (CH), 130.3 (CH), 129.9 (CH), 129.0 (CH), 128.9 (CH), 
128.0 (CH), 126.9 (CH), 126.8 (CH), 126.1 (Cq), 125.6 (Cq), 112.2 (CH), 17.0 (CH3). IR (ATR): 





[M+H]+. HR-MS (ESI) m/z calc. for C20H17N2 [M+H]+: 285.1386, found: 285.1388. The analytical 




The general procedure F was followed using 145c (49 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146n (63 mg, 53%) as a white solid. M.p.: 196 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.57 – 7.49 (m, 1H), 7.33 – 7.27 (m, 3H), 7.25 – 7.16 (m, 5H), 7.15 – -7.12 (m, 1H), 7.10 – 7.02 
(m, 2H), 2.70 (s, 3H), 2.10 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 146.1 (Cq), 137.9 (Cq), 133.9 
(Cq), 133.1 (Cq), 132.4 (CH), 131.6 (Cq), 130.7 (CH), 130.0 (CH), 128.6 (CH), 128.5 (CH), 127.8 
(CH), 127.6 (Cq), 126.8 (CH), 123.2 (Cq), 111.7 (CH), 17.1 (CH3), 13.9 (CH3). IR (ATR): 1979, 
1474, 1442, 1306, 869, 755, 695 cm−1. MS (ESI) m/z (relative intensity): 299 (100) [M+H]+. HR-




The general procedure F was followed using 145d (49 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146o (60 mg, 50%) as a white solid. M.p.: 189 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.42 – 7.36 (m, 3H), 7.32 – 7.28 (m, 2H), 7.23 – 7.17 (m, 3H), 7.16 – 7.12 (m, 3H), 7.10 (s, 1H), 
2.70 (s, 3H), 2.45 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 145.3 (Cq), 142.6 (Cq), 138.8 (Cq), 
133.8 (Cq), 132.5 (Cq), 130.3 (CH), 129.9 (CH), 128.9 (CH), 128.9 (CH), 127.9 (CH), 126.7 (CH), 
126.6 (CH), 125.1 (Cq), 125.0 (Cq), 109.4 (CH), 17.1 (CH3), 14.5 (CH3). IR (ATR): 2017, 1989, 
1476, 1437, 1320, 1180, 768, 699 cm−1. MS (ESI) m/z (relative intensity): 299 (100) [M+H]+. HR-








The general procedure F was followed using 145e (74 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146p (74 mg, 51%) as a white solid. M.p.: 205 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.98 – 7.90 (m, 2H), 7.63 (s, 1H), 7.45 – 7.41 (m, 4H), 7.41 – 7.28 (m, 4H), 7.24 – 7.13 (m, 6H), 
2.79 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 146.0 (Cq), 145.3 (Cq), 138.7 (Cq), 134.2 (Cq), 133.7 
(Cq), 132.8 (Cq), 130.4 (CH), 129.9 (CH), 129.0 (overlapped, CH), 128.6 (CH), 128.0 (CH), 127.7 
(CH), 127.2 (CH), 126.8 (CH), 126.2 (CH), 126.1 (Cq), 125.6 (Cq), 108.0 (CH), 17.1 (CH3). 
IR (ATR): 1979, 1950, 1475, 724, 695, 583, 509 cm−1. MS (ESI) m/z (relative intensity): 361 (100) 




The general procedure F was followed using 145f (55 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146q (50 mg, 40%) as a white solid. M.p.: 185 °C. 1H NMR (400 MHz, CDCl3): δ = 
7.38 – 7.24 (m, 5H), 7.19 – 7.13 (m, 3H), 7.11 – 7.06 (m, 2H), 6.99 (s, 1H), 2.68 (s, 3H), 2.40 (s, 
3H), 1.66 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 144.6 (Cq), 140.5 (Cq), 139.3 (Cq), 133.7 (Cq), 
133.5 (Cq), 131.9 (CH), 130.0 (CH), 128.5 (CH), 127.6 (CH), 127.3 (CH), 126.4 (CH), 126.3 (Cq), 
125.4 (CH), 125.1 (Cq), 118.6 (Cq), 17.2 (CH3), 13.7 (CH3), 12.0 (CH3). IR (ATR): 2148, 2085, 
1978, 1438, 1251, 710, 697, 642 cm−1. MS (ESI) m/z (relative intensity): 313 (100) [M+H]+. HR-








The general procedure F was followed using 145g (80 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146r (75 mg, 50%) as a white solid. M.p.: 256 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.70 (s, 1H), 7.42 – 7.33 (m, 3H), 7.27 – 7.16 (m, 5H), 7.13 – 7.08 (m, 2H), 5.75 (s, 1H), 2.78 (s, 
3H), 2.36 (s, 3H), 2.13 (s, 3H), 2.06 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 149.3 (Cq), 143.8 
(Cq), 137.6 (Cq), 135.6 (Cq), 135.5 (Cq), 134.2 (Cq), 133.8 (overlapped, Cq), 130.9 (CH), 130.4 
(CH), 128.8 (CH), 128.8 (Cq), 128.6 (CH), 127.8 (CH), 126.8 (CH), 126.2 (Cq), 122.7 (Cq), 119.1 
(CH), 114.6 (CH), 20.7 (CH3), 20.5 (CH3), 17.7 (CH3), 14.4 (CH3). IR (ATR): 2152, 2086, 2045, 
1464, 856, 726, 697 cm−1. MS (ESI) m/z (relative intensity): 377 (100) [M+H]+. HR-MS (ESI) m/z 




The general procedure F was followed using 145h (63 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146s (68 mg, 51%) as a white solid. M.p.: 232 °C. 1H NMR (300 MHz,CDCl3): δ = 
7.98 (d, J = 8.0 Hz, 1H), 7.53 – 7.34 (m, 7H), 7.26 – 7.15 (m, 5H), 6.91 (t, J = 7.8 Hz, 1H), 6.20 
(d, J = 8.5 Hz, 1H), 2.82 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 149.3 (Cq), 145.0 (Cq), 138.2 
(Cq), 135.9 (Cq), 133.3 (Cq), 131.1 (CH), 130.7 (CH), 130.4 (Cq), 130.0 (CH), 129.5 (CH), 129.0 
(CH), 127.9 (CH), 126.7 (CH), 126.1 (Cq), 124.8 (CH), 124.5 (Cq), 120.3 (CH), 119.7 (CH), 114.9 
(CH), 17.6 (CH3). IR (ATR): 2149, 2096, 1476, 1448, 1382, 1361, 730, 699 cm−1. MS (ESI) m/z 
(relative intensity): 335 (100) [M+H]+, 357 (10) [M+Na]+. HR-MS (ESI) m/z calc. for C24H19N2 








The general procedure F was followed using 145i (80 mg, 0.4 mmol) and 64a (143 mg, 0.8 
mmol) at 140 °C for 8 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 146t (108 mg, 72%) as a white solid. M.p.: 255 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.97 (dt, J = 8.2, 1.0 Hz, 1H), 7.63 (d, J = 5.2 Hz, 1H), 7.50 – 7.34 (m, 6H), 7.31 – 7.23 (m, 5H), 
7.07 (d, J = 5.2 Hz, 1H), 6.93 (ddd, J = 8.5, 7.1, 1.2 Hz, 1H), 6.10 (dt, J = 8.5, 0.9 Hz, 1H). 13C 
NMR (75 MHz, CDCl3): δ = 145.2 (Cq), 144.9 (Cq), 140.3 (Cq), 136.1 (Cq), 135.0 (Cq), 133.2 (Cq), 
130.8 (CH), 130.8 (CH), 130.7 (Cq), 129.4 (CH), 129.2 (CH), 128.9 (CH), 128.0 (CH), 127.3 (CH), 
125.7 (Cq), 125.3 (CH), 124.5 (CH), 121.5 (Cq), 120.7 (CH), 119.4 (CH), 114.4 (CH). IR (ATR): 
2010, 1979, 1950, 1629, 1483, 1410, 733, 695 cm−1. MS (ESI) m/z (relative intensity): 377 (100) 
[M+H]+, 399 (10) [M+Na]+. HR-MS (ESI) m/z calc. for C25H17N2S [M+H]+: 377.1107, found: 




The general procedure G was followed using 147a (39 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148a (56 mg, 75%) as a white solid. M.p.: 275 °C. 1H NMR (300 MHz, CDCl3): δ = 9.02 
(d, J = 8.3 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.71 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 
7.47 – 7.34 (m, 7H), 7.33 – 7.23 (m, 5H), 6.96 (t, J = 7.8 Hz, 1H), 6.04 (d, J = 8.5 Hz, 1H). 13C 
NMR (101 MHz, CDCl3): δ = 147.8 (Cq), 144.3 (Cq), 135.7 (Cq), 135.1 (Cq), 133.7 (Cq), 132.7 (Cq), 
131.5 (CH), 131.2 (Cq), 130.6 (CH), 129.9 (CH), 129.2 (CH), 128.7 (CH), 128.0 (CH), 127.8 (CH), 
127.3 (CH), 126.4 (CH), 125.1 (CH), 124.1 (CH), 123.5 (Cq), 122.9 (Cq), 121.2 (CH), 119.6 (CH), 
114.1 (CH). IR (ATR): 2142, 2021, 1522, 1487, 1443, 1330, 744, 700 cm−1. MS (ESI) m/z 









The general procedure G was followed using 147b (42 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148b (40 mg, 52%) as a white solid. M.p.: 264 °C. 1H NMR (300 MHz, CDCl3): δ = 8.90 
(d, J = 8.2 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.2, 1.6 Hz, 1H), 7.45 – 7.33 (m, 6H), 
7.33 – 7.28 (m, 3H), 7.26 – 7.21 (m, 2H), 7.13 (s, 1H), 6.93 (td, J = 8.4, 1.1 Hz, 1H), 6.01 (dd, J 
= 8.5, 0.9 Hz, 1H), 2.45 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 148.0 (Cq), 144.3 (Cq), 140.3 
(Cq), 135.8 (Cq), 135.1 (Cq), 133.8 (Cq), 132.8 (Cq), 131.5 (CH), 131.2 (Cq), 130.7 (CH), 129.3 
(CH), 129.1 (CH), 128.7 (CH), 128.0 (CH), 127.2 (CH), 126.1 (CH), 125.0 (CH), 124.0 (CH), 
123.4 (Cq), 121.0 (CH), 120.7 (Cq), 119.4 (CH), 114.1 (CH), 22.0 (CH3). IR (ATR): 2046, 1625, 
1524, 1486, 1444, 1326, 1257, 819, 779 cm−1. MS (ESI) m/z (relative intensity): 385 (100) 
[M+H]+. HR-MS (ESI) m/z calc. for C28H21N2 [M+H]+: 385.1699, found: 385.1699. The analytical 




The general procedure G was followed using 147c (45 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148c (48 mg, 60%) as a white solid. M.p.: 235 °C. 1H NMR (400 MHz, CDCl3): δ = 8.93 
(d, J = 8.8 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.45 – 7.34 (m, 6H), 7.34 – 7.26 (m, 4H), 7.25 – 





3H). 13C NMR (101 MHz, CDCl3): δ = 161.0 (Cq), 148.0 (Cq), 144.4 (Cq), 135.7 (Cq), 135.6 (Cq), 
134.6 (Cq), 133.8 (Cq), 131.4 (CH), 131.2 (Cq), 130.6 (CH), 129.2 (CH), 128.7 (CH), 128.1 (CH), 
127.3 (CH), 127.0 (CH), 124.0 (CH), 123.2 (Cq), 120.8 (CH), 119.2 (CH), 116.8 (Cq), 116.4 (CH), 
114.0 (CH), 108.8 (CH), 55.3 (CH3). IR (ATR): 2138, 1609, 1464, 1444, 1221, 725, 696, 567 
cm−1. MS (ESI) m/z (relative intensity): 401 (100) [M+H]+. HR-MS (ESI) m/z calc. for C28H21N2O 





The general procedure G was followed using 147d (52 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148d (69 mg, 79%) as a white solid. M.p.: 240 °C. 1H NMR (300 MHz, CDCl3): δ = 9.13 
(d, J = 8.4 Hz, 1H), 8.04 (dt, J = 8.2, 1.0 Hz, 1H), 7.92 (ddd, J = 8.4, 1.8, 0.6 Hz, 1H), 7.63 (dt, J 
= 1.7, 0.8 Hz, 1H), 7.50 – 7.40 (m, 4H), 7.39 – 7.30 (m, 5H), 7.26 – 7.20 (m, 2H), 7.01 (ddd, J = 
8.5, 7.2, 1.2 Hz, 1H), 6.05 (dt, J = 8.5, 0.9 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ = 146.8 (Cq), 
144.4 (Cq), 136.7 (Cq), 134.8 (Cq), 133.4 (Cq), 132.6 (Cq), 131.6 (q, 2JC-F = 32 Hz, Cq), 131.5 (CH), 
131.3 (Cq), 130.6 (CH), 129.7 (CH), 129.0 (CH), 128.5 (CH), 127.9 (CH), 126.1 (CH), 125.4 (Cq), 
124.7 (CH), 124.1 (q, 1JC-F = 273 Hz, Cq), 124.0 (q, 3JC-F = 3 Hz, CH), 123.6 (q, 3JC-F = 4 Hz, CH), 
123.3 (Cq), 122.1 (CH), 120.1 (CH), 114.5 (CH). 19F NMR (377 MHz, CDCl3): δ = –62.5 (s). IR 
(ATR): 1450, 1432, 1416, 1321, 1167, 1122, 1065, 1017, 850, 744 cm−1. MS (ESI) m/z (relative 
intensity): 439 (100) [M+H]+. HR-MS (ESI) m/z calc. for C28H18F3N2 [M+H]+: 439.1422 found: 








The general procedure G was followed using 147e (42 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148e (60 mg, 77%) as a white solid. M.p.: 251 °C. 1H NMR (300 MHz, CDCl3): δ = 9.00 
(dd, J = 8.9, 5.7 Hz, 1H), 7.99 (dt, J = 8.2, 0.9 Hz, 1H), 7.50 – 7.28 (m, 10H), 7.26 – 7.19 (m, 2H), 
7.01 (dd, J = 10.4, 2.5 Hz, 1H), 6.95 (t, J = 8.4 Hz, 1H), 6.02 (dt, J = 8.5, 0.9 Hz, 1H). 13C NMR 
(75 MHz, CDCl3): δ = 163.7 (d, 1JC-F = 248 Hz, Cq), 147.3 (Cq), 144.3 (Cq), 136.3 (Cq), 135.1 (Cq), 
134.8 (d, 3JC-F = 9.1 Hz, Cq), 133.4 (Cq), 131.4 (CH), 131.1 (Cq), 130.5 (CH), 129.4 (CH), 128.8 
(CH), 128.2 (CH), 127.7 (d, 3JC-F = 9.3 Hz, CH), 127.6 (CH), 124.3 (CH), 122.9 (d, 4JC-F = 3.4 Hz, 
Cq), 121.3 (CH), 119.5 (CH), 119.5 (Cq), 116.4 (d, 2JC-F = 24 Hz, CH), 114.1 (CH), 111.7 (d, 2JC-F = 
23 Hz, CH). 19F NMR (282 MHz, CDCl3): δ = –108.3 (s). IR (ATR): 2140, 2014, 1467, 1444, 1324, 
1267, 1201, 730 cm−1. MS (ESI) m/z (relative intensity): 389 (100) [M+H]+. HR-MS (ESI) m/z calc. 
for C27H18N2F [M+H]+: 389.1449, found: 389.1447. The characterization data correspond with 




The general procedure G was followed using 147f (46 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148f (55 mg, 68%) as a white solid. M.p.: 295 °C. 1H NMR (400 MHz, CDCl3): δ = 8.94 
(d, J = 8.6 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.49 – 7.38 (m, 4H), 7.38 – 
7.29 (m, 6H), 7.26 – 7.18 (m, 2H), 6.97 (t, J = 7.8 Hz, 1H), 6.02 (d, J = 8.5 Hz, 1H). 13C NMR 





133.4 (Cq), 131.4 (CH), 131.1 (Cq), 130.4 (CH), 129.4 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 
127.6 (CH), 126.7 (CH), 125.7 (CH), 124.4 (CH), 122.6 (Cq), 121.5 (CH), 121.3 (Cq), 119.6 (CH), 
114.2 (CH). IR (ATR): 2141, 2046, 2022, 1920, 1444, 733, 710 cm−1. MS (ESI) m/z (relative 
intensity): 405 (100) [M+H]+, 371 (10). HR-MS (ESI) m/z calc. for C27H18N235Cl [M+H]+: 405.1153, 




The general procedure G was followed using 147g (55 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148g (48 mg, 53%) as a white solid. M.p.: 297 °C. 1H NMR (400 MHz, CDCl3): δ = 8.87 
(d, J = 8.5 Hz, 1H), 7.99 (dd, J = 8.2, 1.0 Hz, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.49 (s, 1H), 7.46 – 
7.38 (m, 4H), 7.37 – 7.29 (m, 5H), 7.24 – 7.19 (m, 2H), 6.97 (t, J = 8.4 Hz, 1H), 6.02 (dd, J = 8.6, 
0.9 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ = 147.2 (Cq), 144.3 (Cq), 136.4 (Cq), 134.9 (Cq), 
134.1 (Cq), 133.4 (Cq), 131.4 (CH), 131.1 (Cq), 131.0 (CH), 130.5 (CH), 129.4 (CH), 128.8 (CH), 
128.8 (CH), 128.2 (CH), 127.6 (CH), 126.7 (CH), 124.6 (Cq), 124.4 (CH), 122.5 (Cq), 121.6 (Cq), 
121.6 (CH), 119.7 (CH), 114.2 (CH). IR (ATR): 3049, 1599, 1486, 1443, 1417, 1324, 732, 702 
cm−1. MS (ESI) m/z (relative intensity): 449 (100) [M+H]+, 631 (30). HR-MS (ESI) m/z calc. for 
C27H18N279Br [M+H]+: 449.0648, found: 449.0647. The analytical data correspond with those 









at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148h (60 mg, 68%) as a white solid. M.p.: 260 °C. 1H NMR (400 MHz, CDCl3): δ = 8.78 
(d, J = 9.0 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.43 – 7.34 (m, 5H), 7.33 – 7.28 (m, 3H), 7.26 – 
7.22 (m, 3H), 7.10 (dd, J = 9.1, 2.6 Hz, 1H), 6.86 (t, J = 7.3 Hz, 1H), 6.35 (d, J = 2.6 Hz, 1H), 
5.95 (d, J = 8.4 Hz, 1H), 3.32 (q, J = 7.1 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, 
CDCl3): δ = 148.8 (Cq), 148.8 (Cq), 144.7 (Cq), 136.3 (Cq), 135.0 (Cq), 134.8 (Cq), 134.2 (Cq), 
131.5 (CH), 131.3 (Cq), 130.7 (CH), 129.0 (CH), 128.6 (CH), 127.8 (CH), 127.0 (CH), 126.6 (CH), 
123.6 (CH), 123.4 (Cq), 120.0 (CH), 118.7 (CH), 113.7 (CH), 113.4 (CH), 111.9 (Cq), 106.2 (CH), 
44.6 (CH2), 12.4 (CH3). IR (ATR): 3051, 2972, 1626, 1604, 1484, 1442, 1253, 1073, 700 cm−1. 
MS (ESI) m/z (relative intensity): 442 (100) [M+H]+. HR-MS (ESI) m/z calc. for C31H28N3 [M+H]+: 





The general procedure G was followed using 147i (52 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148i (45 mg, 51%) as a white solid. M.p.: 285 °C. 1H NMR (400 MHz, CDCl3): δ = 9.32 
(d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.77 (dd, J = 8.6, 1.8 Hz, 1H), 7.50 – 7.37 (m, 7H), 
7.36 – 7.29 (m, 3H), 7.26 – 7.22 (m, 2H), 6.99 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H), 6.05 (d, J = 8.5 Hz, 
1H). 13C NMR (101 MHz, CDCl3): δ = 146.9 (Cq), 144.2 (Cq), 137.2 (Cq), 135.0 (Cq), 134.8 (Cq), 
133.2 (Cq), 131.4 (CH), 131.1 (Cq), 130.4 (CH), 129.6 (q, 2JC-F = 33 Hz, Cq), 129.5 (CH), 128.9 
(CH), 128.3 (CH), 127.6 (CH), 127.2 (CH), 125.8 (q, 3JC-F = 3.4 Hz, CH), 124.6 (CH), 124.0 (q, 
1JC-F = 272 Hz, Cq), 122.8 (Cq), 122.8 (Cq), 122.6 (q, 3JC-F = 4.1 Hz, CH), 121.9 (CH), 119.8 (CH), 
114.3 (CH). 19F NMR (377 MHz, CDCl3): δ = –62.16 (s). IR (ATR): 2270, 2149, 1977, 1948, 1474, 
1070, 1011, 732, 700 cm−1. MS (ESI) m/z (relative intensity): 439 (100) [M+H]+. HR-MS (ESI) 
m/z calc. for C28H18N2F3 [M+H]+: 439.1417, found: 439.1417. The analytical data correspond with 








The general procedure G was followed using 147j (49 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148j (45 mg, 54%) as a white solid. M.p.: 236 °C. 1H NMR (400 MHz, CDCl3): δ = 11.17 
(d, J = 8.5 Hz, 1H), 8.16 (t, J = 8.1 Hz, 1H), 8.06 – 7.94 (m, 3H), 7.76 (t, J = 7.6 Hz, 1H), 7.51 – 
7.38 (m, 7H), 7.37 – 7.29 (m, 5H), 6.99 (t, J = 7.8 Hz, 1H), 6.12 (d, J = 8.4 Hz, 1H). 13C NMR 
(101 MHz, CDCl3): δ = 147.9 (Cq), 144.7 (Cq), 136.4 (Cq), 136.1 (Cq), 134.0 (Cq), 132.6 
(overlapped, Cq), 132.4 (Cq), 131.7 (CH), 130.8 (CH), 130.6 (overlapped, CH), 130.2 (Cq), 129.9 
(Cq), 129.2 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 127.3 (CH), 126.8 (CH), 
124.3 (CH), 124.0 (CH), 121.1 (CH), 119.9 (CH), 118.1 (Cq), 114.4 (CH). IR (ATR): 2905, 1745, 
1590, 1481, 1447, 1377, 1175, 825, 730 cm−1. MS (ESI) m/z (relative intensity): 421 (100) 
[M+H]+. HR-MS (ESI) m/z calc. for C31H21N2 [M+H]+: 421.1699, found: 421.1699. The analytical 
data correspond with those reported in the literature.[237] 
 
5,6-Diphenylnaphtho[2',3':4,5]imidazo[2,1-a]isoquinoline (148k) 
The general procedure G was followed using 147k (49 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148k (42 mg, 50%) as a white solid. M.p.: 287 °C. 1H NMR (300 MHz, CDCl3): δ = 9.18 
(d, J = 7.9 Hz, 1H), 8.49 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.77 (t, J = 7.5 Hz, 1H), 7.68 (t, J = 7.7 
Hz, 1H), 7.59 – 7.38 (m, 8H), 7.37 – 7.26 (m, 6H), 6.40 (s, 1H). 13C NMR (75 MHz, CDCl3): δ = 
135.5 (Cq), 135.2 (overlapped, Cq), 133.8 (Cq), 133.4 (Cq), 131.5 (CH), 131.4 (CH), 131.3 (Cq), 
131.2 (overlapped, Cq), 130.7 (CH), 129.5 (CH), 129.0 (overlapped, Cq), 128.9 (CH), 128.4 (CH), 
128.2 (CH), 128.2 (CH), 127.8 (CH), 127.5 (CH), 126.5 (CH), 126.1 (CH), 124.8 (CH), 124.0 





729, 696 cm−1. MS (ESI) m/z (relative intensity): 421 (100) [M+H]+, 381 (10). HR-MS (ESI) m/z 




The general procedure G was followed using 147l (58 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148l (49 mg, 53%) as a white solid. M.p.: 309 °C. 1H NMR (400 MHz, CDCl3): δ = 9.06 
(d, J = 8.4 Hz, 1H), 7.88 (dd, J = 8.5, 1.8 Hz, 1H), 7.76 (s, 1H), 7.63 – 7.61 (m, 1H), 7.50 – 7.42 
(m, 3H), 7.40 – 7.30 (m, 5H), 7.27 – 7.23 (m, 2H), 5.73 (s, 1H), 2.38 (s, 3H), 2.09 (s, 3H). 13C 
NMR (101 MHz, CDCl3): δ = 145.9 (Cq), 142.9 (Cq), 136.5 (Cq), 134.8 (Cq), 133.8 (Cq), 133.5 (Cq), 
132.1 (Cq), 131.4 (CH), 131.1 (Cq), 130.9 (q, 2JC-F = 32 Hz, Cq), 130.5 (CH), 129.5 (Cq), 
129.2 (CH), 128.7 (CH), 128.2 (CH), 127.6 (CH), 125.6 (CH), 125.2 (Cq), 124.0 (q, 1JC-F = 272 Hz, 
Cq), 123.5 (q, 3JC-F = 3 Hz, CH), 123.3 (q, 3JC-F = 4 Hz, CH), 122.5 (Cq), 119.6 (CH), 114.3 (CH), 
20.7 (CH3), 20.4 (CH3). 19F NMR (377 MHz, CDCl3): δ = –62.3 (s). IR (ATR): 2920, 1487, 1458, 
1357, 1313, 1151, 1125, 698 cm−1. MS (ESI) m/z (relative intensity): 467 (100) [M+H]+. HR-MS 




The general procedure G was followed using 147m (60 mg, 0.2 mmol) and 64a (72 mg, 0.4 





5:1) yielded 148m (48 mg, 50%) as a white solid. M.p.: 307 °C. 1H NMR (400 MHz, CDCl3): δ = 
8.80 (d, J = 8.6 Hz, 1H), 7.76 (dd, J = 8.6, 1.9 Hz, 1H), 7.73 (s, 1H), 7.48 – 7.39 (m, 4H), 7.36 – 
7.28 (m, 5H), 7.25 – 7.21 (m, 2H), 5.69 (s, 1H), 2.37 (s, 3H), 2.08 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 146.5 (Cq), 142.9 (Cq), 136.3 (Cq), 135.1 (Cq), 133.9 (Cq), 133.6 (Cq), 133.6 (Cq), 
131.5 (CH), 130.8 (CH), 130.6 (Cq), 130.5 (CH), 129.5 (Cq), 129.2 (CH), 128.7 (CH), 128.7 (CH), 
128.2 (CH), 127.5 (CH), 126.5 (CH), 124.1 (Cq), 121.9 (Cq), 121.7 (Cq), 119.4 (CH), 114.3 (CH), 
20.8 (CH3), 20.4 (CH3). IR (ATR): 1598, 1522, 1444, 1416, 1072, 872, 703, 661 cm−1. MS (ESI) 
m/z (relative intensity): 477 (100) [M+H]+, 659 (20). HR-MS (ESI) m/z calc. for C29H22N279Br 




The general procedure G was followed using 147a (39 mg, 0.2 mmol) and 64m (46 mg, 0.4 
mmol) at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 
5:1) yielded 148n (51 mg, 83%) as a white solid. M.p.: 238 °C. 1H NMR (300 MHz, CDCl3): δ = 
8.99 (dd, J = 7.6, 1.4 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.82 – 7.72 (m, 2H), 7.73 – 7.65 (m, 3H), 
7.54 – 7.49 (m, 2H), 7.39 – 7.34 (m, 1H), 6.93 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 5.96 (d, J = 8.5 Hz, 
1H), 2.34 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 147.7 (Cq), 144.1 (Cq), 134.7 (Cq), 134.4 (Cq), 
132.5 (Cq), 131.3 (Cq), 130.4 (CH), 130.2 (CH), 129.9 (CH), 129.7 (CH), 127.8 (CH), 125.5 (CH), 
124.2 (CH), 124.0 (CH), 123.3 (Cq), 121.2 (CH), 119.6 (CH), 115.6 (Cq), 114.0 (CH), 14.6 (CH3). 
IR (ATR): 1524, 1448, 1376, 1253, 907, 906, 730, 701, 650 cm−1. MS (ESI) m/z (relative 
intensity): 309 (100) [M+H]+. HR-MS (ESI) m/z calc. for C22H17N2 [M+H]+: 309.1392 found: 







Methyl 5,6-diphenylbenzo[4,5]imidazo[2,1-a]isoquinoline-3-carboxylate (148o) 
The general procedure G was followed using 147n (51 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148o (80 mg, 93%) as a white solid. M.p.: 265 °C.  1H NMR (400 MHz, CDCl3): δ = 9.07 
(d, J = 8.4 Hz, 1H), 8.33 (dd, J = 8.4, 1.6 Hz, 1H), 8.09 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.49 – 
7.40 (m, 4H), 7.40 – 7.26 (m, 6H), 7.26 – 7.24 (m, 1H), 7.00 (t, J = 8.4 Hz, 1H), 6.05 (d, J = 8.5 
Hz, 1H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 166.7 (Cq), 146.9 (Cq), 144.4 (Cq), 136.0 
(Cq), 134.9 (Cq), 133.5 (Cq), 132.3 (Cq), 131.5 (CH), 131.2 (Cq), 131.1 (Cq), 130.6 (CH), 129.4 
(CH), 128.8 (CH), 128.2 (overlapped, CH), 127.9 (CH), 127.6 (CH), 126.0 (Cq), 125.3 (CH), 
124.5 (CH), 123.6 (Cq), 121.9 (CH), 119.9 (CH), 114.3 (CH), 52.4 (CH3). IR (ATR): 2920, 1722, 
1446, 1266, 738, 709, 500, 467, 449 cm−1. MS (ESI) m/z (relative intensity): 429 (100) [M+H]+. 




The general procedure G was followed using 64o (53 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 1:1) 
yielded 148p (50 mg, 57%) as a white solid. M.p.: 310 °C.  1H NMR (400 MHz, CDCl3): δ = 9.04 
(d, J = 8.2 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.74 (dd, J = 8.2, 1.6 Hz, 1H), 7.47 – 7.34 (m, 7H), 
7.33 – 7.22 (m, 5H), 6.98 (t, J = 7.9 Hz, 1H), 6.04 (d, J = 8.5 Hz, 1H), 3.11 (s, 3H), 2.95 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ = 170.8 (Cq), 147.2 (Cq), 144.3 (Cq), 137.6 (Cq), 136.0 (Cq), 135.1 
(Cq), 133.5 (Cq), 132.5 (Cq), 131.5 (CH), 131.2 (Cq), 130.5 (CH), 129.4 (CH), 128.8 (CH), 128.2 
(CH), 127.5 (CH), 126.2 (CH), 125.3 (CH), 125.1 (CH), 124.4 (CH), 123.5 (Cq), 123.3 (Cq), 121.6 
(CH), 119.8 (CH), 114.2 (CH), 39.5 (CH3), 35.3 (CH3). IR (ATR): 1624, 1485, 1442, 1391, 1071, 
839, 744, 722 cm−1. MS (ESI) m/z (relative intensity): 442 (100) [M+H]+. HR-MS (ESI) m/z calc. 








The general procedure G was followed using 147p (47 mg, 0.2 mmol) and 64a (72 mg, 0.4 mmol) 
at 100 °C for 4 h. Purification by column chromatography on silica gel (n-hexane/EtOAc = 5:1) 
yielded 148q (51 mg, 62%) as a white solid. M.p.: 275 °C.  1H NMR (400 MHz, CDCl3): δ = 9.55 
(d, J = 1.9 Hz, 1H), 8.19 (dd, J = 8.6, 1.9 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.51 – 7.40 (m, 5H), 
7.40 – 7.35 (m, 2H), 7.35 – 7.28 (m, 3H), 7.25 – 7.20 (m, 2H), 6.99 (t, J = 8.5 Hz, 1H), 6.05 (d, J 
= 8.5 Hz, 1H), 2.87 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 197.5 (Cq), 147.4 (Cq), 144.2 (Cq), 
137.4 (Cq), 135.8 (Cq), 135.8 (Cq), 135.1 (Cq), 133.3 (Cq), 131.4 (CH), 131.1 (Cq), 130.3 (CH), 
129.5 (CH), 128.9 (CH), 128.3 (CH), 128.2 (CH), 127.6 (CH), 126.9 (CH), 126.2 (CH), 124.6 
(CH), 123.2 (Cq), 122.6 (Cq), 121.7 (CH), 119.7 (CH), 114.3 (CH), 27.0 (CH3). IR (ATR): 1683, 
1608, 1421, 1257, 916, 825, 700 cm−1. MS (ESI) m/z (relative intensity): 413 (100) [M+H]+. HR-
MS (ESI) m/z calc. for C29H21N2O [M+H]+: 413.1648 found: 413.1651.  
5.3.3.2  H/D Exchange Experiment  
 
In an undivided cell equipped with a GF anode (10 mm × 15 mm × 6 mm) and a platinum 
cathode (10 mm × 15 mm × 0.25 mm), 145a (74 mg, 0.4 mmol), alkyne 64a (142.4 mg, 0.8 
mmol), KPF6 (15 mg, 20.0 mol %) and [RuCl2(p-cymene)]2 (12.5 mg, 5.0 mol %) were dissolved 
in DMF (4 mL) and CD3OD (0.2 mL) under N2. Electrocatalysis was performed at 100 °C with a 
constant current of 4.0 mA maintained for 2 h. After the reaction, the GF anode was washed with 
EtOAc (3×10 mL) in an ultrasonic bath. The combined organic phases were added to the 
reaction mixture. Evaporation of the solvent and subsequent column chromatography (n-











In an undivided cell equipped with a GF anode (10 mm × 15 mm × 6 mm) and a platinum 
cathode (10 mm × 15 mm × 0.25 mm), 147a (39 mg, 0.2 mmol), alkyne 64a (71 mg, 0.4 mmol), 
1-AdCO2H (7.2 mg, 20.0 mol %) and [RuCl2(p-cymene)]2 (6.2 mg, 5.0 mol %) were dissolved in 
t-AmOH (3 mL) and D2O (3 mL) under N2. Electrocatalysis was performed at 100 °C with a 
constant current of 4.0 mA maintained for 1 h. The GF anode was washed with ethyl acetate 
(3×10 mL) in an ultrasonic bath. Evaporation of the solvent and subsequent column 
chromatography (n-hexane/EtOAc = 10:1 → 5:1) yielded [D]n-147a (24 mg, 62%) as a white 
solid and [D]n-148a (26 mg, 35%) as a white solid. The D-incorporation was estimated by 


















5.3.3.3 Competition Experiments  
  
The general procedure F was followed using 145a (74 mg, 0.40 mmol), alkyne 64b (82 mg, 0.40 
mmol) and 64d (125 mg, 0.40 mmol). Then, the crude reaction mixture was filtered through a 
short pad of Celite. The conversion to 146b (22%) and 146d (27%) were determined by crude 1H 
NMR spectroscopy with CH2Br2 as the internal standard. Then, repeated this reaction another 








The general procedure G was followed using 147b (42 mg, 0.20 mmol), 147d (52 mg, 
0.20 mmol) and alkyne 64a (36 mg, 0.20 mmol). Then, the crude reaction mixture was filtered 
through a short pad of Celite. The conversions to 148b and 148d were determined by crude 1H 
NMR spectroscopy with CH2Br2 as the internal standard. Then, repeated this reaction another 












5.3.3.4 Synthesis of Ruthenium Complexes 
 
A 15 mL Schlenk tube was charged with 145a (18.4 mg, 0.10 mmol), [RuCl2(p-cymene)]2 (31.2 
mg, 0.05 mmol), KOAc (20 mg, 0.20 mmol), and MeOH (2.0 mL). The mixture was stirred at 
ambient temperature for 24 h, and then MeOH was removed in vacuo. After column 
chromatography on silica gel (CH2Cl2/MeOH = 50 : 1) and crystallization (CH2Cl2 and n-pentane), 
Ru-II was isolated as a red solid (32 mg, 70%). 1H NMR (400 MHz, CDCl3): δ = 10.24 (s, 1H), 
7.37 – 7.29 (m, 4H), 7.17 (t, J = 6.6 Hz, 1H), 7.06 (s, 1H), 6.44 (s, 1H), 5.29 – 5.24 (m, 2H), 4.87 
(d, J = 5.5 Hz, 1H), 4.29 (d, J = 5.5 Hz, 1H), 2.20 (p, J = 6.9 Hz, 1H), 1.93 (s, 3H), 1.55 (s, 3H), 
0.96 (d, J = 7.0 Hz, 3H), 0.79 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 187.0 (Cq), 
157.4 (Cq), 153.2 (Cq), 128.1 (CH), 127.4 (CH), 125.7 (CH), 124.3 (CH), 121.2 (Cq), 115.5 (CH), 
96.7 (Cq), 95.9 (Cq), 89.0 (CH), 87.6 (CH), 84.3 (CH), 83.0 (CH), 30.8 (CH), 23.2 (CH3), 20.9 
(CH3), 18.6 (CH3), 13.3 (CH3). IR (ATR): 3078, 3050, 1626, 1600, 1484, 1442, 1253,760, 704 
cm−1. MS (ESI) m/z (relative intensity): 419 (100) [M-Cl]+. HR-MS (ESI) m/z calcd for C22H25N2Ru 
[M-Cl]+: 419.1062, found: 419.1064. 
 
 
A 15 mL Schlenk tube was charged with Ru-II (13.6 mg, 0.03 mmol), 64a (5.9 mg, 0.033 mmol) 
and MeOH (2.0 mL). The mixture was stirred at ambient temperature for 3 h, and then MeOH 
was removed in vacuo. After column chromatography on silica gel (CH2Cl2/MeOH = 50 : 1), Ru-
IVa was isolated as a yellow solid (10 mg, 53%), which could be crystallized in MeOH and Et2O. 
1H NMR (400 MHz, CDCl3): δ = 14.31 (s, 1H), 7.69 – 7.61 (m, 2H), 7.50 – 7.40 (m, 3H), 7.32 – 





(m, 1H), 1.92 (s, 3H), 1.64 (s, 3H), 0.86 (d, J = 6.9 Hz, 6H). 13C NMR (101 MHz, CDCl3): 
δ = 157.1 (Cq), 134.5 (overlapped, Cq), 134.1 (Cq), 129.3 (CH), 128.9 (overlapped, CH), 128.6 
(overlapped, CH), 127.6 (overlapped, CH), 127.0 (overlapped, CH), 126.6 (CH), 118.4 (CH), 
117.1 (Cq), 108.6 (Cq), 106.7 (Cq), 96.1 (overlapped, Cq), 87.8 (overlapped, CH), 86.4 
(overlapped, CH), 61.8 (Cq), 30.3 (CH), 22.4 (overlapped, CH3), 20.8 (CH3), 17.7 (CH3). IR (ATR): 
2958, 2148, 1706, 1494, 1293, 1208, 726, 693 cm−1. MS (ESI) m/z (relative intensity): 597 (100) 
[M-Cl]+. HR-MS (ESI) m/z calcd for C36H35N2Ru [M-Cl]+: 597.1848, found: 597.1842. 
 
A 15 mL Schlenk tube was charged with Ru-II (13.6 mg, 0.03 mmol), 64i (7.9 mg, 0.033 mmol) 
and MeOH (2 mL). The mixture was stirred at ambient temperature for 3 h, and then MeOH was 
removed in vacuo. After column chromatography on silica gel (CH2Cl2/MeOH = 50 : 1), Ru-IVb 
was isolated as yellow solid (14 mg, 67%), which could be crystallized in MeOH and diethyl ether. 
1H NMR (400 MHz, CDCl3): δ = 14.38 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 0.9 Hz, 3H), 
7.13 – 7.06 (m, 3H), 7.05 – 6.99 (m, 3H), 6.97 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 5.06 
(dd, J = 18.7, 5.9 Hz, 2H), 4.81 (d, J = 39.5 Hz, 2H), 3.90 (s, 3H), 3.82 (s, 3H), 2.42 – 2.32 (m, 
1H), 1.94 (s, 3H), 1.62 (s, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ = 160.0 (Cq), 159.0 (Cq), 157.2 (Cq), 134.9 (Cq), 130.0 (CH), 128.9 (CH), 
128.6 (CH), 127.4 (CH), 126.9 (CH), 126.6 (Cq), 126.3 (CH), 126.0 (Cq), 118.4 (CH), 116.6 (Cq), 
114.4 (CH), 113.9 (CH), 108.2 (Cq), 107.3 (Cq), 96.4 (Cq), 95.5 (Cq), 87.3 (CH), 87.1 (CH), 86.1 
(CH), 85.7 (CH), 61.7 (Cq), 55.4 (CH3), 55.4 (CH3), 30.3 (CH), 22.7 (CH3), 22.3 (CH3), 20.9 (CH3), 
17.9 (CH3). IR (ATR): 2959, 1604, 1499, 1439, 1288, 1245, 1173, 1022, 832 cm−1. MS (ESI) m/z 
(relative intensity): 657 (100) [M-Cl]+. HR-MS (ESI) m/z calcd for C38H39N2RuO2 [M-Cl]+: 








5.3.3.5 Ruthenium Complexes Catalyzed C–H/N–H Activation  
 
In an undivided cell with GF anode (10 mm × 10 mm × 6 mm) and a platinum cathode (20 mm × 
10 mm × 0.25 mm), alkenyl imidazole 145a (0.4 mmol, 1.0 equiv), alkyne 64a (0.8 mmol, 2.0 
equiv), KPF6 (14.7 mg, 20 mol %) and Ru-II (18 mg, 10.0 mol %) were dissolved in DMF (4.0 mL) 
under N2. Electrocatalysis was performed at 140 °C with a constant current of 4.0 mA 
maintained for 8 h. The GF anode was washed with EtOAc (3×10 mL) in an ultrasonic bath. The 
combined organic phases were added to the reaction mixture. Evaporation of the solvent and 
subsequent column chromatography on silica gel afforded the corresponding product 146a (74% 
based on 145a). The analogous procedure with Ru-IVa (25 mg, 10.0 mol %) yielded 146a (61% 
based on 145a).  
 






A 15 mL Schlenk tube was charged with Ru-IVa (9.5 mg, 0.015 mmol) and KPF6 (14.7 mg, 0.08 
mmol). The tube was evacuated and filled with N2 three times. Then, DMF (4 mL) was added 
and the mixture was electrolyzed at a constant current of 4 mA for 10 min or 60 min at ambient 
temperature or 80 ℃ or 140 ℃ (GF anode, (10 mm × 15 mm × 6 mm) and a platinum cathode 
(10 mm × 15 mm × 0.25 mm). The solvent was removed in vacuo and trimethoxybenzene (5.05 
mg, 0.03 mmol) was added as standard. Then, the residue was dissolved in CDCl3 (0.8 mL) and 
subjected to 1H NMR spectroscopy. 
 
5.3.3.7 On-Line NMR Monitoring in Flow 
On-line monitoring in flow was performed by Dr. Lars H. Finger. The 19F NMR spectroscopy 
experiments in flow were performed on a Magritek Spinsolve 60ULTRA (from Magritek GmbH, 
Germany) with the reaction monitoring kit supplied by the manufacturer. For pumping the 
solution to the spectrometer, an Ismatec REGLO Digital MS-2/12 (ISM 596) peristaltic pump was 
employed. The flow rate was 0.4 mL/min.  
 
 
A 15 mL Schlenk tube was charged with 145a (110.4 mg, 0.60 mmol, 1.0 equiv), 64e (256.8 mg, 
1.2 mmol, 2.0 equiv), KPF6 (22.1 mg, 0.12 mmol), 2-fluoronaphthalene (65.8 μL, 0.6 mmol), 
[RuCl2(p-cymene)]2 (18.7 mg, 5.0 mol %) and DMF (6 mL). The solution was pumped to the 
NMR spectrometer by a peristaltic pump with a flow speed of 0.4 mL/min. The electrocatalysis 
was performed at 140 °C with a constant current of 4.0 mA maintained for 8 h. After evaporation 








Scheme 5.3.3.7a Reaction profile determined by 19F NMR spectroscopic monitoring in flow. 
Scheme 5.3.3.7b 19F NMR spectra recorded in flow from the reaction mixture at 4 mA in air at 
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5.3.3.8 GC-Headspace Detection   
 
In an undivided cell equipped with a GF anode (10 mm × 15 mm × 6 mm) and a platinum 
cathode (10 mm × 15 mm × 0.25 mm), 147a (39 mg, 0.2 mmol), alkyne 64a (71 mg, 0.4 mmol), 
KOAc (39 mg, 0.4 mmol), 1-AdCO2H (7.2 mg, 20.0 mol %) and [RuCl2(p-cymene)]2 (6.2 mg, 5.0 
mol %) were dissolved in t-AmOH (3 mL) and H2O (3 mL) under N2. Electrocatalysis was 
performed at 100 °C with a constant current of 8.0 mA maintained for 4 h. After the reaction, 1.0 
mL of the headspace volume was removed for GC analysis. The graphite felt anode was washed 
with EtOAc (3 × 20 mL) in an ultrasonic bath. The yield of 148a (76%) was determined by 1H 


































5.3.3.9 Cyclic Voltammetry 
CV measurements were conducted with a Metrohm Autolab PGSTAT204 potentiostat and Nova 
2.1 software. For all experiments, a glassy carbon working electrode (disk, diameter: 3mm), a 
platinum wire counter electrode and a saturated calomel reference electrode (SCE) were 
employed. The voltammograms were recorded at room temperature in DMF at a substrate 
concentration of 5 mmol/L and with 0.1 mol/L KPF6 as supporting electrolyte. All solutions were 
saturated with N2 prior to the measurement and an overpressure of N2 was maintained 
throughout the experiment. The scan rate is 100 mV/s. Deviations from the general experimental 
setup were indicated in the respective figures and descriptions.  
 

































Cyclic voltammograms of [RuCl2(p-cymene)]2 (2.5 mM; black line), 145a (red line), 64a (blue 


































Cyclic voltammograms of Ru-II (black line), Ru-IVa (red line) in DMF under N2 at rt, 100 mM 
KPF6 at 100 mV/s. 
 
5.3.4 Regioselective B(3,4)–H Arylation of o-Carboranes  
5.3.4.1 Characterization Data 
 
150a. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 4-iodotoluene 19a (105 mg, 0.48 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 150a (71 mg, 71%) as a colorless solid. M.p. = 
171–172 °C. 1H NMR (500 MHz, CDCl3): δ = 7.45 (d, J = 8.5 Hz, 2H), 7.39–7.32 (m, 3H), 7.22 
(dd, J = 8.5, 7.3 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.94–6.90 (m, 4H), 3.49–3.44 (m, 2H), 3.26–
3.22 (m, 2H), 2.28 (s, 3H), 2.24 (s, 3H), 1.00 (t, J = 7.0 Hz, 6H). 13C NMR (125 MHz, CDCl3): δ = 
156.6 (Cq), 138.1 (Cq), 137.7(Cq), 136.5 (CH), 133.9 (CH), 133.3(Cq), 130.0 (CH), 129.3 (CH), 
128.1 (CH), 127.6 (CH), 127.5 (CH), 85.5 (Cq), 79.3 (Cq), 43.7 (CH2), 21.2 (CH3), 21.1 (CH3), 
12.9 (CH3). 11B NMR (160 MHz, CDCl3): δ = 0.65 (2B), -1.38 (1B), -3.61 (1B), -6.20 (1B), -10.54 
(5B). IR (ATR): 2978, 2566, 1653, 1608, 1415, 1264, 1191, 772 cm–1. MS (ESI) m/z (relative 





C27H3810B211B8NO [M+H]+: 500.3964, found: 500.3951. 
 
 
150b. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and iodobenzene 19b (98 mg, 0.48 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 150b (64 mg, 68%) as a colorless solid. M.p. = 
197–198 °C. 1H NMR (400 MHz, CDCl3): δ = 7.53–7.42 (m, 4H), 7.37–7.32 (m, 1H), 7.29–7.15 
(m, 6H), 7.14–7.04 (m, 4H), 3.50–3.41 (m, 2H), 3.26–3.20 (m, 2H), 0.99 (t, J = 7.0 Hz, 6H). 13C 
NMR (100 MHz, CDCl3): δ = 156.6 (Cq), 136.6 (CH), 134.0 (CH), 133.2 (Cq), 130.1 (CH), 129.4 
(CH), 128.4 (CH), 128.0 (CH), 127.6 (CH), 127.2 (CH), 126.6 (CH), 86.0 (Cq), 79.7 (Cq), 43.8 
(CH2), 12.9 (CH3). 11B NMR (128 MHz, CDCl3): δ = 0.34 (2B), -1.31 (1B), -3.28 (1B), -5.82 (1B), -
10.20 (5B). IR (ATR): 2973, 2567, 1647, 1430, 1266, 1208, 696 cm–1. MS (ESI) m/z (relative 
intensity): 494 (100) [M+Na]+, 472 (40) [M+H]+. HR-MS (ESI): m/z calcd. for 




150c. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1-bromo-4-iodobenzene 19c (136 mg, 0.48 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 150c (76 mg, 61%) as a colorless 
solid. M.p. = 205–206 °C. 1H NMR (300 MHz, CDCl3): δ = 7.50–7.39 (m, 3H), 7.32–7.27 (m, 5H), 
7.25–7.22 (m, 3H), 7.21–7.14 (m, 2H), 3.60–3.42 (m, 4H), 1.05 (t, J = 6.9 Hz, 6H). 13C NMR (75 
MHz, CDCl3): δ = 156.2 (Cq), 138.0 (CH), 135.6 (CH), 132.0 (Cq), 130.5 (CH), 129.8 (CH), 129.7 
(CH), 129.6 (CH), 127.9 (CH), 123.6 (Cq), 123.2 (Cq), 84.6 (Cq), 78.5 (Cq), 44.0 (CH2), 13.1 (CH3). 
11B NMR (96 MHz, CDCl3): δ = 0.22 (3B), -3.11 (1B), -6.02 (1B), -9.94 (5B). IR (ATR): 2573, 
1647, 1578, 1487, 1381, 1205,1010,693 cm–1. MS (ESI) m/z (relative intensity): 652 (100) 
[M+Na]+, 630 (10) [M+H]+. HR-MS (ESI): m/z calcd. for C25H3111B1079Br2NONa [M+Na]+: 








150d. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1-chloro-4-iodobenzene 19d (115 mg, 0.48 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 150d (73 mg, 68%) as a colorless 
solid. M.p. = 185–186 °C. 1H NMR (300 MHz, CDCl3): δ = 7.48–7.40 (m, 3H), 7.35–7.22 (m, 6H), 
7.17–7.08 (m, 4H), 3.54–3.40 (m, 4H), 1.06 (t, J = 7.0 Hz, 6H). 13C NMR (75 MHz, CDCl3): δ = 
156.2 (Cq), 137.8 (CH), 135.3 (CH), 135.0 (Cq), 134.7 (Cq), 132.1 (Cq), 129.9 (CH), 129.6 (CH), 
128.0 (CH), 127.5 (CH), 126.9 (CH), 84.9 (Cq), 78.9 (Cq), 44.2 (CH2), 12.9 (CH3). 11B NMR (96 
MHz, CDCl3): δ = 0.49 (3B), -3.10 (1B), -6.38 (1B), -10.40 (5B). IR (ATR): 2571, 1648, 1584, 
1489, 1268, 1205, 1092, 730 cm–1. MS (ESI) m/z (relative intensity): 564 (100) [M+Na]+, 542 (10) 





150e. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1-(4-iodophenyl)ethanone 19e (118 mg, 0.48 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 150e (64 mg, 58%) as a colorless 
solid. M.p. = 244–245 °C. 1H NMR (300 MHz, CDCl3): δ = 7.74 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 
8.3 Hz, 2H), 7.51–7.39 (m, 7H), 7.34–7.27 (m, 2H), 3.60–3.45 (m, 4H), 2.56 (s, 3H), 2.55 (s, 3H), 
1.09 (t, J = 6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3): δ = 198.3 (Cq), 198.1 (Cq), 156.0 (Cq), 136.6 
(Cq), 136.5 (CH), 136.4 (Cq), 134.2 (CH), 131.8 (Cq), 130.1 (CH), 129.7 (CH), 128.0 (CH), 127.0 
(CH), 126.0 (CH), 84.9 (Cq), 78.5 (Cq), 43.9 (CH2), 26.7 (CH3), 26.5 (CH3), 13.0 (CH3). 11B NMR 
(96 MHz, CDCl3): δ = 0.58 (3B), -2.61 (1B), -5.98 (1B), -9.67 (5B). IR (ATR): 2572, 1679, 1642, 










150f. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1,2-dichloro-4-iodobenzene 19f (131 mg, 0.48 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 150f (78 mg, 64%) as a 
colorless solid. M.p. = 208–209 °C. 1H NMR (300 MHz, CDCl3): δ = 7.48–7.40 (m, 4H), 7.36–
7.26 (m, 4H), 7.22–7.11 (m, 3H), 3.60–3.45 (m, 4H), 1.13 (t, J = 6.9 Hz, 6H). 13C NMR (75 MHz, 
CDCl3): δ = 155.8 (Cq), 138.1 (CH), 135.6 (CH), 135.4 (CH), 133.2 (CH), 133.0 (Cq), 132.9 (Cq), 
132.0 (Cq), 131.5 (Cq), 130.9 (Cq), 130.2 (CH), 129.7 (CH), 129.5 (CH), 128.7 (CH), 128.2 (CH), 
85.0 (Cq), 78.2 (Cq), 44.2 (CH2), 13.0 (CH3). 11B NMR (96 MHz, CDCl3): δ = 0.76 (3B), -3.10 (1B), 
-6.49 (1B), -10.24 (5B). IR (ATR): 2578, 1646, 1473, 1424, 1203, 1028, 695 cm–1. MS (ESI) m/z 
(relative intensity): 632 (100) [M+Na]+, 610 (10) [M+H]+. HR-MS (ESI): m/z calcd. for 




150g. The representative procedure H was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1-iodo-3,5-dimethylbenzene 19g (112 mg, 0.48 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 150g (66 mg, 63%) as a 
colorless solid. M.p. = 203–205 °C. 1H NMR (300 MHz, CDCl3): δ = 7.52 (d, J = 7.4 Hz, 2H), 
7.40–7.32 (m, 1H), 7.29–7.18 (m, 4H), 7.00–6.90 (m, 3H), 6.87 (s, 1H), 3.62 (q, J = 7.0 Hz, 2H), 





CDCl3): δ = 156.8 (Cq), 136.2 (Cq), 135.6 (Cq), 134.3 (CH), 134.3 (Cq), 131.8 (CH), 130.4 (CH), 
130.2 (CH), 129.7 (CH), 129.3 (CH), 127.5 (CH), 87.6 (Cq), 80.3 (Cq), 43.5 (CH2), 21.4 (CH3), 
21.2 (CH3), 12.7 (CH3). 11B NMR (96 MHz, CDCl3): δ = 0.69 (2B), -1.17 (1B), -3.10 (1B), -5.90 
(1B), -10.05 (5B). IR (ATR): 2916, 2557, 1646, 1420, 1264, 1183, 855, 689 cm–1. MS (ESI) m/z 
(relative intensity): 550 (100) [M+Na]+, 528 (10) [M+H]+. HR-MS (ESI): m/z calcd. for 





152a. The representative procedure H was followed using o-carborane 151a (1-CONMe2-2-Ph-
o-C2B10H10) (58 mg, 0.20 mmol) and 4-iodotoluene 19a (105 mg, 0.48 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 152a (48 mg, 51%) as a colorless solid. 
M.p. = 158–159 °C. 1H NMR (400 MHz, CDCl3): δ = 7.45 (d, J = 7.4 Hz, 2H), 7.40–7.36 (m, 1H), 
7.34–7.23 (m, 4H), 7.20 (d, J = 7.9 Hz, 2H), 6.99–6.90 (m, 4H), 3.04 (s, 6H), 2.31 (s, 3H), 2.29 
(s, 3H). 13C NMR (100 MHz, CDCl3): δ = 157.7 (Cq), 138.3 (Cq), 137.9 (Cq), 136.3 (CH), 133.9 
(CH), 133.1 (Cq), 130.0 (CH), 129.5 (CH), 128.4 (CH), 127.8 (CH), 127.6 (CH), 85.9 (Cq), 78.6 
(Cq), 40.8 (CH3), 21.3 (CH3), 21.2 (CH3). 11B NMR (128 MHz, CDCl3): δ = 0.7 (2B), -1.3 (1B), -
3.2 (1B), -6.4 (1B), -10.6 (5B). IR (ATR): 2921, 2570, 1644, 1393, 1195, 743, 693 cm–1. MS (ESI) 
m/z (relative intensity): 473 (100) [M+H]+. HR-MS (ESI): m/z calcd. for C25H3410B111B9NO [M+H]+: 




152b. The representative procedure H was followed using o-carborane 151a (1-CONMe2-2-Ph-
o-C2B10H10) (58 mg, 0.20 mmol) and iodobenzene 19b (98 mg, 0.48 mmol). Isolation by column 





99–100 °C. 1H NMR (400 MHz, CDCl3): δ = 7.47–7.41 (m, 4H), 7.40–7.35 (m, 1H), 7.32–7.29 (m, 
2H), 7.28–7.20 (m, 4H), 7.18–7.10 (m, 4H), 3.03 (s, 6H). 13C NMR (100 MHz, CDCl3): δ = 157.7 
(Cq), 136.4 (CH), 133.9 (CH), 133.0 (Cq), 130.0 (CH), 129.6 (CH), 128.6 (CH), 128.2 (CH), 127.9 
(CH), 127.5 (CH), 126.8 (CH), 86.4 (Cq), 79.0 (Cq), 40.8 (CH3). 11B NMR (128 MHz, CDCl3): δ = 
0.57 (2B), -1.13 (1B), -3.10 (1B), -6.27 (1B), -10.23 (5B). IR (ATR): 3053, 2581, 1654, 1493, 
1373, 1167, 744 cm–1. MS (ESI) m/z (relative intensity): 444 (100) [M+H]+, 466 (10) [M+Na]+. 




152c. The representative procedure H was followed using o-carborane 151b (1-CON(CH2)4-2-
Ph-o-C2B10H10) (63 mg, 0.20 mmol) and 4-iodotoluene 19a (105 mg, 0.48 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 152c (59 mg, 60%) as a pink solid. M.p. 
= 228–230 °C. 1H NMR (400 MHz, CDCl3): δ = 7.44–7.38 (m, 2H), 7.36–7.28 (m, 3H), 7.22–7.16 
(m, 2H), 7.16–7.10 (m, 2H), 6.96–6.87 (m, 4H), 3.65–3.28 (m, 4H), 2.25 (s, 3H), 2.23 (s, 3H), 
1.80–1.63 (m, 4H). 13C NMR (100 MHz, CDCl3): δ = 155.7 (Cq), 138.1 (Cq), 137.7 (Cq), 136.6 
(CH), 133.6 (CH), 132.9 (Cq), 129.9 (CH), 129.4 (CH), 128.3 (CH), 127.7 (CH), 127.5 (CH), 85.0 
(Cq), 78.7 (Cq), 50.5 (overlapped, CH2), 21.2 (CH3), 21.2 (CH3). 11B NMR (128 MHz, CDCl3): δ = 
0.57 (2B), -1.61 (1B), -3.32 (1B), -6.45 (1B), -10.78 (5B). IR (ATR):  2975, 2878, 2570, 1639, 
1446, 1225, 865, 753, 690 cm-1. MS (ESI) m/z (relative intensity): 498 (20) [M+H]+, 520 (100) 




152d. The representative procedure H was followed using o-carborane 151b (1-CON(CH2)4-2-





column chromatography (n-hexane/EtOAc: 20/1) yielded 152d (50 mg, 53%) as a colorless solid. 
M.p. = 176–177 °C. 1H NMR (500 MHz, CDCl3): δ = 7.51–7.44 (m, 2H), 7.43–7.38 (m, 2H), 
7.35–7.30 (m, 1H), 7.25–7.24 (m, 1H), 7.24–7.16 (m, 5H), 7.13–7.04 (m, 4H), 3.63–3.41 (m, 4H), 
1.83–1.61 (m, 4H). 13C NMR (125 MHz, CDCl3): δ = 155.7 (Cq), 136.7 (CH), 133.6 (CH), 132.8 
(Cq), 129.9 (CH), 129.5 (CH), 128.4 (CH), 128.1 (CH), 127.7 (CH), 127.4 (CH), 126.6 (CH), 85.5 
(Cq), 79.1 (Cq), 50.5 (overlapped, CH2). 11B NMR (96 MHz, CDCl3): δ = 0.48 (2B), -1.36 (1B), -
3.15 (1B), -6.18 (1B), -10.26 (5B). IR (ATR): 2921, 2570, 1643, 1389, 1195, 861, 743, 692 cm–1. 
MS (ESI) m/z (relative intensity): 471 (100) [M+H]+, 493 (10) [M+Na]+. HR-MS (ESI): m/z calcd. 




152e. The representative procedure H was followed using o-carborane 151c (1-CONiPr2-2-Ph-o-
C2B10H10) (70 mg, 0.20 mmol) and 1-chloro-4-iodobenzene 19d (114 mg, 0.48 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 152e (61 mg, 54%) as a colorless 
solid. M.p. = 232–233 °C. 1H NMR (400 MHz, CDCl3): δ = 7.52 (d, J = 7.4 Hz, 2H), 7.45–7.41 (m, 
1H), 7.35 (d, J = 8.4 Hz, 2H), 7.32–7.27 (m, 2H), 7.19 (d, J = 8.6 Hz, 2H), 7.14 (d, J = 8.4 Hz, 
2H), 7.07 (d, J = 8.4 Hz, 2H), 5.24–5.18 (m, 1H), 3.44–3.39 (m, 1H), 1.29 (d, J = 6.7 Hz, 6H), 
1.04 (d, J = 6.7 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ = 154.5 (Cq), 137.9 (CH), 136.1 (CH), 
134.7 (Cq), 134.5 (Cq), 132.0 (Cq), 129.9 (CH), 129.5 (CH), 128.0 (CH), 127.5 (CH), 126.5 (CH), 
83.9 (Cq), 79.1 (Cq), 50.3 (CH), 49.4 (CH), 20.5 (CH3), 20.3 (CH3), 19.7 (CH3), 19.6 (CH3). 11B 
NMR (128 MHz, CDCl3): δ = 1.47 (1B), -1.05 (2B), -3.30 (1B), -6.75 (1B), -10.90 (5B). IR (ATR): 
2968, 2620, 2585, 1657, 1586, 1491, 1369, 1296, 691 cm–1. MS (ESI) m/z (relative intensity): 
569 (100) [M+H]+, 591 (10) [M+Na]+. HR-MS (ESI): m/z calcd. for C27H3610B111B935Cl2NO [M+H]+: 








152f. The representative procedure H was followed using o-carborane 151d (1-CON(CH2)4O-2-
Ph-o-C2B10H10) (67 mg, 0.20 mmol) and 4-iodotoluene 19a (105 mg, 0.48 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 152f (54 mg, 52%) as a colorless solid. 
M.p. = 258–259 °C. 1H NMR (400 MHz, CDCl3): δ = 7.49–7.41 (m, 2H), 7.40–7.32 (m, 3H), 
7.28–7.21 (m, 2H), 7.21–7.14 (m, 2H), 7.01 (d, J = 7.9 Hz, 2H), 6.96 (d, J = 7.8 Hz, 2H), 3.73–
3.58 (m, 4H), 3.48–3.32 (m, 4H), 2.34 (s, 3H), 2.28 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 
157.6 (Cq), 138.7 (Cq), 138.2 (Cq), 136.2 (CH), 134.2 (CH), 133.4 (Cq), 130.1 (CH), 129.6 (CH), 
128.5 (CH), 128.0 (CH), 127.8 (CH), 86.7 (Cq), 78.6 (Cq), 66.5 (CH2), 47.9 (CH2), 21.3 (CH3), 
21.2 (CH3). 11B NMR (128 MHz, CDCl3): δ = 0.67 (2B), -0.88 (1B), -3.11 (1B), -6.12 (1B), -10.53 
(5B). IR (ATR): 2843, 2549, 1660, 1447, 1411, 1264, 1225, 771 cm–1. MS (ESI) m/z (relative 
intensity): 514 (70) [M+H]+, 536 (100) [M+Na]+. HR-MS (ESI): m/z calcd. for 
C27H3510B211B8NO2Na [M+Na]+: 536.3576, found: 536.3557. 
 
 
152g. The representative procedure H was followed using o-carborane 151e (1-CONEt2-2-
nBu-
o-C2B10H10) (60 mg, 0.20 mmol) and 4-iodotoluene 19a (105 mg, 0.48 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 152g (45 mg, 47%) as a colorless solid. 
M.p. = 88–89 °C. 1H NMR (400 MHz, CDCl3): δ = 7.39 (d, J = 7.9 Hz, 2H), 7.17 (d, J = 7.8 Hz, 
2H), 7.12 (d, J = 7.9 Hz, 2H), 6.99 (d, J = 7.8 Hz, 2H), 4.15–3.66 (m, 2H), 3.66–3.46 (m, 2H), 
2.56–2.46 (m, 1H), 2.38 (s, 3H), 2.30 (s, 3H), 2.29–2.18 (m, 1H), 1.66–1.56 (m, 1H), 1.54–1.42 
(m, 1H), 1.35–1.19 (m, 8H), 0.91 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 156.3 (Cq), 
137.9 (Cq), 137.8 (Cq), 134.8 (CH), 133.3 (CH), 128.6 (CH), 127.7 (CH), 83.6 (Cq), 73.6 (Cq), 
44.2 (CH2), 34.5 (CH2), 32.0 (CH2), 22.4 (CH2), 21.4 (CH3), 21.3 (CH3), 13.8 (CH3), 13.1 (CH3). 
11B NMR (128 MHz, CDCl3): δ = 2.34 (2B), -1.13 (2B), -2.77 (1B), -7.74 (1B), -10.36 (2B), -12.42 





(relative intensity): 480 (100) [M+H]+, 502 (20) [M+Na]+. HR-MS (ESI): m/z calcd. for 





153a. The representative procedure I was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 4-iodotoluene 19a (53 mg, 0.24 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 153a (45 mg, 55%) as a colorless solid. M.p. = 
180–181 °C. 1H NMR (400 MHz, CDCl3): δ = 7.45–7.39 (m, 4H), 7.28–7.22 (m, 1H), 7.16–7.05 
(m, 4H), 3.55–3.35 (m, 4H), 2.34 (s, 3H), 1.00 (t, J = 7.1 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ 
= 158.3 (Cq), 139.1 (Cq), 134.6 (CH), 134.0 (Cq), 131.9 (CH), 129.2 (CH), 128.5 (CH), 127.0 
(CH), 89.5 (Cq), 82.4 (Cq), 43.6 (CH2), 21.3 (CH3), 12.2 (CH3). 11B NMR (128 MHz, CDCl3): δ = -
1.0 (1B), -2.26 (1B), -3.69 (1B), -7.91 (3B), -10.32 (4B). IR (ATR): 2635, 2563, 1648, 1476, 1418, 
1269, 1208, 1080, 689 cm–1. MS (ESI) m/z (relative intensity): 432 (100) [M+Na]+, 410 (10) 




153b. The representative procedure I was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1-iodo-4-nitrobenzene 19h (60 mg, 0.24 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 153b (54 mg, 61%) as a colorless solid. 
M.p. = 147–148 °C. 1H NMR (300 MHz, CDCl3): δ = 8.14 (d, J = 8.7 Hz, 2H), 7.78 (d, J = 8.7 Hz, 
2H), 7.41–7.30 (m, 3H), 7.22–7.16 (m, 2H), 3.43–3.32 (m, 4H), 1.03 (t, J = 7.0 Hz, 6H). 13C NMR 
(75 MHz, CDCl3): δ = 158.0 (Cq), 148.3 (Cq), 135.5 (CH), 133.5 (Cq), 131.4 (CH), 129.8 (CH), 
127.6 (CH), 122.3 (CH), 90.8 (Cq), 83.0 (Cq), 43.7 (CH2), 14.0 (CH3). 11B NMR (96 MHz, CDCl3): 
δ = -0.10 (2B), -3.09 (2B), -7.61 (3B), -8.98 (2B), -10.71 (1B). IR (ATR): 2980, 2561, 1647, 1513, 









153c. The representative procedure I was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 1-iodo-3-bromobenzene 19i (60 mg, 0.24 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 153c (47.3 mg, 50%) as a colorless 
solid. M.p. = 168–169 °C. 1H NMR (400 MHz, CDCl3): δ = 7.66–7.61 (m, 1H), 7.52–7.45 (m, 2H), 
7.40–7.35 (m, 2H), 7.31–7.23 (m, 1H), 7.17–7.09 (m, 3H), 3.36–3.10 (m, 4H), 1.01 (t, J = 7.2 Hz, 
6H). 13C NMR (100 MHz, CDCl3): δ = 158.0 (Cq), 137.1 (CH), 133.8 (Cq), 133.2 (CH), 132.3 (CH), 
131.8 (CH), 129.5 (CH), 129.4 (CH), 127.3(CH), 122.5 (Cq), 90.5 (Cq), 82.8 (Cq), 44.1 (CH2), 
43.7 (CH2), 14.0 (CH3), 12.2 (CH3). 11B NMR (128 MHz, CDCl3): δ = -0.49 (2B), -3.35 (2B), -7.81 
(3B), -9.66 (3B). IR (ATR): 2976, 2575, 1645, 1420, 1266, 1156, 770, 689 cm-1. MS (ESI) m/z 
(relative intensity): 497 (100) [M+Na]+, 475 (20) [M+H]+. HR-MS (ESI) m/z calcd for 




153d. The representative procedure I was followed using o-carborane 149a (1-CONEt2-2-Ph-o-
C2B10H10) (64 mg, 0.20 mmol) and 4-iodobenzaldehyde 19j (56 mg, 0.24 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 20/1) yielded 153d (43 mg, 51%) as a colorless solid. 
M.p. = 211–212 °C. 1H NMR (300 MHz, CDCl3): δ = 10.07 (s, 1H), 7.88–7.70 (m, 4H), 7.44–7.37 
(m, 2H), 7.35–7.29 (m, 1H), 7.20–7.11 (m, 2H), 3.43–3.30 (m, 4H), 1.03 (t, J = 7.0 Hz, 6H). 13C 
NMR (75 MHz, CDCl3): δ = 192.3 (CH), 158.0 (Cq), 136.3 (Cq), 135.3 (CH), 133.7 (Cq), 131.8 
(CH), 129.7 (CH), 128.5 (CH), 127.2 (CH), 90.8 (Cq), 83.0 (Cq), 43.7 (CH2), 13.2 (CH3). 11B NMR 





2560, 1719, 1650, 1627, 1420, 1266, 1181, 761, 688 cm–1. MS (ESI) m/z (relative intensity): 424 




5.3.5 Electrochemical B–H Nitrogenation of nido-Carboranes 
5.3.5.1 Characterization Data 
 
156a. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and pyridine 155a (24.0 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156a (30.0 mg, 83%) as a colorless solid. M.p. = 280 – 282 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 8.75 (d, J = 5.2 Hz, 2H), 8.07 (tt, J = 7.7, 1.5 Hz, 1H), 7.56 – 
7.48 (m, 2H), 7.35 – 7.28 (m, 2H), 7.08 – 6.96 (m, 3H), 6.94 – 6.82 (m, 5H), -1.97 (s, 1H). 13C 
NMR (101 MHz, CD2Cl2): δ = 147.7 (CH), 142.4 (CH), 138.7 (Cq), 136.2 (Cq), 132.1 (CH), 131.1 
(CH), 127.5 (CH), 127.1 (CH), 126.6 (CH), 126.3 (CH), 125.8 (CH). 11B NMR (96 MHz, CD2Cl2): 
δ = 4.92 (1B), -3.89 (1B), -11.50 (1B), -15.73 (2B), -20.65 (1B), -26.08 (1B), -30.97 (1B), -35.87 
(1B). IR (ATR): 2558, 2536, 2510, 1486, 1456, 1445, 1171, 764, 698 cm–1. MS (ESI) m/z 
(relative intensity): 387 (100) [M+Na]+, 365 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C19H2410B111B8N [M+Na]+: 387.2688, found: 387.2680. The analytical data corresponds with 
those reported in the literature.[225] 
 
 
156b. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 3-methylpyridine 155b (27.9 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156b (26.0 mg, 68%) as a white solid. M.p. = 280 – 283 °C. 1H 
NMR (500 MHz, CDCl3): δ = 8.54 (d, J = 6.1 Hz, 1H), 8.45 (s, 1H), 7.76 (d, J = 7.7 Hz, 1H), 





2.27 (s, 3H), -2.08 (s, 1H). 13C NMR (126 MHz, CDCl3): δ = 147.5 (CH), 144.9 (CH), 142.4 (CH), 
138.5 (Cq), 136.4 (Cq), 136.4 (Cq), 132.1 (CH), 131.1 (CH), 127.4 (CH), 127.1 (CH), 126.6 (CH), 
126.2 (CH), 124.9 (CH), 18.5 (CH3). 11B NMR (128 MHz, CDCl3): δ = 4.46 (1B), -4.56 (1B), -
11.28 (1B), -15.95 (2B), -21.01 (1B), -26.04 (1B), -30.94 (1B), -35.69 (1B). IR (ATR): 3059, 1487, 
1443, 1201, 1155, 1056, 907, 734, 696 cm-1. MS (ESI) m/z (relative intensity): 401 (90) [M+Na]+, 
379 (20) [M+H]+. HR-MS (ESI): m/z calcd. for C20H2610B111B8N [M+Na]+: 401.2845, found: 
401.2850. The analytical data corresponds with those reported in the literature.[225] 
 
 
156c. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 3-methoxypyridine 155c (32.0 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156c (30.0 mg, 75%) as a yellow solid. M.p. = 220 – 223 °C. 
1H NMR (500 MHz, CD2Cl2): δ = 8.47 (d, J = 5.8 Hz, 1H), 8.13 (d, J = 2.7 Hz, 1H), 7.51 (ddd, J = 
8.7, 2.7, 1.1 Hz, 1H), 7.40 (dd, J = 8.7, 5.8 Hz, 1H), 7.28 – 7.25 (m, 2H), 6.99 – 6.93 (m, 3H), 
6.91 – 6.83 (m, 5H), 3.65 (s, 3H), -2.01 (s, 1H). 13C NMR (126 MHz, CD2Cl2): δ = 157.1 (Cq), 
140.8 (CH), 139.0 (Cq), 136.7 (Cq), 134.7 (CH), 132.4 (CH), 131.5 (CH), 128.2 (CH), 127.8 (CH), 
127.4 (CH), 127.0 (CH), 126.6 (CH), 126.3 (CH), 56.8 (CH3). 11B NMR (128 MHz, CD2Cl2): δ = 
4.82 (1B), -4.05 (1B), -11.74 (1B), -15.83 (2B), -20.58 (1B), -26.13 (1B), -31.13 (1B), -35.90 (1B). 
IR (ATR): 2526, 1572, 1487, 1443, 1298, 1259, 1056, 881, 693 cm-1 MS (ESI) m/z (relative 
intensity): 417 (100) [M+Na]+, 395 (20) [M+H]+. HR-MS (ESI): m/z calcd. for C20H2610B111B8NO 




156d. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and pyridin-3-amine 155d (28.2 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156d (30.0 mg, 79%) as a yellow solid. M.p. = 250 – 253 °C. 





(m, 2H), 7.20 – 7.14 (m, 2H), 6.99 – 6.92 (m, 3H), 6.88 – 6.82 (m, 5H), 4.13 (s, 2H), -2.00 (s, 1H). 
13C NMR (126 MHz, CD2Cl2): δ = 145.0 (Cq), 139.1 (Cq), 137.8 (CH), 136.8 (Cq), 134.2 (CH), 
132.4 (CH), 131.3 (CH), 127.5 (CH), 127.3 (overlapped, CH), 126.8 (CH), 126.5 (CH), 126.0 
(CH). 11B NMR (128 MHz, CD2Cl2): δ = 4.99 (1B), -4.38 (1B), -12.03 (1B), -15.78 (2B), -21.02 
(1B), -26.20 (1B), -31.14 (1B), -36.05 (1B). IR (ATR): 3480, 3388, 2539, 1623, 1583, 1442, 1164, 
697 cm-1. MS (ESI) m/z (relative intensity): 402 (100) [M+Na]+, 380 (50) [M+H]+. HR-MS (ESI): 
m/z calcd. for C19H2510B111B8N2 [M+Na]+: 402.2797, found: 402.2796. The analytical data 
corresponds with those reported in the literature.[225] 
 
 
156e. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 4-methylpyridine 155e (27.9 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156e (33.0 mg, 87%) as a white solid. M.p. = 247 – 250 °C. 
1H NMR (500 MHz, CDCl3): δ = 8.52 (d, J = 6.6 Hz, 2H), 7.26 – 7.24 (m, 1H), 7.24 – 7.23 (m, 
1H), 7.21 (d, J = 7.5 Hz, 2H), 6.95 – 6.88 (m, 3H), 6.85 – 6.77 (m, 5H), 2.45 (s, 3H), -2.06 (s, 
1H). 13C NMR (126 MHz, CDCl3): δ = 155.4 (Cq), 146.9 (CH), 138.5 (Cq), 136.5 (Cq), 132.1 (CH), 
131.1 (CH), 127.1 (CH), 127.1 (CH), 126.6 (CH), 126.2 (overlapped, CH), 21.7 (CH3). 11B NMR 
(128 MHz, CDCl3): δ = 4.43 (1B), -3.98 (1B), -11.46 (1B), -15.82 (2B), -20.70 (1B), -26.00 (1B), -
30.91 (1B), -35.77 (1B). IR (ATR): 3058, 2540, 2159, 1495, 1444, 761, 697 cm-1. MS (ESI) m/z 
(relative intensity): 401 (100) [M+Na]+, 479 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C20H2610B111B8N [M+Na]+: 401.2845, found: 401.2842. The analytical data corresponds with 









mmol) and 4-methoxypyridine 155f (32.7 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156f (32.0 mg, 81%) as a white solid. M.p. = 314 – 317 °C. 
1H NMR (500 MHz, CD2Cl2): δ = 8.49 (d, J = 7.5 Hz, 2H), 7.27 (d, J = 6.6 Hz, 2H), 7.00 – 6.93 
(m, 3H), 6.89 – 6.82 (m, 7H), 3.92 (s, 3H), -2.02 (s, 1H). 13C NMR (126 MHz, CD2Cl2): δ = 169.8 
(Cq), 149.5 (CH), 139.1 (Cq), 136.8 (Cq), 132.4 (CH), 131.4 (CH), 127.6 (CH), 127.3 (CH), 126.8 
(CH), 126.5 (CH), 111.5 (CH), 57.3 (CH3). 11B NMR (128 MHz, CD2Cl2): δ = 4.80 (1B), -3.95 (1B), 
-11.52(1B), -15.65 (2B), -20.30 (1B), -25.96 (1B), -30.82 (1B), -35.66 (1B). IR (ATR): 2570, 2525, 
1631, 1516, 1319, 1162, 1005, 847 cm-1 MS (ESI) m/z (relative intensity): 417 (100) [M+Na]+, 
395 (20) [M+H]+. HR-MS (ESI): m/z calcd. for C20H2610B111B8NO [M+Na]+: 417.2794, found: 
417.2794. The analytical data corresponds with those reported in the literature.[225] 
 
 
156g. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 4-phenylpyridine 155g (46.5 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156g (43.2 mg, 98%) as a yellow solid. M.p. = 242 – 245 °C. 
1H NMR (500 MHz, CD2Cl2): δ = 8.67 (d, J = 7.0 Hz, 2H), 7.68 – 7.65 (m, 4H), 7.58 – 7.53 (m, 
3H), 7.31 – 7.27 (m, 2H), 7.01 – 6.95 (m, 3H), 6.93 – 6.89 (m, 2H), 6.87 – 6.83 (m, 3H), -1.91 (s, 
1H). 13C NMR (126 MHz, CD2Cl2): δ = 154.4 (Cq), 147.8 (CH), 139.1 (Cq), 136.6 (Cq), 134.6 (Cq), 
132.4 (CH), 131.9 (CH), 131.5 (CH), 129.9 (CH), 127.8 (CH), 127.7 (CH), 127.4 (CH), 
126.9 (CH), 126.6 (CH), 123.1 (CH). 11B NMR (128 MHz, CDCl3): δ = 6.28 (1B), -0.08 (1B), -7.92 
(1B), -10.65 (2B), -16.32 (1B), -20.79 (1B), -26.45 (1B), -31.72 (1B). IR (ATR): 2532, 1626, 1486, 
1431, 1219, 1172, 1013, 763, 698 cm-1. MS (ESI) m/z (relative intensity): 463 (100) [M+Na]+, 441 
(50) [M+H]+. HR-MS (ESI): m/z calcd. for C25H2810B111B8N [M+Na]+: 463.3005, found: 463.2997. 







156h. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and methyl isonicotinate 155h (41.0 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156h (29.0 mg, 69%) as a colorless solid. M.p. = 242 – 246 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 8.84 (d, J = 6.9 Hz, 2H), 8.00 (d, J = 7.0 Hz, 2H), 7.34 – 7.28 
(m, 2H), 7.06 – 6.97 (m, 3H), 6.94 – 6.87 (m, 5H), 4.00 (s, 3H), -1.89 (s, 1H). 13C NMR (101 MHz, 
CD2Cl2): δ = 162.5 (Cq), 148.4 (CH), 142.2(Cq), 138.6(Cq), 135.9(Cq), 132.1 (CH), 131.2 (CH), 
127.7 (CH), 127.1 (CH), 126.9 (CH), 126.4 (CH), 125.2 (CH), 53.7 (CH3). 11B NMR (128 MHz, 
CD2Cl2): δ = 4.45 (1B), -3.67 (1B), -11.05 (1B), -15.83 (2B), -20.08 (1B), -26.03 (1B), -30.77 (1B), 
-35.42 (1B). IR (ATR): 2529, 1743, 1440, 1427, 1289, 1112, 767, 690 cm–1. MS (ESI) m/z 
(relative intensity): 445 (100) [M+Na]+, 423 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C21H2610B111B8NO2 [M+H]+: 423.2925, found: 423.2897. The analytical data corresponds with 
those reported in the literature.[225] 
 
 
156i. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and N, N-diethylisonicotinamide 155i (53.4 mg, 0.30 mmol). Isolation by column 
chromatography (CH2Cl2) yielded 156i (24.0 mg, 51%) as a yellow solid. M.p. = 251 – 254 °C. 
1H NMR (400 MHz, CD2Cl2): δ = 8.72 (d, J = 6.8 Hz, 2H), 7.41 – 7.34 (m, 2H), 7.31 – 7.23 (m, 
2H), 7.00 – 6.91 (m, 3H), 6.89 – 6.80 (m, 5H), 3.47 (q, J = 7.1 Hz, 2H), 2.99 (q, J = 7.1 Hz, 2H), 
1.19 (t, J = 7.2 Hz, 3H), 1.02 (t, J = 7.1 Hz, 3H), -2.00 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 
165.4 (Cq), 150.9 (Cq), 148.4 (CH), 138.9 (Cq), 136.4 (Cq), 132.4 (CH), 131.5(CH), 127.9 (CH), 
127.4 (CH), 127.1 (CH), 126.7 (CH), 123.3 (CH), 43.4 (CH2), 39.9 (CH2), 14.2 (CH3), 12.7 (CH3). 
11B NMR (128 MHz, CD2Cl2): δ = 4.59 (1B), -3.84 (1B), -11.22 (1B), -15.78 (2B), -20.43 (1B), -
26.04 (1B), -30.87 (1B), -35.68 (1B). IR (ATR): 2530, 2223, 2177, 2035, 1991, 1628, 1053, 696 
cm-1. MS (ESI) m/z (relative intensity): 486 (50) [M+Na]+, 464 (100) [M+H]+. HR-MS (ESI): m/z 







156j. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 4-chloropyridine hydrochloride 155j (45.0 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/CH2Cl2: 3/1) yielded 156j (20.0 mg, 53%) as a yellow solid. M.p. = 
232 – 234 °C. 1H NMR (300 MHz, CDCl3): δ = 8.62 (d, J = 7.0 Hz, 2H), 7.44 (d, J = 7.1 Hz, 2H), 
7.31 – 7.29 (m, 1H), 7.28 – 7.26 (m, 1H), 7.02 – 6.94 (m, 3H), 6.91 – 6.85 (m, 5H), -2.09 (s, 1H). 
13C NMR (101 MHz, CDCl3): δ = 151.3 (Cq), 148.1 (CH), 138.4 (Cq), 136.1 (Cq), 132.04 (CH), 
131.2 (CH), 127.7 (CH), 127.2 (CH), 126.9 (CH), 126.4 (CH), 126.1(CH). 11B NMR (128 MHz, 
CDCl3): δ = 4.15 (1B), -3.56 (1B), -10.88 (1B), -15.95 (2B), -20.21 (1B), -25.97 (1B), -30.85 (1B), 
-35.56 (1B). IR (ATR): 3112, 2538, 1615, 1487, 1433, 1115, 1055, 696 cm-1. MS (ESI) m/z 
(relative intensity): 421 (100) [M+Na]+, 399 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C19H2310B111B835ClN [M+Na]+: 421.2303, found: 421.2298. The analytical data corresponds with 
those reported in the literature.[225] 
 
 
156k. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 4-bromopyridine hydrochloride 155k (58.2 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/CH2Cl2: 3/1) yielded 156k (21.0 mg, 45%) as a yellow solid. M.p. = 
233 – 236 °C. 1H NMR (500 MHz, CD2Cl2): δ = 8.46 (d, J = 7.0 Hz, 2H), 7.65 – 7.61 (m, 2H), 
7.28 – 7.24 (m, 2H), 7.02 – 6.92 (m, 4H), 6.88 – 6.86 (m, 4H), -2.05 (s, 1H). 13C NMR (126 MHz, 
CD2Cl2): δ = 147.9 (CH), 141.1 (Cq), 138.9 (Cq), 136.2 (Cq), 132.4 (CH), 131.5 (CH), 129.7 (CH), 
128.0 (CH), 127.4 (CH), 127.2 (CH), 126.7 (CH). 1B NMR (128 MHz, CD2Cl2): δ = 4.35 (1B), -
3.85 (1B), -11.36 (1B), -15.88 (2B), -20.30 (1B), -26.02 (1B), -30.90 (1B), -35.68 (1B). IR (ATR): 
2923, 2852, 2149, 2030, 1974, 1723, 1459, 697 cm-1. MS (ESI) m/z (relative intensity): 465 (100) 
[M+Na]+. HR-MS (ESI) m/z calcd for C19H2310B11B879BrN [M+Na]+ 465.1808, found 465.1807. The 







156l. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and pyridin-4-amine 155l (28.0 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156l (37.0 mg, 97%) as a colorless solid. M.p. = 293 – 296 °C. 
1H NMR (400 MHz, Acetone-d6): δ = 8.32 – 8.23 (m, 2H), 7.35 – 7.26 (m, 2H), 7.10 (s, 2H), 7.02 
– 6.88 (m, 5H), 6.85 – 6.75 (m, 3H), 6.72 – 6.64 (m, 2H), -1.84 (s, 1H). 13C NMR (101 MHz, 
Acetone-d6): δ = 158.0 (Cq), 147.7 (CH), 139.4 (Cq), 137.4 (Cq), 132.2 (CH), 131.2 (CH), 126.8 
(CH), 126.0 (CH), 125.9 (CH), 108.7 (CH), 108.6 (CH). 11B NMR (96 MHz, Acetone-d6): δ = 5.24 
(1B), -5.39 (1B), -13.34 (1B), -15.81 (2B), -22.06 (1B), -26.12 (1B), -31.54 (1B), -36.82 (1B). IR 
(ATR): 3475, 3375, 2538, 1644, 1527, 1182, 831, 694 cm–1. MS (ESI) m/z (relative intensity): 
402 (100) [M+Na]+, 380 (30) [M+H]+. HR-MS (ESI): m/z calcd. for C19H2510B111B8N [M+Na]+: 




156m. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and N,N-dimethylpyridin-4-amine 155m (37.0 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/CH2Cl2: 1/1) yielded 156m (21.0 mg, 52%) as a colorless solid. M.p. 
= 336 – 338 °C. 1H NMR (300 MHz, DMSO-d6): δ = 8.29 (d, J = 7.1 Hz, 2H), 7.30 (d, J = 6.4 Hz, 
2H), 7.02 – 6.90 (m, 5H), 6.83 – 6.75 (m, 3H), 6.70 (d, J = 7.4 Hz, 2H), 3.05 (s, 6H), -1.56 (s, 
1H). 13C NMR (101 MHz, DMSO-d6): δ = 155.7 (Cq), 147.0 (CH), 139.4 (Cq), 137.3 (Cq), 132.5 
(CH), 131.4 (CH), 127.3 (CH), 127.2 (CH), 126.6 (CH), 126.5 (CH), 106.9 (CH), 39.8 (CH3). 11B 
NMR (128 MHz, DMSO-d6): δ = 5.14 (1B), -6.22 (1B), -15.59 (3B), -21.95 (1B), -26.05 (1B), -
31.52 (1B), -37.12 (1B). IR (ATR): 2554, 2528, 2502, 1643, 1565, 1441, 1166, 820, 696 cm–1. 





for C21H2910B111B8N2 [M+Na]+: 430.3111, found: 430.3110. 
 
 
156n. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and isoquinoline 155n (39.0 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156n (38.0 mg, 92%) as a yellow solid. M.p. = 280 – 282 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 9.35 (s, 1H), 8.56 (dd, J = 6.8, 1.0 Hz, 1H), 8.03 – 7.96 (m, 3H), 
7.87 – 7.81 (m, 2H), 7.37 – 7.32 (m, 2H), 7.06 – 6.99 (m, 3H), 6.97 – 6.93 (m, 2H), 6.85 – 6.78 
(m, 3H), -1.85 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 151.9 (CH), 139.1 (Cq), 139.0 (CH), 
136.9 (Cq), 136.7 (Cq), 135.9 (CH), 132.5 (CH), 131.5 (CH), 130.7 (CH), 129.8 (CH), 127.7 (CH), 
127.6 (Cq), 127.4 (CH), 126.9 (CH), 126.9 (CH), 126.6 (CH), 123.6 (CH). 11B NMR (128 MHz, 
CD2Cl2): δ = 4.98 (1B), -4.07 (1B), -11.80 (1B), -15.78 (2B), -20.56 (1B), -26.09 (1B), -31.06 (1B), 
-35.86 (1B). IR (ATR): 3376, 2544, 1644, 1598, 1494, 1443, 1179, 697 cm–1. MS (ESI) m/z 
(relative intensity): 437 (100) [M+Na]+, 415 (30) [M+H]+. HR-MS (ESI): m/z calcd. for 
C23H2610B111B8N [M+Na]+: 437.2847, found: 437.2849. 
 
 
156o. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 5-bromoisoquinoline 155o (62.0 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/CH2Cl2: 1/1) yielded 156o (31.0 mg, 63%) as a yellow solid. M.p. = 
280 – 283 °C. 1H NMR (400 MHz, CD2Cl2): δ = 9.30 – 9.23 (m, 1H), 8.70 – 8.59 (m, 1H), 8.32 – 
8.21 (m, 1H), 8.18 – 8.11 (m, 1H), 7.95 – 7.88 (m, 1H), 7.74 – 7.63 (m, 1H), 7.37 – 7.28 (m, 2H), 
7.04 – 6.97 (m, 3H), 6.96 – 6.91 (m, 2H), 6.87 – 6.79 (m, 3H), -1.84 (s, 1H). 13C NMR (101 MHz, 
CD2Cl2): δ = 151.5 (CH), 139.9 (CH), 139.0 (CH), 138.7 (Cq), 136.2 (Cq), 135.8 (Cq), 132.1 (CH), 
131.3 (CH), 131.0 (CH), 129.3 (CH), 128.4 (Cq), 127.6 (CH), 127.1 (CH), 126.8 (CH), 126.3 (CH), 





15.75 (2B), -20.22 (1B), -26.03 (1B), -31.02 (1B), -35.73 (1B). IR (ATR): 2923, 2543, 1637, 1595, 
1490, 1443, 1215, 748, 698 cm–1. MS (ESI) m/z (relative intensity): 516 (100) [M+Na]+, 494 (30) 
[M+H]+. HR-MS (ESI): m/z calcd. for C23H2511B979BrN [M+Na]+: 516.1952, found: 516.1946. 
 
 
156p. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and isoquinolin-5-amine 155p (43.0 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156p (22.0 mg, 51%) as a yellow solid. M.p. = 291 – 293 °C. 
1H NMR (400 MHz, CD2Cl2): δ = 9.24 (s, 1H), 8.48 – 8.40 (m, 1H), 7.74 – 7.68 (m, 1H), 7.64 – 
7.57 (m, 1H), 7.40 – 7.31 (m, 3H), 7.23 – 7.18 (m, 1H), 7.04 – 6.93 (m, 5H), 6.86 – 6.77 (m, 3H), 
4.45 (s, 2H), -1.84 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 151.9 (CH), 142.1 (Cq), 138.8 (Cq), 
137.0 (CH), 136.4 (Cq), 132.2 (CH), 131.2 (CH), 131.2 (CH), 128.2 (Cq), 127.4 (CH), 127.1 (CH), 
126.6 (CH), 126.3 (CH), 125.7 (Cq), 119.3 (CH), 117.7 (CH), 117.4 (CH). 11B NMR (96 MHz, 
CD2Cl2): δ = 5.02 (1B), -4.05 (1B), -11.73 (1B), -15.70 (2B), -20.59 (1B), -26.07 (1B), -31.04 (1B), 
-35.90 (1B). IR (ATR): 2529, 1627, 1596, 1494, 1399, 1385, 744, 693 cm–1. MS (ESI) m/z 
(relative intensity): 452 (100) [M+Na]+, 430 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C23H2710B111B8N2 [M+Na]+: 452.2956, found: 452.2954. 
 
 
156q. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and tert-butyl isoquinolin-5-ylcarbamate 155q (53.4 mg, 0.30 mmol). Isolation by column 
chromatography (CH2Cl2) yielded 156q (25.1 mg, 54%) as a yellow solid. M.p. = 198 – 201 °C. 
1H NMR (400 MHz, CD2Cl2): δ = 9.27 (s, 1H), 8.49 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 7.7 Hz, 1H), 
7.81 – 7.73 (m, 2H), 7.71 – 7.66 (m, 1H), 7.32 – 7.27 (m, 2H), 7.01 – 6.94 (m, 3H), 6.93 – 6.86 
(m, 3H), 6.82 – 6.76 (m, 3H), 1.52 (s, 9H), -1.88 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 152.9 





(CH), 130.0 (Cq), 128.2 (Cq), 127.8 (CH), 127.4 (overlapped, CH), 127.0 (CH), 126.6 (CH), 125.6 
(CH), 117.7 (CH), 82.2 (Cq), 28.2 (CH3). 11B NMR (128 MHz, CD2Cl2): δ = 4.81 (1B), -3.96 (1B), -
11.51 (1B), -15.65 (2B), -20.31 (1B), -25.95 (1B), -30.82 (1B), -35.66 (1B). IR (ATR): 2540, 1682, 
1521, 1491, 1444, 1252, 1151, 696 cm-1. MS (ESI) m/z (relative intensity): 530 (50) [M+H]+, 552 




156r. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 9-(pyridin-4-yl)-9H-carbazole 155r (73.0 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/CH2Cl2: 1/1) yielded 156r (30.0 mg, 56%) as a yellow solid. 
M.p. = 320 – 321 °C. 1H NMR (300 MHz, DMSO-d6): δ = 9.09 (d, J = 7.0 Hz, 2H), 8.28 (d, J = 
7.4 Hz, 2H), 8.12 (d, J = 7.1 Hz, 2H), 7.66 – 7.59 (m, 2H), 7.52 (t, J = 7.1 Hz, 2H), 7.46 – 7.40 
(m, 2H), 7.37 (d, J = 6.7 Hz, 2H), 7.09 – 6.94 (m, 5H), 6.90 – 6.81 (m, 3H), -1.42 (s, 1H). 
13C NMR (101 MHz, DMSO-d6): δ = 150.7 (CH), 150.0 (Cq), 139.1 (Cq), 138.3 (Cq), 136.6 (Cq), 
132.5 (CH), 131.5 (CH), 127.7 (CH), 127.5 (CH), 127.4 (CH), 126.9 (CH), 126.7 (CH), 125.1 (Cq), 
123.4 (CH), 121.5 (CH), 121.4 (CH), 111.1 (CH). 11B NMR (161 MHz, DMSO-d6): δ = 19.79 (1B), 
5.14 (1B), -5.31 (1B), -15.72 (2B), -21.29 (1B), -26.27 (1B), -31.13 (1B), -36.92 (1B). IR (ATR): 
2216, 2176, 2149, 1961, 1510, 1443, 749 cm–1. MS (ESI) m/z (relative intensity): 552 (100) 




156s. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and imidazole 155s (20.4 mg, 0.30 mmol). Isolation by column chromatography (CH2Cl2) 





d6): δ = 8.47 (t, J = 1.4 Hz, 1H), 7.33 (t, J = 1.6 Hz, 1H), 7.32 – 7.24 (m, 3H), 7.04 – 6.98 (m, 2H), 
6.97 – 6.91 (m, 2H), 6.92 – 6.85 (m, 1H), 6.86 – 6.77 (m, 3H), 2.87 (s, 1H), -1.81 (s, 1H). 13C 
NMR (126 MHz, Acetone-d6): δ = 140.4 (Cq), 138.4 (Cq), 133.0 (CH), 132.1 (CH), 127.7 (CH), 
127.6 (overlapped, CH), 127.3 (CH), 126.9 (CH), 126.7 (CH), 119.3 (CH). 11B NMR (128 MHz, 
Acetone d6): δ = 6.28 (1B), -0.05 (1B), -7.84 (1B), -10.55 (2B), -16.20 (1B), -20.71 (1B), -26.25 
(1B), -31.58 (1B). IR (ATR): 3350, 3151, 2535, 1693, 1494, 1444, 1245, 1058 cm-1 MS (ESI) m/z 
(relative intensity): 376 (100) [M+Na]+, 354 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C17H2310B111B8N2 [M+Na]+: 376.2639, found: 376.2637. The analytical data corresponds with 
those reported in the literature.[225] 
 
 
156t. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and thiazole 155t (25.5 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156t (23.0 mg, 62%) as a white solid. M.p. = 278 – 280 °C. 1H NMR 
(500 MHz, Acetone-d6): δ = 9.62 (dd, J = 2.4, 1.2 Hz, 1H), 8.19 (dd, J = 3.6, 1.2 Hz, 1H), 8.01 
(dd, J = 3.6, 2.3 Hz, 1H), 7.33 – 7.28 (m, 2H), 7.04 – 6.99 (m, 2H), 6.96 – 6.87 (m, 3H), 6.85 – 
6.80 (m, 3H), -1.75 (s, 1H). 13C NMR (126 MHz, Acetone-d6): δ = 160.8 (CH), 142.5 (Cq), 
139.9 (Cq), 137.7 (CH), 132.9 (CH), 131.9 (CH), 127.9 (CH), 127.7 (CH), 127.3 (CH), 126.9 (CH), 
124.5 (CH). 11B NMR (128 MHz, Acetone-d6): δ = 2.16 (1B), -4.51 (1B), -11.95 (1B), -15.68 (2B), 
-20.65 (1B), -25.91 (1B), -30.68 (1B), -36.28 (1B). IR (ATR): 3110, 2922, 2852, 1975, 1492, 1442, 
1248, 688 cm-1. MS (ESI) m/z (relative intensity): 393 (100) [M+Na]+, 371 (30) [M+H]+. HR-MS 
(ESI): m/z calcd. for C17H2210B111B8NS [M+Na]+: 393.2252, found: 393.2252. The analytical data 
corresponds with those reported in the literature.[225] 
 
 
156u. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 1-methyl-1H-imidazole 155u (25.0 mg, 0.30 mmol). Isolation by column 





= 270 – 272 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.74 (s, 1H), 7.34 – 7.28 (m, 2H), 7.04 – 6.90 
(m, 9H), 6.85 (t, J = 1.8 Hz, 1H), 3.67 (s, 3H), -1.98 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 
139.1 (Cq), 137.3 (Cq), 137.2 (CH), 132.2 (CH), 131.2 (CH), 127.2 (CH), 127.1 (CH), 127.0 (CH), 
126.4 (CH), 126.1 (CH), 121.6 (CH), 35.5 (CH3). 11B NMR (96 MHz, CD2Cl2): δ = 0.89 (1B), -
4.66 (1B), -12.39 (1B), -15.64 (2B), -20.80 (1B), -25.99 (1B), -31.34 (1B), -36.47 (1B). IR (ATR): 
3143, 2547, 2506, 1541, 1442, 1172, 829, 750, 689 cm–1. MS (ESI) m/z (relative intensity): 390 
(100) [M+Na]+, 368 (20) [M+H]+. HR-MS (ESI): m/z calcd. for C18H2510B111B8N2 [M+Na]+: 




156v. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 1-mesityl-1H-imidazole 155v (56.0 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/CH2Cl2: 1/1) yielded 156v (33.0 mg, 70%) as a colorless solid. 
M.p. = 237 – 239 °C. 1H NMR (300 MHz, CD2Cl2): δ = 7.72 (t, J = 1.5 Hz, 1H), 7.47 (t, J = 1.6 Hz, 
1H), 7.36 – 7.30 (m, 2H), 7.04 – 6.95 (m, 7H), 6.93 – 6.87 (m, 4H), 2.35 (s, 3H), 1.94 (s, 3H), 
1.60 (s, 3H), -2.01 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 141.3 (Cq), 139.3 (Cq), 137.7 (Cq), 
137.4 (CH), 134.8 (Cq), 134.7 (Cq), 132.5 (CH), 131.4 (CH), 131.0 (Cq), 129.7 (CH), 128.3 (CH), 
127.6 (CH), 127.3 (CH), 126.7 (CH), 126.4 (CH), 122.5 (CH), 21.1 (CH3), 17.2 (CH3), 17.0 (CH3). 
11B NMR (128 MHz, CD2Cl2): δ = 0.52 (1B), -4.70 (1B), -12.44 (1B), -15.97 (2B), -21.20 (1B), -
26.06 (1B), -31.28 (1B), -36.54 (1B). IR (ATR): 3475, 3375, 2534, 1644, 1527, 1181, 832, 695 
cm–1. MS (ESI) m/z (relative intensity): 494 (100) [M+Na]+, 472 (30) [M+H]+. HR-MS (ESI): m/z 
calcd. for C26H3310B111B8N2 [M+Na]+: 494.3427, found: 494.3417. 
 
 
156w. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 





chromatography (n-hexane/CH2Cl2: 1/1) yielded 156w (35.0 mg, 89%) as a colorless solid. M.p. 
= 213 – 216 °C. 1H NMR (300 MHz, CD2Cl2): δ = 7.50 (t, J = 1.6 Hz, 1H), 7.34 – 7.30 (m, 2H), 
7.21 (t, J = 1.7 Hz, 1H), 7.05 – 6.97 (m, 3H), 6.96 – 6.91 (m, 6H), 4.24 (hept, J = 6.7 Hz, 1H), 
1.35 (d, J = 2.5 Hz, 3H), 1.33 (d, J = 2.5 Hz, 3H), -2.07 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 
139.4 (Cq), 137.8 (Cq), 134.8 (CH), 132.4 (CH), 131.5 (CH), 127.6 (CH), 127.5 (CH), 127.3 (CH), 
126.7 (CH), 126.4 (CH), 118.7 (CH), 52.4 (CH), 23.1 (CH3), 22.9 (CH3). 11B NMR (128 MHz, 
CD2Cl2): δ = 0.72 (1B), -5.08 (1B), -12.70 (1B), -15.94 (2B), -21.04 (1B), -26.22 (1B), -31.68 (1B), 
-36.64 (1B). IR (ATR): 3142, 2557, 2519, 1537, 1442, 1177, 838, 759, 657 cm–1. MS (ESI) m/z 
(relative intensity): 418 (100) [M+Na]+, 396 (30) [M+H]+. HR-MS (ESI): m/z calcd. for 
C20H2910B111B8N2 [M+Na]+: 418.3111, found: 418.3114. 
 
 
156x. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 1H-pyrrolo[3,2-c]pyridine 155x (35.4 mg, 0.30 mmol). Isolation by column 
chromatography (CH2Cl2) yielded 156x (27.0 mg, 67%) as a white solid. M.p. = 280 – 283 °C. 
1H NMR (500 MHz, Acetone-d6): δ = 11.51 (s, 1H), 9.40 (s, 1H), 8.57 (d, J = 7.8 Hz, 1H), 7.75 
(dd, J = 3.4, 1.9 Hz, 1H), 7.66 (d, J = 6.8 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.04 – 6.99 (m, 2H), 6.97 
– 6.85 (m, 4H), 6.75 – 6.60 (m, 3H), -1.65 (s, 1H). 13C NMR (126 MHz, Acetone-d6): δ = 144.2 
(CH), 141.7 (Cq), 140.2 (Cq), 139.9 (CH), 138.0 (Cq), 133.0 (CH), 132.0 (CH), 131.9 (CH), 127.7 
(CH), 127.5 (CH), 126.8 (CH), 126.8 (CH), 125.6 (Cq), 108.8 (CH), 104.6 (CH). 11B NMR (128 
MHz, Acetone-d6): δ = 6.10 (1B), -4.91 (1B), -12.91 (1B), -15.57 (2B), -21.64 (1B), -26.01 (1B), -
30.95 (1B), -36.54 (1B). IR (ATR): 3386, 2923, 2536, 1631, 1493, 1357, 1225, 697 cm-1 MS (ESI) 
m/z (relative intensity): 426 (100) [M+Na]+, 404 (30) [M+H]+. HR-MS (ESI): m/z calcd. for 







156y. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 1H-pyrrolo[2,3-c]pyridine 155y (35.4 mg, 0.30 mmol). Isolation by column 
chromatography (CH2Cl2) yielded 156y (28.2 mg, 70%) as a white solid. M.p. = 171 – 175 °C. 
1H NMR (500 MHz, Acetone-d6): δ = 11.55 (s, 1H), 9.23 (s, 1H), 8.53 (d, J = 6.6 Hz, 1H), 8.07 (d, 
J = 2.9 Hz, 1H), 7.80 (d, J = 6.6 Hz, 1H), 7.31 (d, J = 7.2 Hz, 2H), 6.99 (d, J = 6.8 Hz, 2H), 6.93 
(t, J = 7.4 Hz, 2H), 6.92 – 6.85 (m, 1H), 6.79 (d, J = 2.9 Hz, 1H), 6.73 – 6.63 (m, 3H), -1.64 (s, 
1H). 13C NMR (126 MHz, Acetone-d6): δ = 140.1 (Cq), 138.3 (CH), 137.9 (Cq), 137.9 (CH), 136.4 
(Cq), 134.8 (CH), 133.0 (CH), 132.6 (Cq), 131.9 (CH), 127.7(CH), 127.6 (CH), 126.9 (CH), 126.8 
(CH), 116.7 (CH), 103.6 (CH). 11B NMR (128 MHz, Acetone-d6): δ = 6.24 (1B), -4.58 (1B), -12.66 
(1B), -15.43 (2B), -21.41 (1B), -25.92 (1B), -30.88 (1B), -36.41 (1B). IR (ATR): 2539, 1710, 1639, 
1494, 1321, 1140, 836, 693 cm-1. MS (ESI) m/z (relative intensity): 426 (100) [M+Na]+, 404 (50) 
[M+H]+. HR-MS (ESI): m/z calcd. for C21H2510B111B8N2 [M+Na]+: 426.2798, found: 426.2798. The 
analytical data corresponds with those reported in the literature.[225] 
 
 
156z. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 1H-pyrrolo[3,2-b]pyridine 155z (35.4 mg, 0.30 mmol). Isolation by column 
chromatography (CH2Cl2) yielded 156z (20.1 mg, 50%) as a white solid. M.p. = 283 – 285 °C. 
1H NMR (500 MHz, Acetone-d6): δ = 11.57 (s, 1H), 8.69 (d, J = 6.0 Hz, 1H), 8.30 (d, J = 8.1 Hz, 
1H), 8.22 (d, J = 3.3 Hz, 1H), 7.76 (d, J = 3.3 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.02 – 6.85 (m, 5H), 
6.62 – 6.50 (m, 3H), -1.67 (s, 1H). 13C NMR (126 MHz, Acetone-d6): δ = 144.0 (Cq), 142.6 (CH), 
140.0 (Cq), 137.9 (Cq), 135.3 (CH), 133.1 (CH), 132.7 (CH), 131.6 (Cq), 127.8 (CH), 126.9 (CH), 
126.9 (CH), 126.7 (CH), 126.6 (CH), 116.9 (CH), 101.9 (CH). 11B NMR (128 MHz, Acetone-d6): δ 
= 4.40 (1B), -4.77 (1B), -12.03 (1B), -15.09 (1B), -15.66 (1B), -22.01 (1B), -25.70 (1B), -29.83 
(1B), -36.66 (1B). IR (ATR): 3386, 2540, 2199, 2021, 14958, 1425, 1367, 763, 698. cm-1. MS 
(ESI) m/z (relative intensity): 426 (100) [M+Na]+, 404 (30) [M+H]+. HR-MS (ESI): m/z calcd. for 







156aa. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and H-imidazo[1,2-a]pyridine 155aa (35.4 mg, 0.30 mmol). Isolation by column 
chromatography (CH2Cl2) yielded 156aa (30.0 mg, 75%) as a white solid. M.p. = 265 – 268 °C. 
1H NMR (500 MHz, CD2Cl2): δ = 8.76 (d, J = 9.3 Hz, 1H), 8.16 (dt, J = 6.7, 1.2 Hz, 1H), 7.82 
(ddd, J = 9.3, 7.0, 1.3 Hz, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.34 – 7.28 (m, 
2H), 7.25 (td, J = 6.9, 1.1 Hz, 1H), 7.01 – 6.92 (m, 3H), 6.83 – 6.76 (m, 2H), 6.70 – 6.61 (m, 3H), 
-1.87 (s, 1H). 13C NMR (126 MHz, CD2Cl2): δ = 143.8 (Cq), 139.4 (Cq), 137.8 (Cq), 132.4 (CH), 
132.1 (CH), 130.9 (CH), 130.5 (CH), 127.9 (CH), 127.3 (CH), 127.0 (CH), 126.4 (CH), 126.2 
(CH), 116.9 (CH), 115.0 (CH), 113.1 (CH). 11B NMR (128 MHz, CD2Cl2): δ = 0.00 (1B), -4.98 (1B), 
-11.82 (1B), -15.41 (1B), -16.03 (1B), -21.34 (1B), -25.59 (1B), -30.16 (1B), -36.53 (1B). IR (ATR): 
3144, 2532, 1707, 1642, 1444, 1202, 752, 697 cm-1. MS (ESI) m/z (relative intensity): 426 (100) 




156bb. The representative procedure J was followed using nido-carborane 154b (29.1 mg, 0.10 
mmol) and pyridine 155a (24.0 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/CH2Cl2: 1/1) yielded 156bb (19.5 mg, 66%) as a yellow solid. M.p. = 199 – 200 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 9.09 (d, J = 4.9 Hz, 2H), 8.33 (tt, J = 7.8, 1.5 Hz, 1H), 7.85 (dd, 
J = 7.7, 6.6 Hz, 2H), 2.04 – 1.85 (m, 6H), 1.01 – 0.86 (m, 5H), 0.61 (t, J = 7.3 Hz, 3H), -2.76 (s, 
1H). 13C NMR (75 MHz, CD2Cl2): δ = 148.9 (CH), 143.1 (CH), 126.5 (CH), 36.7 (CH2), 33.4 (CH2), 
24.1 (CH2), 22.9 (CH2), 14.3 (CH3), 14.1 (CH3). 11B NMR (96 MHz, CD2Cl2): δ = 4.42 (1B), -5.99 
(1B), -12.19 (1B), -13.83 (1B), -17.06 (1B), -20.53 (1B), -27.25 (1B), -30.97 (1B), -37.54 (1B). IR 
(ATR): 2558, 2527, 2231, 2032, 1960, 1629, 572, 480 cm-1. MS (ESI) m/z (relative intensity): 319 








156cc. The representative procedure J was followed using nido-carborane 154c (26.3 mg, 0.10 
mmol) and 4-phenylpyridine 155g (46.5 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane/CH2Cl2: 1/1) yielded 156cc (25.0 mg, 73%) as a yellow solid. M.p. = 84 – 85 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 9.06 (d, J = 5.6 Hz, 2H), 8.02 (d, J = 5.6 Hz, 2H), 7.90 – 7.80 
(m, 2H), 7.71 – 7.62 (m, 3H), 2.19 – 1.98 (m, 2H), 1.92 – 1.80 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H), 
0.65 (t, J = 7.5 Hz, 3H), -2.72 (s, 1H). 13C NMR (75 MHz, CD2Cl2): δ = 155.0 (Cq), 148.8 (CH), 
134.4 (Cq), 131.8 (CH), 129.8 (CH), 127.6 (CH), 123.6 (CH), 27.1 (CH2), 23.7 (CH2), 14.9 (CH3), 
13.9 (CH3). 11B NMR (96 MHz, CD2Cl2): δ = 4.3 (1B), -6.1 (1B), -12.5 (1B), -14.0 (1B), -17.2 (1B), 
-20.7 (1B), -27.3 (1B), -31.1 (1B), -37.6 (1B). IR (ATR): 2527, 2032, 1994, 1961, 1629, 766, 692, 
446 cm-1. MS (ESI) m/z (relative intensity): 367 (100) [M+Na]+, 345 (50) [M+H]+. HR-MS (ESI): 
m/z calcd. for C17H2810B111B8N [M+Na]+: 367.0000, found: 367.2993. 
 
 
157a. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and dimethyl isonicotinoyl-L-aspartate 155bb (80.0 mg, 0.30 mmol). Isolation by column 
chromatography (MeOH/CH2Cl2: 1/100) yielded 157a (46.0 mg, 84%) as a yellow solid. 
M.p. = 183 – 187 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.83 (d, J = 6.7 Hz, 2H), 7.82 (d, J = 7.0 
Hz, 2H), 7.49 – 7.42 (m, 1H), 7.32 (d, J = 6.5 Hz, 2H), 7.04 – 6.98 (m, 3H), 6.96 – 6.89 (m, 5H), 
5.03 – 4.96 (m, 1H), 3.80 (s, 3H), 3.72 (s, 3H), 3.20 – 3.11 (m, 1H), 3.02 – 2.94 (m, 1H), -1.89 (s, 
1H). 13C NMR (101 MHz, CD2Cl2): δ = 171.4 (Cq), 170.2 (Cq), 161.8 (Cq), 148.3 (CH), 145.7 (Cq), 
138.6 (Cq), 135.8 (Cq), 132.1 (CH), 131.2 (CH), 127.8 (CH), 127.1 (CH), 127.0 (CH), 126.4 (CH), 
123.5 (CH), 53.1 (CH3), 52.2 (CH3), 49.3 (CH), 35.4 (CH2). 11B NMR (96 MHz, CD2Cl2): δ = 4.58 
(1B), -3.63 (1B), -11.19 (1B), -15.79 (2B), -20.13 (1B), -26.06 (1B), -30.87 (1B), -35.56 (1B). IR 





intensity): 574 (100) [M+Na]+, 552 (20) [M+H]+. HR-MS (ESI): m/z calcd. for 
C26H3310B111B8N2O5 [M+Na]+: 574.3174, found: 574.3165. 
 
 
157b. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 
0.10 mmol) and tert-butyl (S)-(1-oxo-1-(pyridin-4-ylamino)propan-2-yl)carbamate 155cc 
(80.0 mg, 0.30 mmol). Isolation by column chromatography (MeOH/CH2Cl2: 1/100) yielded 157b 
(44.0 mg, 80%) as a colorless solid. M.p. = 230 – 233 °C. 1H NMR (400 MHz, CDCl3): δ = 10.00 
(s, 1H), 8.47 (d, J = 3.3 Hz, 2H), 7.51 (t, J = 6.5 Hz, 2H), 7.33 – 7.28 (m, 2H), 7.00 – 6.93 (m, 
3H), 6.89 – 6.80 (m, 5H), 4.98 – 4.84 (m, 1H), 4.33 – 4.20 (m, 1H), 1.48 (s, 9H), 1.42 (d, J = 7.2 
Hz, 3H), -2.02 (s, 1H). 13C NMR (101 MHz, CDCl3): δ = 171.8 (Cq), 157.2 (Cq), 149.5 (Cq), 148.3 
(CH), 138.6 (Cq), 136.5 (Cq), 132.1 (CH), 131.1 (CH), 127.4 (CH), 127.1 (CH), 126.6 (CH), 
126.2 (CH), 113.9 (CH), 82.2 (Cq), 51.1 (CH), 28.2 (CH3), 15.7 (CH3). 11B NMR (96 MHz, CDCl3): 
δ = 5.18 (1B), -3.87 (1B), -10.82 (1B), -15.36 (2B), -20.60 (1B), -26.03 (1B), -30.80 (1B), -35.93 
(1B). IR (ATR): 3475, 3375, 2535, 1681, 1644, 1494, 1443, 1162, 695 cm–1. MS (ESI) m/z 
(relative intensity): 573 (100) [M+Na]+, 551 (50) [M+H]+. HR-MS (ESI): m/z calcd. for 
C27H3810B111B8N3O3 [M+Na]+: 573.3698, found: 573.3708. 
 
 
157c. The representative procedure J was followed using the toluene derivative of the nido- 
carborane 154d (38.8 mg, 0.10 mmol) and tert-butyl (S)-(1-oxo-1-(pyridin-4-ylamino)propan -2-
yl)carbamate 155dd (80.0 mg, 0.30 mmol). Isolation by column chromatography (CH2Cl2) 





δ = 9.91 (s, 1H), 8.48 (d, J = 7.3 Hz, 2H), 7.57 (d, J = 9.7 Hz, 2H), 7.19 (d, J = 8.1 Hz, 2H), 6.90 
– 6.76 (m, 4H), 6.71 (d, J = 7.8 Hz, 2H), 5.01 (d, J = 6.5 Hz, 1H), 4.29 (q, J = 7.0 Hz, 1H), 2.18 
(s, 3H), 2.10 (s, 3H), 1.48 (s, 9H), 1.42 (d, J = 7.1 Hz, 3H), -1.98 (s, 1H). 13C NMR (101 MHz, 
CD2Cl2): δ = 171.9 (Cq), 149.7 (Cq), 148.3 (CH), 136.2 (Cq), 136.2 (Cq), 136.2 (Cq), 135.8 (Cq), 
133.5 (Cq), 132.0 (CH), 131.0 (CH), 128.1 (CH), 127.8 (CH), 113.8 (CH), 81.8 (Cq), 29.7 (CH), 
27.9 (CH3), 20.6 (CH3), 20.6 (CH3), 20.5 (CH3). 11B NMR (128 MHz, CD2Cl2): δ = 6.10 (1B), -4.91 
(1B), -12.91 (1B), -15.57 (2B), -21.64 (1B), -26.01 (1B), -30.95 (1B), -36.54 (1B). IR (ATR): 3210, 
2539, 1633, 1517, 1312, 1171, 845, 697 cm–1. MS (ESI) m/z (relative intensity): 596 (100) 
[M+NH4]+. HR-MS (ESI): m/z calcd. for C29H4210B111B8N3O3 [M+NH4]+: 596.4458, found: 596.4449. 
 
 
157d. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 5,5-difluoro-1,3,7,9-tetramethyl-10-(pyridin-4-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2', 1'-
f][1,3,2]diazaborinine 155ee (98.0 mg, 0.30 mmol). Isolation by column chromatography 
(MeOH/CH2Cl2: 1/100) yielded 157d (43.0 mg, 71%) as a red solid. M.p. = 318 – 319 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 8.94 (d, J = 6.8 Hz, 2H), 7.59 (d, J = 6.8 Hz, 2H), 7.37 – 7.30 
(m, 2H), 7.07 – 6.87 (m, 8H), 6.09 (s, 2H), 2.55 (s, 6H), 1.25 (s, 6H), -1.96 (s, 1H). 13C NMR 
(101 MHz, CD2Cl2): δ = 158.0 (Cq), 150.7 (Cq), 148.5 (CH), 142.1 (Cq), 138.5 (Cq), 136.0 (Cq), 
133.5 (Cq), 132.1 (CH), 131.0 (CH), 129.4 (Cq), 127.7 (CH), 127.2 (CH), 126.9 (CH), 126.4 
(overlapped, CH), 122.5 (CH), 15.1 (CH3), 15.1 (CH3), 14.5 (CH3), 14.5 (CH3). 11B NMR (128 
MHz, CD2Cl2): δ = 4.61 (1B), 0.53 (t, J = 31.9 Hz, BF2), -3.67 (1B), -10.68 (1B), -15.76 (2B), -
20.49 (1B), -26.01 (1B), -30.72 (1B), -35.65 (1B). 19F NMR (377 MHz, CD2Cl2): δ = -146.29 (dd, 
J = 64.0, 32.5 Hz). IR (ATR): 3478, 3376, 2541, 1644, 1518, 1443, 1197, 1161, 695 cm–1. MS 
(ESI) m/z (relative intensity): 633 (100) [M+Na]+. HR-MS (ESI): m/z calcd. for 







157e. The representative procedure J was followed using nido-carborane 154a (36.0 mg, 0.10 
mmol) and 5,5-difluoro-3,7-diphenyl-10-(pyridin-4-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3, 
2]diazaborinine 155ff (126.0 mg, 0.30 mmol). Isolation by column chromatography 
(MeOH/CH2Cl2: 1/100) yielded 157e (35.0 mg, 50%) as a purple solid. M.p. = 310 – 312 °C. 
1H NMR (300 MHz, CD2Cl2): δ = 8.91 (d, J = 6.8 Hz, 2H), 7.92 – 7.85 (m, 4H), 7.70 (d, J = 6.9 
Hz, 2H), 7.55 – 7.47 (m, 6H), 7.40 – 7.33 (m, 2H), 7.09 – 6.95 (m, 8H), 6.78 (d, J = 4.3 Hz, 2H), 
6.62 (d, J = 4.4 Hz, 2H), -1.90 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 161.2 (Cq), 148.5 (Cq), 
147.8 (CH), 138.6 (Cq), 136.2 (Cq), 135.4 (Cq), 134.9 (Cq), 132.1 (CH), 131.8 (Cq), 131.2 (CH), 
130.3 (CH), 129.7 (CH), 129.5 (CH), 129.5 (CH), 129.4 (CH), 128.3 (CH), 127.7 (CH), 
127.2 (CH), 127.0 (CH), 126.9 (CH), 126.4 (CH), 122.6 (CH). 11B NMR (128 MHz, CD2Cl2): δ = 
4.61 (1B), 1.24 ( (t, J = 31.3 Hz, BF2), -3.79 (1B), -10.90 (1B), -16.09 (2B), -20.64 (1B), -26.21 
(1B), -31.07 (1B), -35.67 (1B). 19F NMR (377 MHz, CD2Cl2): δ = -132.08 (dd, J = 63.1, 31.2 Hz). 
IR (ATR): 2220, 2160, 2148, 1990, 1569, 1289, 1136, 1073, 699 cm–1. MS (ESI) m/z (relative 
intensity): 729 (100) [M+Na]+. HR-MS (ESI): m/z calcd. for C40H3710B111B9F2N3 [M+Na]+: 
729.3822, found: 729.3833. 
 
 
159a. The representative procedure J was followed using nido-carborane 158a (43.0 mg, 0.10 
mmol). Isolation by column chromatography (MeOH/CH2Cl2: 1/100) yielded 159a (29.0 mg, 83%) 
as a yellow solid. M.p. = 292 – 294 °C. 1H NMR (300 MHz, CD2Cl2): δ = 9.30 (d, J = 5.4 Hz, 1H), 
8.63 (dd, J = 8.4, 1.6 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.79 – 7.67 (m, 2H), 7.60 – 7.55 (m, 1H), 
7.54 – 7.48 (m, 2H), 7.38 – 7.26 (m, 3H), 3.46 (d, J = 18.8 Hz, 1H), 3.10 (d, J = 18.8 Hz, 1H), -
1.86 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 145.5 (CH), 143.3 (CH), 138.9 (Cq), 137.6 (Cq), 





120.9 (CH), 33.9 (CH2). 11B NMR (96 MHz, CD2Cl2): δ = 1.14 (1B), -4.04 (1B), -13.02 (3B), -
19.21 (1B), -27.64 (1B), -29.35 (1B), -34.55 (1B). IR (ATR): 2571, 2543, 2521, 1518, 1373, 829, 
766, 695 cm–1. MS (ESI) m/z (relative intensity): 373 (100) [M+Na]+, 351 (20) [M+H]+. HR-MS 
(ESI): m/z calcd. for C18H2210B111B8N [M+Na]+: 373.2531, found: 373.2524. The analytical data 
corresponds with those reported in the literature.[225] 
 
 
159b. The representative procedure J was followed using nido-carborane 158b (41.0 mg, 0.10 
mmol). Isolation by column chromatography (MeOH/CH2Cl2: 1/100) yielded 159b (29.0 mg, 88%) 
as a yellow solid. M.p. = 235 – 237 °C. 1H NMR (300 MHz, CD2Cl2): δ = 9.26 (d, J = 4.8 Hz, 1H), 
8.61 (dd, J = 8.4, 1.6 Hz, 1H), 8.01 – 7.93 (m, 1H), 7.83 – 7.69 (m, 3H), 3.88 (d, J = 18.4 Hz, 1H), 
3.64 (d, J = 18.4 Hz, 1H), 2.09 – 1.86 (m, 2H), 1.73 – 1.47 (m, 2H), 1.43 – 1.29 (m, 2H), 0.95 (t, 
J = 7.3 Hz, 3H), -2.44 (s, 1H). 13C NMR (101 MHz, CD2Cl2): δ = 145.3 (CH), 143.0 (CH), 137.7 
(Cq), 134.5 (CH), 132.7 (Cq), 129.6 (Cq), 128.9 (CH), 127.6 (CH), 120.9 (CH), 34.1 (CH2), 33.1 
(CH2), 33.0 (CH2), 23.1 (CH2), 13.8 (CH3). 11B NMR (96 MHz, CD2Cl2): δ = 0.54 (1B), -5.34 (1B), 
-12.19 (1B), -15.65 (2B), -18.83 (1B), -27.89 (1B), -29.97 (1B), -35.37 (1B). IR (ATR): 2931, 
2850, 2581, 2522, 1518, 1374, 1005, 826, 767 cm–1. MS (ESI) m/z (relative intensity): 353 (100) 
[M+Na]+, 331 (20) [M+H]+. HR-MS (ESI): m/z calcd. for C16H2610B111B8N [M+Na]+: 353.2843, 
found: 353.2834. 
 
5.3.5.2 Competition Experiments 
 
 
The general procedure J was followed using nido-carborane 154a (36 mg, 0.10 mmol), pyridine 
155a (12 mg, 0.15 mmol) and imidazole 155s (10 mg, 0.15 mmol). The conversions to 156a and 







5.3.5.3 GC-Headspace Detection   
 
In an undivided cell equipped with a GF anode (10 mm × 15 mm × 6 mm) and a platinum 
cathode (10 mm × 15 mm × 0.25 mm), nido-Carborane 154a (0.1 mmol, 1.0 equiv), pyridine 
155a (0.3 mmol, 3.0 equiv), and NMe4Cl (0.2 mmol, 2.0 equiv) were dissolved in DME (4.0 mL) 
and H2O (0.2 mL). Electrocatalysis was performed at room temperature under a constant current 
of 6.0 mA maintained for 3 h. After the reaction, 1.0 mL of the headspace volume was removed 
for GC analysis. The graphite felt anode was washed with CH2Cl2 (3 × 10 mL) in an ultrasonic 










5.3.5.3 Cyclic Voltammetry 
CV measurements were conducted with a Metrohm Autolab PGSTAT204 potentiostat and Nova 
2.1 software. A glassy carbon working electrode (disk, diameter: 3mm), a coiled platinum wire 
counter electrode and a non-aqueous Ag/Ag+ reference electrode (ALS Japan) were employed. 
The voltammograms were recorded at room temperature in dry 1,2-dimethoxyethane (DME) at a 
substrate concentration of 1 mmol/L and with 100 mmol/L n-Bu4NPF6 as supporting electrolyte. 
All solutions were degassed with DME-saturated N2 prior to measurement and an overpressure 
of protective gas was maintained throughout the experiment. The scan rate is 100 mV/s. 
Deviations from the general experimental conditions are indicated in the respective figures and 
descriptions. The measured half-peak potential for the irreversible oxidation process of the nido-
carborane standard substrate is: +0.87 V vs. SCE in DME/H2O 19:1, +0.55 V vs. Ag/Ag+ in 



























1) Reagents  
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Potential vs. SCE (V)
 154a
 
2) Effect of H2O 










































5.3.5.3 Stability Test 
Thermal stability test: compound 156a was dissolved in an NMR tube (0.4 mL DMSO-d6), then 





NMR tracking experiments show that 156a was quite stable at 100 °C and 120 °C . 
Chemical stability test: compound 156a was dissolved in an NMR tube (0.4 mL CD3CN), then 
0.1 mL H2O, HCl (1M) or NaOH (1M) was added into the NMR tube, respectively. The 11B NMR 
tracking experiments show that 156a was stable in a neutral environment. However, 156a starts 
to decompose in a strong acidic or alkaline environment. 
Note: although 156a was not stable in a strong acidic or alkaline environments, but during our 
experiments, we found these B–N coupling compounds are very stable in the solid state or 
even in liquid solution at room temperature for a long time. 
 
1H NMR spectra of compound 156a in DMSO-d6 at different temperature for stability test. 
3aa 120 °C 10h 
3aa 120 °C 3h 







 11B NMR spectra of compound 156a in DMSO-d6 at different temperature for thermal stability test. 
 
11B NMR spectra of compound 156a in CD3CN in 0.1 mL H2O for chemical stability test. 
156a 120 °C 
3h 
156a 120 °C 10h 











 11B NMR spectra of compound 156a in CD3CN in 0.1 mL HCl (1M) for chemical stability test.
 














5.3.6 Cupraelectro-Catalyzed Chalcogenations of o-Carboranes 
5.3.6.1 Characterization Data 
 
162a. The representative procedure K was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and 4-methoxybenzenethiol 161a (36.9 µL, 0.30 mmol). Isolation by column 
chromatography (n-hexane) yielded 162a (30.5 mg, 85%) as a colorless solid. M.p. = 141 – 
143 °C. 1H NMR (400 MHz, CDCl3): δ = 7.66 (d, J = 8.0 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.48 (t, 
J = 7.6 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.77 (d, J = 8.8 Hz, 2H), 3.83 (s, 3H). 13C NMR 
(101 MHz, CDCl3): δ = 161.8 (Cq), 138.5 (CH), 132.2 (CH), 131.0 (Cq), 130.8 (CH), 128.5 (CH), 
120.8 (Cq), 114.5 (CH), 87.9 (Cage C), 86.9 (Cage C), 55.4 (CH3). 11B NMR (96 MHz, CDCl3): δ 
= -2.78 (2B), -9.14 (3B), -10.46 (3B), -11.59 (2B). IR (ATR): 2924, 2853, 2601, 2574, 2561, 1588, 
1253, 1170, 1027 cm–1. MS (EI) m/z: 358 [M]+. HR-MS (EI): m/z calcd. for C15H2210B211B8OS [M]+: 
358.2397, found: 358.2386.  
 
 
162b. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 4-(tert-butyl)benzenethiol 161b (49.9 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162b (24.0 mg, 62%) as a colorless 
solid. M.p. = 177 – 179 °C. 1H NMR (400 MHz, CDCl3): δ = 7.69 – 7.64 (m, 2H), 7.62 – 7.53 (m, 
1H), 7.51 – 7.46 (m, 2H), 7.30 – 7.26 (m, 2H), 6.92 – 6.85 (m, 2H), 1.33 (s, 9H). 13C NMR (101 
MHz, CDCl3): δ = 154.7 (Cq), 136.5 (CH), 132.2 (CH), 131.0 (Cq), 130.8 (CH), 128.5 (CH), 126.4 
(Cq), 126.1 (CH), 88.1 (Cage C), 86.6 (Cage C), 34.9 (Cq), 31.1 (CH3). 11B NMR (96 MHz, 
CDCl3): δ = -3.00 (2B), -9.24 (3B), -10.43 (2B), -11.65 (3B). IR (ATR): 2966, 2924, 2866, 2577, 
2564, 1446, 1073, 687 cm–1. MS (EI) m/z: 384 [M]+. HR-MS (EI): m/z calcd. for 
C18H2810B211B8S [M]+: 384.2919, found: 384.2904.  
 
 
162c. The representative procedure K with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 4-methylbenzenethiol 161c (37.2 mg, 0.30 mmol). 





solid. M.p. = 146 – 148 °C. 1H NMR (400 MHz, CDCl3): δ = 7.65 – 7.58 (m, 1H), 7.55 – 7.49 (m, 
2H), 7.47 – 7.39 (m, 2H), 7.03 (d, J = 7.8 Hz, 2H), 6.79 (d, J = 8.2 Hz, 2H), 2.32 (s, 3H). 13C 
NMR (101 MHz, CDCl3): δ = 141.6 (Cq), 136.7 (CH), 132.2 (CH), 130.9 (Cq), 130.8 (CH), 129.8 
(CH), 128.5 (Cq), 126.5 (CH), 88.0 (Cage C), 86.5 (Cage C), 21.37 (CH3). 11B NMR (128 MHz, 
CDCl3): δ = -2.59 (1B), -3.22 (1B), -8.51 (2B), -9.22 (2B), -10.42 (2B), -11.56 (2B). IR (ATR): 
2954, 2598, 2568, 1973, 1492, 1446, 1179, 1073, 885 cm-1. MS (EI) m/z: 342 [M]+. HR-MS (EI): 
m/z calcd. for C15H2210B211B8S [M]+: 342.2448, found: 342.2435. 
 
 
162d. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 4-(trifluoromethyl)benzenethiol 161d (41.1 µL, 0.30 
mmol). Isolation by column chromatography (n-hexane) yielded 162d (30.6 mg, 77%) as a 
colorless solid. M.p. = 84 – 86 °C. 1H NMR (400 MHz, CDCl3): δ = 7.62 – 7.58 (m, 2H), 7.57 – 
7.52 (m, 1H), 7.51 – 7.47 (m, 2H), 7.47 – 7.42 (m, 2H), 7.05 – 7.00 (m, 2H). 13C NMR (101 MHz, 
CDCl3): δ = 137.0 (CH), 133.8 (Cq), 133.0 (q, 2JC-F = 33 Hz, Cq), 132.1 (CH), 131.0 (CH), 130.7 
(Cq), 128.6 (CH), 125.9 (q, 3JC-F = 3.7 Hz, CH), 123.4 (q, 1JC-F = 273 Hz, Cq), 88.0 (Cage C), 
84.7 (Cage C). 11B NMR (128 MHz, CDCl3): δ = -2.47 (2B), -9.09 (4B), -10.22 (2B), -11.48 (2B). 
19F NMR (376 MHz, CDCl3): δ = -63.07. IR (ATR): 2925, 2572, 1495, 1447, 1322, 1172, 1135, 
1062, 842 cm-1. MS (EI) m/z: 396 [M]+. HR-MS (EI): m/z calcd. for C15H1910B211B8F3S [M]+: 
396.2165, found: 396.2158. 
 
 
162e. The representative procedure K with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 4-fluorobenzenethiol 161e (32.0 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162e (21.0 mg, 61%) as a colorless 
solid. M.p. = 103 – 105 °C. 1H NMR (400 MHz, CDCl3): δ = 7.69 – 7.61 (m, 2H), 7.61 – 7.54 (m, 
1H), 7.51 – 7.44 (m, 2H), 7.01 – 6.87 (m, 4H). 13C NMR (101 MHz, CDCl3): δ = 164.4 (d, 1JC-F = 
254 Hz, Cq), 139.0 (d, 3JC-F = 8.9 Hz, CH), 132.1 (CH), 130.9 (CH), 130.8 (Cq), 128.6 (CH), 125.3 
(d, 4JC-F = 3.6 Hz, Cq), 116.4 (d, 2JC-F = 22 Hz, CH), 87.8 (Cage C), 85.8 (Cage C). 11B NMR (96 
MHz, CDCl3): δ = -2.67 (2B), -8.91 (4B), -10.32 (2B), -11.54 (2B). 19F NMR (282 MHz, CDCl3): δ 
= -107.68. IR (ATR): 2609, 2572, 2561, 1585, 1486, 1233, 1155, 835, 687 cm–1. MS (EI) m/z: 







162f. The representative procedure K was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and 4-chlorobenzenethiol 161f (43.0 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane) yielded 162f (26.0 mg, 71%) as a colorless solid. M.p. = 108 – 
110 °C. 1H NMR (400 MHz, CDCl3): δ = 7.68 – 7.62 (m, 2H), 7.61 – 7.54 (m, 1H), 7.52 – 7.44 (m, 
2H), 7.28 – 7.22 (m, 2H), 6.90 – 6.81 (m, 2H). 13C NMR (101 MHz, CDCl3): δ = 138.0 (CH), 
137.9 (Cq), 132.1 (CH), 131.0 (CH), 130.8 (Cq), 129.4 (CH), 128.6 (CH), 128.1 (Cq), 87.9 (Cage 
C), 85.4 (Cage C). 11B NMR (96 MHz, CDCl3): δ = -2.60 (2B), -8.90 (4B), -10.31 (2B), -11.54 
(2B). IR (ATR): 2610, 2567, 1572, 1473, 1445, 1092, 1073, 746 cm–1. MS (EI) m/z: 362 [M]+. HR-
MS (EI): m/z calcd. for C14H1910B211B835ClS [M]+: 362.1904, found: 362.1893.  
 
 
162g. The representative procedure L with KI (16.6 mg, 0.10 mmol) and CuI (2.9 mg, 15 mol %) 
was followed using o-carborane 160a (22.0 mg, 0.10 mmol) and 4-bromobenzenethiol 161g 
(56.1 mg, 0.30 mmol). Isolation by column chromatography (n-hexane) yielded 162g (29.0 mg, 
71 %) as a colorless solid. M.p. = 126 – 128 °C. 1H NMR (400 MHz, CDCl3): δ = 7.62 – 7.58 (m, 
2H), 7.56 – 7.50 (m, 1H), 7.46 – 7.41 (m, 2H), 7.39 – 7.34 (m, 2H), 6.78 – 6.70 (m, 2H). 13C 
NMR (101 MHz, CDCl3): δ = 138.1 (CH), 132.4 (CH), 132.1 (CH), 130.9 (CH), 130.7 (Cq), 128.6 
(Cq), 128.5 (CH), 126.3 (Cq), 87.9 (Cage C), 85.2 (Cage C). 11B NMR (128 MHz, CDCl3): δ = -
2.46 (2B), -9.13 (4B), -10.31 (2B), -11.52 (2B). IR (ATR): 2622, 2596, 1564, 1471, 1446, 1386, 
1070, 1010, 810 cm-1. MS (EI) m/z: 408 [M]+. HR-MS (EI): m/z calcd. for C14H1911B10S79Br [M]+: 
408.1363, found: 408.1358. 
 
 
162h. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 3-methylbenzenethiol 161h (35.6 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162h (30.3 mg, 88%) as a colorless 
solid. M.p. = 58 – 60 °C. 1H NMR (400 MHz, CDCl3): δ = 7.63 – 7.59 (m, 2H), 7.56 – 7.51 (m, 





6.55 (s, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 138.9 (Cq), 137.3 (CH), 133.6 (CH), 
132.2 (CH), 131.8 (CH), 130.8 (Cq), 130.7 (CH), 129.4 (Cq), 128.8 (CH), 128.4 (CH), 87.8 (Cage 
C), 86.2 (Cage C), 21.1 (CH3). 11B NMR (128 MHz, CDCl3): δ = -2.43 (1B), -3.16 (1B), -8.42 (1B), 
-9.16 (2B), -10.45 (3B), -11.42 (2B). IR (ATR): 2922, 2564, 1591, 1494, 1474, 1446, 1377, 885, 
780 cm-1. MS (EI) m/z: 342 [M]+. HR-MS (EI): m/z calcd. for C15H2210B211B8S [M]+: 342.2448, 
found: 342.2434.  
 
 
162i. The representative procedure L was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and 3-methoxylbenzenethiol 161i (37.2 µL, 0.30 mmol). Isolation by column 
chromatography (n-hexane) yielded 162i (22.2 mg, 62%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.66 (d, J = 8.0 Hz, 2H), 7.59 – 7.54 (m, 1H), 7.51 – 7.44 (m, 2H), 7.18 (t, J = 8.0 Hz, 
1H), 6.97 (dd, J = 8.4, 2.5 Hz, 1H), 6.56 (d, J = 7.6 Hz, 1H), 6.50 (s, 1H), 3.75 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ = 159.5 (Cq), 132.2 (CH), 131.0 (Cq), 130.8 (CH), 130.6 (Cq), 
129.8 (CH), 129.0 (CH), 128.5 (CH), 121.5 (CH), 117.4 (CH), 88.1 (Cage C), 86.1 (Cage C), 
55.4 (CH3). 11B NMR (96 MHz, CDCl3): δ = -2.69 (2B), -9.12 (4B), -10.34 (2B), -11.44 (2B). 
IR (ATR): 2961, 2934, 2597, 2564, 1589, 1479, 1249, 1231, 1040, 688 cm–1. MS (EI) m/z: 358 
[M]+. HR-MS (EI): m/z calcd. for C15H2210B211B8OS [M]+: 358.2397, found: 358.2385.  
 
 
162j. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 3-(trifluoromethyl)benzenethiol 161j (40.8 µL, 0.30 
mmol). Isolation by column chromatography (n-hexane) yielded 162j (29.5 mg, 74%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3): δ = 7.65 (d, J = 7.8 Hz, 1H), 7.61 – 7.52 (m, 3H), 7.47 
– 7.40 (m, 3H), 7.34 – 7.30 (m, 1H), 6.93 – 6.87 (m, 1H). 13C NMR (101 MHz, CDCl3): δ = 
139.9 (CH), 133.5 (q, 3JC-F = 3.8 Hz, CH), 132.0 (CH), 131.5 (q, 2JC-F = 33 Hz, Cq), 131.1 (CH), 
130.8 (Cq), 130.5 (Cq), 129 (CH), 128.7 (CH), 127.9 (q, 3JC-F = 3.7 Hz, CH), 123.2 (q, 1JC-F = 273 
Hz, Cq), 88.0 (Cage C), 84.9 (Cage C). 11B NMR (128 MHz, CDCl3): δ = -2.31 (2B), -9.02 (4B), -
10.25 (2B), -11.46 (2B). 19F NMR (376 MHz, CDCl3): δ = -62.78. IR (ATR): 2755, 1580, 1420, 
1320, 1272, 1165, 1122, 1071, 792 cm–1. MS (EI) m/z: 396 [M]+. HR-MS (EI): m/z calcd. for 







162k. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 3-chlorobenzenethiol 161k (34.5 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162k (21.4 mg, 59%) as a colorless 
solid. M.p. = 60 – 62 °C. 1H NMR (400 MHz, CDCl3): δ = 7.63 – 7.52 (m, 3H), 7.49 – 7.42 (m, 
2H), 7.37 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.23 – 7.17 (m, 1H), 6.95 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 
6.62 (ddd, J = 2.1, 1.7, 0.4 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ = 136.4 (CH), 134.7 (CH), 
134.4 (Cq), 132.1 (CH), 131.3 (CH), 131.1 (Cq), 131.0 (CH), 130.6 (Cq), 130.1 (CH), 128.6 (CH), 
87.8 (Cage C), 85.1 (Cage C). 11B NMR (128 MHz, CDCl3): δ = -2.37 (1B), -2.90 (1B), -9.11 (4B), 
-10.37 (2B), -11.46 (2B). IR (ATR): 2922, 2565, 1573, 1459, 1398, 1116, 1071, 864, 771 cm-1. 




162l. The representative procedure L with KI (16.6 mg, 0.10 mmol) and CuI (2.9 mg, 15 mol %) 
was followed using o-carborane 160a (22.0 mg, 0.10 mmol) and 3-bromobenzenethiol 161l (31.0 
µL, 0.30 mmol). Isolation by column chromatography (n-hexane) yielded 162l (24.1 mg, 59%) as 
a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 7.62 – 7.57 (m, 2H), 7.57 – 7.50 (m, 2H), 7.49 – 
7.42 (m, 2H), 7.15 (t, J = 7.9 Hz, 1H), 7.02 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 6.75 (t, J = 1.8 Hz, 
1H). 13C NMR (101 MHz, CDCl3): δ = 139.2 (CH), 135.1 (CH), 134.2 (CH), 132.1 (CH), 131.4 
(Cq), 131.0 (CH), 130.5 (Cq), 130.4 (CH), 128.7 (CH), 122.4 (Cq), 87.8 (Cage C), 85.1 (Cage C). 
11B NMR (128 MHz, CDCl3): δ = -2.35 (2B), -9.11 (4B), -10.37 (2B), -11.44 (2B). IR (ATR): 2918, 
2589, 1559, 1455, 1394, 1066, 866, 770, 672 cm-1. MS (EI) m/z: 408 [M]+. HR-MS (EI): m/z 
calcd. for C14H1911B10S79Br [M]+: 408.1363, found: 408.1360. 
 
 
162m. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 2-florobenzenethiol 161m (32.0 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162m (18.5 mg, 53%) as a colorless 





1H), 7.53 – 7.44 (m, 3H), 7.17 – 7.03 (m, 2H), 6.94 – 6.84 (m, 1H). 13C NMR (101 MHz, CDCl3): 
δ = 163.3 (d, 1JC-F = 253 Hz, Cq), 139.4 (CH), 134.1 (d, 3JC-F = 8.4 Hz, CH), 132.1 (CH), 
130.9 (Cq), 130.9 (CH), 128.5 (CH), 124.5 (d, 3JC-F = 4.0 Hz, CH), 117.0 (d, 2JC-F = 18.2 Hz, Cq), 
116.5 (d, 2JC-F = 23.1 Hz, CH), 88.7 (Cage C), 85.2 (Cage C). 11B NMR (96 MHz, CDCl3): δ = -
2.87 (2B), -8.30 (2B), -9.21 (1B), -9.90 (3B), -11.53 (2B). 19F NMR (282 MHz, CDCl3): δ = -
102.48. IR (ATR): 2598, 2557, 1470, 1261, 1223, 1067, 755, 689 cm–1. MS (EI) m/z: 346 [M]+. 
HR-MS (EI): m/z calcd. for C14H1910B211B8FS [M]+: 346.2197, found: 346.2183.  
 
 
162n. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 2-chlorobenzenethiol 161n (33.6 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162n (27.5 mg, 76%) as a colorless 
solid. M.p. = 146 – 148 °C. 1H NMR (400 MHz, CDCl3): δ = 7.72 – 7.64 (m, 2H), 7.56 – 7.47 (m, 
1H), 7.49 – 7.40 (m, 3H), 7.40 – 7.31 (m, 1H), 7.21 – 7.12 (m, 1H), 7.02 (d, J = 7.8 Hz, 1H). 13C 
NMR (101 MHz, CDCl3): δ = 141.1 (Cq), 140.0 (CH), 132.7 (CH), 132.1 (CH), 131.1 (Cq), 130.9 
(CH), 130.6 (CH), 128.9 (Cq), 128.6 (CH), 127.1 (CH), 89.5 (Cage C), 85.7 (Cage C). 11B NMR 
(128 MHz, CDCl3): δ = -2.90 (2B), -8.40 (2B), -9.57 (4B), -11.70 (2B). IR (ATR): 2500, 1945, 
1447, 1321, 1259, 1166, 1134, 1070, 749 cm-1. MS (EI) m/z: 362 [M]+. HR-MS (EI): m/z calcd. for 
C14H1910B211B8S35Cl [M]+: 362.1904, found: 362.1893. 
 
 
162o. The representative procedure L was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and benzenethiol 161o (31.0 µL, 0.30 mmol). Isolation by column chromatography (n-
hexane) yielded 162o (20.0 mg, 61%) as a colorless solid. M.p. = 112 – 114 °C. 1H NMR (300 
MHz, CDCl3): δ = 7.66 (d, J = 7.6 Hz, 2H), 7.61 – 7.54 (m, 1H), 7.51 – 7.40 (m, 3H), 7.32 – 7.25 
(m, 2H), 6.96 (d, J = 7.7 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ = 136.8 (CH), 132.2 (CH), 131.1 
(CH), 130.9 (Cq), 130.9 (CH), 129.8 (Cq), 129.1 (CH), 128.5 (CH), 88.1 (Cage C), 86.1 (Cage C). 
11B NMR (96 MHz, CDCl3): δ = -2.78 (2B), -9.14 (3B), -10.35 (3B), -11.50 (2B). IR (ATR): 2612, 
2589, 2560, 1585, 1486, 1232, 1077, 686 cm–1. MS (EI) m/z: 328 [M]+. HR-MS (EI): m/z calcd. 







162p. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 2,4-dimethylbenzenethiol 161p (40.3 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162p (23.1 mg, 65%) as a colorless 
solid. M.p. = 97 – 99 °C. 1H NMR (400 MHz, CDCl3): δ = 7.71 – 7.64 (m, 2H), 7.55 – 7.47 (m, 
1H), 7.49 – 7.40 (m, 2H), 7.05 – 6.99 (m, 1H), 6.91 – 6.84 (m, 1H), 6.75 (d, J = 7.9 Hz, 1H), 2.29 
(s, 3H), 2.21 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 143.9 (Cq), 141.9 (Cq), 138.6 (CH), 
132.1 (CH), 131.7 (CH), 131.3 (Cq), 130.7 (CH), 128.6 (CH), 127.3 (CH), 126.1 (Cq), 89.5 (Cage 
C), 87.4 (Cage C), 21.3 (CH3), 20.7 (CH3). 11B NMR (128 MHz, CDCl3): δ = -3.05 (2B), -8.58 
(2B), -9.80 (4B), -11.72 (2B). IR (ATR): 2919, 2851, 2586, 2569, 1600, 1446, 1232, 1074, 886 




162q. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and 2,4-difluorobenzenethiol 161q (33.1 µL, 0.30 mmol). 
Isolation by column chromatography (n-hexane) yielded 162q (32.8 mg, 65%) as a colorless 
solid. M.p. = 109 – 111 °C. 1H NMR (400 MHz, CDCl3): δ = 7.69 – 7.60 (m, 2H), 7.56 – 7.48 (m, 
1H), 7.48 – 7.39 (m, 2H), 6.88 – 6.71 (m, 3H). 13C NMR (101 MHz, CDCl3): δ = 165.4 (dd, 1JC-F = 
257 Hz, 3JC-F = 10.8 Hz, Cq), 163.9 (dd, 1JC-F = 256 Hz, 3JC-F = 13.4 Hz, Cq), 140.6 (dd, 3JC-F = 
10.2, 10.2 Hz, CH), 132.1 (CH), 131.0 (CH), 130.9 (Cq), 128.6 (CH), 112.9 (dd, 2JC-F = 18.5 Hz, 
4JC-F = 3.9 Hz, Cq), 112.2 (dd, 2JC-F = 22.0 Hz, 4JC-F = 3.9 Hz, CH), 105.1 (dd, 2JC-F = 25.8, 25.9 
Hz, CH), 88.5 (Cage C), 84.9 (Cage C). 11B NMR (128 MHz, CDCl3): δ = -2.20 (1B), -3.38 (1B), -
7.71 (2B), -9.26 (2B), -10.50 (2B), -12.38 (2B). 19F NMR (282 MHz, CDCl3): δ = -97.08 (d, J = 
11.5 Hz), -101.85 (d, J = 11.5 Hz). IR (ATR): 3059, 1487, 1443, 1201, 1155, 1056, 907, 734 cm-1. 








162r. The representative procedure L was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and naphthalene-2-thiol 161r (43.2 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane) yielded 162r (35.2 mg, 93%) as a colorless solid. M.p. = 129 – 131 °C. 1H NMR (400 
MHz, CDCl3): δ = 7.83 – 7.79 (m, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.64 – 7.44 (m, 8H), 7.18 – 7.15 
(m, 1H), 7.08 (dd, J = 8.5, 1.8 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ = 137.6 (CH), 133.9 (Cq), 
132.8 (Cq), 132.3 (CH), 132.1 (CH), 130.9 (Cq), 130.8 (CH), 128.8 (CH), 128.5 (CH), 128.3 (CH), 
128.0 (CH), 127.7 (CH), 126.8 (CH), 126.8 (Cq) 87.8 (Cage C), 85.9 (Cage C). 11B NMR (128 
MHz, CDCl3): δ = -2.37 (1B), -3.12 (1B), -8.44 (2B), -9.14 (2B), -10.49 (3B), -11.39 (1B). IR 
(ATR): 3057, 2594, 1581, 1494, 1446, 1072, 901, 859, 808, 743 cm-1. MS (EI) m/z: 378 [M]+. 
HR-MS (EI): m/z calcd. for C18H2210B211B8S [M]+: 378.2449, found: 378.2436. 
 
 
162s. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and benzenethiol 161s (27.8 µL, 0.30 mmol). Isolation by 
column chromatography (n-hexane) yielded 162s (18.0 mg, 54%) as a colorless solid. M.p. = 83 
– 85 °C. 1H NMR (300 MHz, CDCl3): δ = 7.68 (d, J = 7.6 Hz, 2H), 7.59 – 7.45 (m, 4H), 6.97 (dd, 
J = 5.3, 3.6 Hz, 1H), 6.64 (d, J = 3.9 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ = 139.3 (CH), 134.1 
(CH), 132.1 (CH), 130.9 (CH), 130.6 (Cq), 128.6 (CH), 127.7 (CH), 127.6 (Cq), 87.4 (Cage C), 
85.6 (Cage C). 11B NMR (96 MHz, CDCl3): δ = -2.70 (2B), -9.16 (3B), -10.37 (3B), -11.72 (2B). 
IR (ATR): 2922, 2852, 2605, 2589, 2559, 1399, 1218, 852, 710 cm–1. MS (EI) m/z: 334 [M]+. HR-
MS (EI): m/z calcd. for C12H1810B211B8S2 [M]+: 334.1854, found: 334.1845. 
 
 
162t. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160a (22.0 mg, 0.10 mmol) and cyclohexanethiol 161t (35.5 µL, 0.30 mmol). Isolation 
by column chromatography (n-hexane) yielded 162t (20.0 mg, 60%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3): δ = 7.65 – 7.58 (m, 2H), 7.47 – 7.41 (m, 1H), 7.41 – 7.33 (m, 2H), 2.76 – 2.68 
(m, 1H), 1.69 – 1.60 (m, 2H), 1.51 – 1.40 (m, 2H), 1.33 – 0.98 (m, 6H). 13C NMR (101 MHz, 
CDCl3): δ = 131.8 (CH), 131.0 (Cq), 130.6 (CH), 128.3 (CH), 88.6 (Cage C), 87.0 (Cage C), 50.5 
(CH), 33.9 (CH2), 25.7 (CH2), 25.0 (CH2). 11B NMR (128 MHz, CDCl3): δ = -2.81 (2B), -8.18 (2B), 
-9.37 (2B), -10.21 (2B), -11.07 (2B). IR (ATR): 2932, 2852, 2557, 1494, 1447, 1321, 1261, 1075, 








162u. The representative procedure B was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and 1-undecanethiol 161u (67.9 µL, 0.30 mmol). Isolation by column chromatography (n-
hexane) yielded 162u (22.0 mg, 54%) as a colorless oil. 1H NMR (300 MHz, CDCl3): δ = 7.65 (d, 
J = 7.6 Hz, 2H), 7.52 – 7.46 (m, 1H), 7.45 – 7.37 (m, 2H), 2.65 (t, J = 7.2 Hz, 2H), 1.37 – 1.12 (m, 
18H), 0.95 – 0.88 (m, 3H). 13C NMR (75 MHz, CDCl3): δ = 131.6 (CH), 131.1 (Cq), 130.7 (CH), 
128.5 (CH), 88.7 (Cage C), 86.7 (Cage C), 36.9 (CH2), 31.9 (CH2), 29.6 (CH2), 29.5 (CH2), 29.3 
(2CH2), 28.8 (CH2), 28.3 (CH2), 28.0 (CH2), 22.7 (CH2), 14.1 (CH3). 11B NMR (96 MHz, CDCl3): δ 
= -2.96 (2B), -8.35 (2B), -10.02 (5B), -11.34 (1B). IR (ATR): 2957, 2923, 2853, 2593, 1447, 1276, 




163a. The representative procedure L was followed using o-carborane 160b (23.4 mg, 0.10 
mmol) and benzenethiol 161o (30.8 µL, 0.30 mmol). Isolation by column chromatography (n-
hexane) yielded 163a (32.2 mg, 94%) as a colorless solid. M.p. = 114 – 116 °C. 1H NMR (400 
MHz, CDCl3): δ = 7.51 – 7.46 (m, 2H), 7.42 – 7.37 (m, 1H), 7.28 – 7.21 (m, 4H), 7.01 – 6.96 
(m, 2H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 141.3 (Cq), 137.0 (CH), 132.1 (CH), 131.1 
(CH), 129.9 (Cq), 129.2 (CH), 129.1 (CH), 128.2 (Cq), 88.6 (Cage C), 86.3 (Cage C), 21.2 (CH3). 
11B NMR (128 MHz, CDCl3): δ = -2.90 (2B), -9.10 (3B), -10.40 (3B), -11.55 (2B). IR (ATR): 2922, 
2564, 1612, 1509, 1471, 1439, 1260, 1193, 888 cm-1. MS (EI) m/z: 342 [M]+. HR-MS (EI): m/z 







163b. The representative procedure L was followed using o-carborane 160b (23.0 mg, 0.10 
mmol) and 4-(tert-butyl)benzenethiol 161b (49.9 µL, 0.30 mmol). Isolation by column 
chromatography (n-hexane) yielded 163b (24.7 mg, 62%) as a colorless solid. M.p. = 106 – 
108 °C. 1H NMR (400 MHz, CDCl3): δ = 7.51 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 6.0 Hz, 2H), 7.25 (d, 
J = 6.0 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 2.45 (s, 3H), 1.30 (s, 9H). 13C NMR (101 MHz, CDCl3): 
δ = 154.6 (Cq), 141.2 (Cq), 136.6 (CH), 132.1 (CH), 129.2 (CH), 128.3 (Cq), 126.5 (Cq), 126.1 
(CH), 88.6 (Cage C), 86.7 (Cage C), 34.9 (Cq), 31.1 (CH3), 21.2 (CH3). 11B NMR (96 MHz, 
CDCl3): δ = -3.14 (2B), -9.15 (3B), -10.52 (3B), -11.76 (2B). IR (ATR): 2962, 2924, 2852, 2594, 
2572, 1460, 1259, 765 cm–1. MS (EI) m/z: 398 [M]+. HR-MS (EI): m/z calcd. for 
C19H3010B211B8S [M]+: 398.3076, found: 398.3064. 
 
 
163c. The representative procedure L was followed using o-carborane 160b (23.4 mg, 0.10 
mmol) and naphthalene-2-thiol 161r (43.2 mg, 0.30 mmol). Isolation by column chromatography 
(n-hexane) yielded 163c (39.2 mg, 62%) as a colorless solid. M.p. = 165 – 166 °C. 1H NMR (400 
MHz, CDCl3): δ = 7.84 – 7.79 (m, 1H), 7.72 (dd, J = 8.5, 0.6 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.57 – 
7.53 (m, 1H), 7.53 – 7.47 (m, 3H), 7.27 – 7.24 (m, 2H), 7.22 (dd, J = 1.8, 0.9 Hz, 1H), 7.12 (dd, J 
= 8.5, 1.8 Hz, 1H), 2.49 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 141.3 (Cq), 137.6 (CH), 133.9 
(Cq), 132.9 (Cq), 132.2 (CH), 132.2 (CH), 129.2 (CH), 128.8 (CH), 128.2 (CH), 128.2 (Cq), 128.0 
(CH), 127.7 (CH), 126.9 (Cq), 126.8 (CH), 88.1 (Cage C), 86.0 (Cage C), 21.3 (CH3). 11B NMR 
(128 MHz, CDCl3): δ = -2.63 (2B), -9.08 (4B), -10.53 (2B), -11.48 (2B). IR (ATR): 2591, 1276, 





392.2606, found: 392.2600. 
 
 
163d. The representative procedure L was followed using o-carborane 160c (25.1 mg, 0.10 
mmol) and benzenethiol 161o (30.8 µL, 0.30 mmol). Isolation by column chromatography (n-
hexane) yielded 163d (25.1 mg, 70%) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 7.51 (d, 
J = 9.0 Hz, 2H), 7.42 – 7.37 (m, 1H), 7.28 – 7.22 (m, 2H), 6.99 (dd, J = 8.3, 1.3 Hz, 2H), 
6.92 (d, J = 9.0 Hz, 2H), 3.88 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 161.6 (Cq), 136.9 (CH), 
133.7 (CH), 131.1 (CH), 129.9 (Cq), 129.1 (CH), 123.3 (Cq), 113.7 (CH), 88.9 (Cage C), 86.7 
(Cage C), 55.5 (CH3). 11B NMR (128 MHz, CDCl3): δ = -3.01 (2B), -9.06 (4B), -10.52 (2B), -11.55 
(2B). IR (ATR): 2588, 1971, 1607, 1511, 1302, 1261, 1184, 835, 748 cm-1. MS (EI) m/z: 358 [M]+. 
HR-MS (EI): m/z calcd. for C15H2210B211B8SO [M]+: 358.2395, found: 358.2391. 
 
 
163e. The representative procedure L with KI (16.6 mg, 0.10 mmol) was followed using o-
carborane 160d (25.4 mg, 0.10 mmol) and benzenethiol 161o (30.8 µL, 0.30 mmol). Isolation by 
column chromatography (n-hexane) yielded 163e (28.2 mg, 78%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3): δ = 7.55 (d, J = 8.6 Hz, 2H), 7.49 – 7.40 (m, 3H), 7.29 (t, J = 7.8 Hz, 2H), 
7.00 (d, J = 7.6 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ = 137.5 (Cq), 136.8 (CH), 133.4 (CH), 
131.3 (CH), 129.7 (Cq), 129.6 (Cq), 129.2 (CH), 128.7 (CH), 87.1 (Cage C), 86.2 (Cage C). 
11B NMR (128 MHz, CDCl3): δ = -2.39 (1B), -3.00 (1B), -8.40 (2B), -9.20 (1B), -10.19 (3B), -
11.56 (2B). IR (ATR): 2924, 2593, 1593, 1492, 1401, 1100, 1070, 1016, 887 cm-1. MS (EI) m/z: 
362 [M]+. HR-MS (EI): m/z calcd. for C14H1910B211B8S35Cl [M]+: 362.1904, found: 362.1894. 
 
 
163f. The representative procedure L was followed using o-carborane 160e (23.4 mg, 0.10 
mmol) and benzenethiol 161o (31.0 µL, 0.30 mmol). Isolation by column chromatography (n-





MHz, CDCl3): δ = 7.70 – 7.66 (m, 2H), 7.60 – 7.55 (m, 1H), 7.53 – 7.46 (m, 2H), 7.43 – 7.33 
(m, 3H), 7.29 – 7.25 (m, 2H), 3.80 (s, 2H). 13C NMR (75 MHz, CDCl3): δ = 137.2 (CH), 135.6 (Cq), 
131.5 (CH), 130.4 (CH), 130.0 (Cq), 129.6 (CH), 128.6 (CH), 128.0 (CH), 84.3 (Cage C), 84.2 
(Cage C), 40.9 (CH2). 11B NMR (96 MHz, CDCl3): δ = -3.85 (2B), -9.37 (4B), -10.84 (4B). IR 
(ATR): 2923, 2852, 2577, 2560, 1493, 1470, 1439, 1419, 745 cm–1. MS (EI) m/z: 342 [M]+. HR-
MS (EI): m/z calcd. for C15H2210B211B8S [M]+: 342.2448, found: 342.2432. 
 
 
163g. The representative procedure K was followed using o-carborane 160f (20.0 mg, 0.10 
mmol) and 4-methoxybenzenethiol 161a (36.9 µL, 0.30 mmol). Isolation by column 
chromatography (n-hexane) yielded 163g (18.0 mg, 53%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3): δ = 7.48 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 3.88 (s, 3H), 2.52 – 2.47 (m, 2H), 
1.59 – 1.53 (m, 2H), 1.49 – 1.41 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 
= 162.0 (Cq), 138.8 (CH), 120.9 (Cq), 114.9 (CH), 84.7 (Cage C), 84.6 (Cage C), 55.5 (CH3), 35.0 
(CH2), 31.8 (CH2), 22.5 (CH2), 13.8 (CH3). 11B NMR (96 MHz, CDCl3): δ = -4.27 (2B), -9.91 (4B), 
-10.94 (4B). IR (ATR): 2959, 2930, 2564, 1591, 1493, 1254, 1172, 830 cm–1. MS (EI) m/z: 338 
[M]+. HR-MS (EI): m/z calcd. for C13H2610B211B8OS [M]+: 338.2709, found: 338.2703. 
 
 
163h. The representative procedure L was followed using o-carborane 160f (20.0 mg, 0.10 
mmol) and 1-undecanethiol 161u (67.9 µL, 0.30 mmol). Isolation by column chromatography (n-
hexane) yielded 163h (20.7 mg, 54%) as a colorless oil. 1H NMR (300 MHz, CDCl3): δ = 2.86 (t, 
J = 7.2 Hz, 2H), 2.35 – 2.26 (m, 2H), 1.67 – 1.59 (m, 2H), 1.57 – 1.47 (m, 2H), 1.45 – 1.21 (m, 
18H), 1.01 – 0.85 (m, 6H). 13C NMR (75 MHz, CDCl3): δ = 85.0 (Cage C), 83.9 (Cage C), 37.2 
(CH2), 34.6 (CH2), 31.9 (CH2), 31.8 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 29.0 
(CH2), 28.7 (CH2), 28.2 (CH2), 22.7 (CH2), 22.4 (CH2), 14.1 (CH3), 13.7 (CH3). 11B NMR (96 MHz, 
CDCl3): δ = -4.29 (2B), -9.85 (4B), -10.95 (4B). IR (ATR): 2958, 2924, 2853, 2606, 2569, 1466, 
1259, 748 cm–1. MS (EI) m/z: 386 [M]+. HR-MS (EI): m/z calcd. for C17H4210B211B8S [M]+: 







163i. The representative procedure L was followed using o-carborane 160g (15.8 mg, 0.10 
mmol) and 4-methoxybenzenethiol 161a (36.9 µL, 0.30 mmol). Isolation by column 
chromatography (n-hexane) yielded 163i (20.0 mg, 68%) as a colorless solid. M.p. = 81 – 83 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.49 (d, J = 8.9 Hz, 2H), 6.94 (d, J = 9.0 Hz, 2H), 3.87 (s, 3H), 
2.24 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 162.0 (Cq), 138.9 (CH), 121.0 (Cq), 114.9 (CH), 82.7 
(Cage C), 79.3 (Cage C), 55.5 (CH3), 23.6 (CH3). 11B NMR (96 MHz, CDCl3): δ = -3.86 (1B), -
4.97 (1B), -8.82 (2B), -9.90 (6B). IR (ATR): 2838, 2600, 2571, 2557, 1590, 1493, 1254, 828 cm–1. 




163j. The representative procedure L was followed using o-carborane 160a (22.0 mg, 0.10 
mmol) and benzeneselenol 161v (31.9 µL, 0.30 mmol). Isolation by column chromatography (n-
hexane) yielded 163j (22.0 mg, 59%) as a colorless solid. M.p. = 112 – 114 °C. 1H NMR (300 
MHz, CDCl3): δ = 7.63 – 7.52 (m, 3H), 7.45 (t, J = 7.5 Hz, 3H), 7.29 (t, J = 7.6 Hz, 2H), 7.16 (d, J 
= 7.3 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ = 137.6 (CH), 132.0 (CH), 131.7 (Cq), 130.8 (CH), 
130.7 (CH), 129.2 (CH), 128.5 (CH), 127.1 (Cq), 86.3 (Cage C), 72.7 (Cage C). 11B NMR (96 
MHz, CDCl3): δ = -2.44 (2B), -8.29 (1B), -9.00 (1B), -9.78 (3B), -11.45 (3B). IR (ATR): 2630, 
2609, 2572, 2561, 1585, 1486, 1233, 754 cm–1. MS (EI) m/z: 376 [M]+. HR-MS (EI): m/z calcd. 
for C14H2010B211B8Se [M]+: 376.1729, found: 376.1726. 
 
5.3.6.2 Late-stage Diversification 
 
Compound 162g (40.7 mg, 0.10 mmol), trimethylsilylacetylene (56.5 µL, 0.40 mmol), 
PdCl2(PPh3)2 (3.5 mg, 0.005 mmol), CuI (1.9 mg, 0.01 mmol) and NHiPr2 (28.2 µL, 0.20 mmol) 





under N2. Then, the reaction was quenched with with water (10 mL) and extracted with diethyl 
ether (10 mL x 3). The organic layers were combined and concentrated to dryness in vacuo. The 
residue was subjected to flash column chromatography on silica gel using n-hexane as eluent to 
give the product 164a as a colorless oil (52%). 1H NMR (300 MHz, CDCl3): δ = 7.66 – 7.60 (m, 
2H), 7.60 – 7.53 (m, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 
2H), 0.28 (s, 9H). 13C NMR (101 MHz, CDCl3): δ = 136.6 (CH), 132.5 (CH), 132.3 (CH), 131.0 
(CH), 130.9 (Cq), 129.9 (Cq), 128.7 (CH), 126.3 (Cq), 103.6 (Cq), 98.0 (Cq), 88.1 (Cage C), 
85.8 (Cage C), 0.0 (CH3). 11B NMR (96 MHz, CDCl3): δ = -2.65 (2B), -8.99 (3B), -10.46 (5B). IR 
(ATR): 2958, 2923, 2594, 2575, 2158, 1480, 1250, 862, 841 cm–1. MS (EI) m/z: 424 [M]+. HR-MS 




Compound 162g (40.7 mg, 0.10 mmol), carbazole (33.4 mg, 0.20 mmol), Pd(OAc)2 (1.1 mg, 
0.005 mmol), PtBu3 (3.0 mg, 0.015 mmol), and K2CO3 (41.4 mg, 0.30 mmol) were combined 
together in toluene (2.5 mL). The resulting mixture was heated at 120 °C for 12 h. Then, the 
reaction was quenched with with water (10 mL) and extracted with diethyl ether (10 mL x 3). The 
organic layers were combined and concentrated to dryness in vacuo. The residue was subjected 
to flash column chromatography on silica gel using n-hexane and ethyl acetate (20/1) as eluent 
to give the product 164b as a colorless solid (83%). M.p. = 214 – 216 °C. 1H NMR (300 MHz, 
CDCl3): δ = 8.14 (d, J = 7.8 Hz, 2H), 7.70 (d, J = 7.7 Hz, 2H), 7.58 – 7.53 (m, 1H), 7.49 (d, J = 
8.5 Hz, 4H), 7.45 – 7.39 (m, 4H), 7.32 (ddd, J = 8.0, 6.1, 2.1 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H). 
13C NMR (101 MHz, CDCl3): δ = 140.5 (Cq), 140.1 (Cq), 138.4 (CH), 132.2 (CH), 131.0 (CH), 
130.9 (Cq), 128.6 (CH), 128.0 (Cq), 127.0 (CH), 126.2 (CH), 123.8 (Cq), 120.7 (CH), 120.5 (CH), 
109.6 (CH), 87.9 (Cage C), 85.7 (Cage C). 11B NMR (96 MHz, CDCl3): δ = -2.51 (2B), -9.09 (4B), 
-10.13 (4B). IR (ATR): 2921, 2851, 2595, 2565, 2555, 1586, 1446, 1223, 720 cm–1. MS (EI) m/z: 








5.3.6.3 Mechanistic Studies 
 
 
The general procedure K was followed using o-carborane 160a (0.10 mmol, 1.0 equiv), 4-
methoxybenzenethiol 161a (36.9 µL, 0.30 mmol) and TEMPO or Ph2CH2=CH2 (0.1 mmol, 1.0 
equiv). Electrocatalysis was performed at room temperature with a constant current of 2.0 mA 
maintained for 16 h. The GF anode was washed with ethyl acetate (3×10 mL). Evaporation of 
the solvent and subsequent purification by column chromatography on silica gel with n-hexane 
afforded the corresponding product 162a (TEMPO: 75%, Ph2CH2=CH2: 72%).  
 
The general procedure K was followed using o-carborane 160a (0.10 mmol, 1.0 equiv), 4-
methoxybenzenethiol 161a (36.9 µL, 0.30 mmol). Electrocatalysis was performed in the dark at 
room temperature with a constant current of 2.0 mA maintained for 16 h. The GF anode was 
washed with ethyl acetate (3×10 mL). Evaporation of the solvent and subsequent purification by 
column chromatography on silica gel with n-hexane afforded the corresponding product 162a 
(81%).  
 
5.3.6.4 Cyclic Voltammetry 
CV measurements were conducted by Alexej Scheremetjew with a Metrohm Autolab 
PGSTAT204 potentiostat and Nova 2.1 software. A glassy carbon working electrode (disk, 
diameter: 3mm), a coiled platinum wire counter electrode and a non-aqueous Ag/Ag+ reference 





employed. The voltammograms were recorded at room temperature in dry acetonitrile at a 
substrate concentration of 5 mmol/L and with 100 mmol/L n-Bu4NPF6 as supporting electrolyte. 
Prior to each measurement, the working electrode was thoroughly polished with 0.05 µm 
alumina polishing powder and rinsed with water and methanol. All measured solutions were 
saturated with nitrogen gas and an overpressure of protective gas was maintained throughout 
the experiment. The nitrogen gas was previously saturated with solvent vapour by passing it 
through a gas washing bottle with acetonitrile. The scan rate is 100 mV/s. Deviations from the 
general experimental conditions are indicated in the respective figures.  













































































































WE Potential vs. Ag/Ag
+
 (V)
 161a + 4 equiv. tBuOLi
 CuOAc + 4 equiv. 161a + 4 equiv. tBuOLi
 TBAI
 CuOAc




























 6 Phpy + CuOAc
 6 Phpy + CuOAc + 4 tBuOLi








































 160a + 4 LiOtBu
 160a + 4 LiOtBu + CuOAc
 160a + 4 LiOtBu + CuOAc + PhPy
 160a + 4 LiOtBu + CuOAc + 3 PhPy
 
5.3.6.5 EPR studies 
(EPR spectroscopy analysis did by Dr. A. Claudia Stcükl). The electrocatalysis was carried out in 
an undivided cell under air, with a graphite felt (GF) anode (10 mm × 15 mm × 6 mm) and a 
platinum cathode (10 mm × 15 mm × 0.25 mm). o-Carborane 160a (0.10 mmol, 1.0 equiv), 4-
methoxybenzenethiol 161a (0.30 mmol, 3.0 equiv), CuOAc (15 mol %), 2-PhPy (15 mol %), 
LiOtBu (0.2 mmol, 2.0 equiv) and TBAI (0.2 mmol, 2.0 equiv) were dissolved in THF (3.0 mL). 
Electrocatalysis was performed at room temperature with a constant current of 2.0 mA 
maintained for 2 h. Then PBN (N-tert-butyl-alpha-Phenylnitrone) (5 equiv.) (if noted) was added 
into the reaction system. After stirring 2 minutes, the mixture was immediately transferred into 
the EPR tube for EPR measurement.  
















 standard conditions + electricity 
a)














standard conditions + PBN + electricity 
b)
 
The electrocatalysis was carried out in an undivided cell under air, with a graphite felt (GF) 
anode (10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). 4-
methoxybenzenethiol 161a (0.30 mmol) and LiOtBu (0.2 mmol) were dissolved in THF (3.0 mL). 
Electrocatalysis was performed at room temperature with a constant current of 2.0 mA 
maintained for 2 h. Then PBN (N-tert-butyl-alpha-Phenylnitrone) (5 equiv.) was added into the 





tube for EPR measurement. This EPR result showed a small radical signal, which is not stable 
for longer time even after trapping with PBN and might be attributed to one of the possible thiols 
containing radical species.[239] 














 4-MeOPhSH + LiOtBu + THF + electricity
c)






















The electrocatalysis was carried out in an undivided cell under air, with a graphite felt (GF) 
anode (10 mm × 15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). o-
carborane 160a (0.10 mmol) and LiOtBu (0.2 mmol) were dissolved in THF (3.0 mL). 
Electrocatalysis was performed at room temperature with a constant current of 2.0 mA 
maintained for 2 h. Then PBN (N-tert-butyl-alpha-Phenylnitrone) (5 equiv.) was added into the 
reaction system. After stirring 2 minutes, the mixture was immediately transferred into the EPR 
tube for EPR measurement. 














 160a + LiOtBu + THF + electricity
e) 
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7. NMR Spectra 
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